呼吸器内科学レビュー　2022-’23

出版社： 総合医学社
著者：
発行日： 2021-12-30
分野： 臨床医学：内科  >  呼吸器一般
ISBN： 9784883787470
電子書籍版： 2021-12-30 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

14,300 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

14,300 円(税込)

購入する

商品紹介

呼吸器分野のエキスパートによって厳選された、直近2年間を中心に国内外で発表された最新の文献レビューです。広く呼吸器内科関連の最近のトピックスを把握でき、呼吸器内科専門医だけでなく、専門医を目指す方にも必携の1冊です。

目次

  • I章　呼吸器感染症
    　1．ウイルス肺炎（COVID-19を除く）
    　2．COVID-19
    　3．市中肺炎（細菌性肺炎を中心に）
    　4．市中肺炎（非定型肺炎）
    　5．誤嚥性肺炎
    　6．院内肺炎
    　7．肺結核症
    　8．肺非結核性抗酸菌症
    　9．肺真菌症
    　10．医療・介護関連肺炎

    II章　閉塞性肺疾患
    　11．COPDの薬物療法
    　12．COPD（リハビリテーション）
    　13．気管支拡張症
    　14．その他の慢性気道炎症

    III章　間質性肺疾患
    　15．特発性間質性肺炎
    　16．特発性肺線維症・間質性肺疾患の急性増悪

    IV章　肺胞性肺疾患
    　17．肺胞性肺疾患（肺胞蛋白症、特発性肺ヘモジデローシス）

    V章　肺循環障害に起因する肺疾患
    　18．肺動脈性肺高血圧症
    　19．肺血栓塞栓症

    VI章　アレルギー性肺疾患
    　20．気管支喘息
    　21．慢性咳嗽（咳喘息）
    　22．好酸球性肺疾患
    　23．過敏性肺炎

    VII章　全身性疾患と肺病変
    　24．膠原病に合併する肺病変
    　25．ANCA 関連肺疾患
    　26．サルコイドーシス

    VIII章　じん肺
    　27．じん肺

    IX章　医原性肺疾患
    　28．薬剤性肺障害
    　29．放射線肺臓炎

    X章　胸膜の疾患
    　30．胸膜中皮腫およびその他の胸膜疾患
    　31．胸膜炎

    XI章　呼吸不全と換気障害
    　32．睡眠時無呼吸症候群
    　33．慢性呼吸不全
    　34．急性呼吸不全と急性呼吸促拍症候群

    XII章　肺腫瘍
    　35．肺癌の画像診断
    　36．肺癌の内視鏡診断
    　37．限局型小細胞肺癌
    　38．進展型小細胞肺癌
    　39．I期、II期非小細胞肺癌
    　40．III期非小細胞肺癌
    　41．IV期非小細胞肺癌

    XIII章　縦隔の疾患
    　42．縦隔腫瘍の治療
    　43．胸腺腫の薬物療法

    XIV章　新テクノロジーと肺疾患
    　44．呼吸器画像診断と新テクノロジー
    　45．呼吸器病理診断と新テクノロジー
    　46．間質性肺炎診療と新テクノロジー

    XV章　その他
    　47．希少肺疾患（リンパ脈管筋腫症とα1-アンチトリプシン欠乏症）
    　48．肺移植

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I章 呼吸器感染症

P.3 掲載の参考文献
1) Gadsby NJ, Russel CD, McHugh MP et al : Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis 62 : 817-823, 2016
 
2) Shorr AF, Fisher K, Micek ST et al : The burden of viruses in pneumonia associated with acute respiratory failure : an under-appreciated issue. Chest 154 : 84-90, 2018
 
3) Palekar RS, Rolfes MA, Arriola CS et al : Burden of influenza-associated respiratory hospitalizations in the Americas, 2010-2015. PLoS One 14 : e0221479, 2019
PubMed
4) Shorr AF, Ziberberg MD, Micek ST et al : Viruses are prevalent in non-ventilated hospital-acquired pneumonia. Respir Med 122 : 76-80, 2017
 
5) Boonyaratanakornkit J, Vivek M, Xie H et al : Predictive value of respiratory viral detection in the upper respiratory tract for infection of the lower respiratory tract with hematopoietic stem cell transplantation. J Infect Dis 221 : 379-388, 2020
PubMed
P.4 掲載の参考文献
6) Self WH, Balk RA, Grijalva CG et al : Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis 65 : 183-190, 2017
PubMed
7) Uyeki TM, Bernstein HH, Bradley JS et al : Clinical practice guidelines by the Infectious Diseases Society of America : 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin infect Dis 68 : 895-902, 2019
 
8) Evans SE, Jennerich AL, Azar MM et al : Nucleic acid-based testing for noninfluenza viral pathogens in adults with suspected community-acquired pneumonia : an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 203 : 1070-1087, 2021
PubMed
9) Metlay JP, Waterer GW, Long AC et al : Diagnosis and treatment of adults with community-acquired pneumonia : an official clinical guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 200 : e45-e67, 2019
 
10) Hanson KE, Azar MM, Banerjee R et al : Molecular testing for acute respiratory tract infections : clinical and diagnostic recommendations from the IDSA's diagnostics committee. Clin Infect Dis 71 : 2744-2751, 2020
PubMed
P.5 掲載の参考文献
11) Mitton B, Rule R, Said M : Laboratory evaluation of the BioFire FilmArray Pneumonia plus panel compared to conventional methods for the identification of bacteria in lower respiratory tract specimens : a prospective cross-sectional study from South Africa. Diagn Microbiol Infect Dis 99 (2) : 115236, 2021
PubMed
12) Gilbert DN, Leggett JE, Wang L et al : Enhanced detection of community-acquired pneumonia pathogens with the BioFire(R) Pneumonia FilmArray(R) panel. Diagn Microbiol Infect Dis 99 (3) : 115246, 2021
 
13) Buchan BW, Windham S, Balada-Llasat JM et al : Practical comparison of the BioFire FilmArray Pneumonia Panel to routine diagnostic methods and potential impact on antimicrobial stewardship in adult hospitalized patients with lower respiratory tract infections. J Clin Microbiol 58 (7) : e00135-20, 2020
 
14) Shenchen D, Gu X, Fan G et al : Evaluation of a molecular point-of-care testing for viral and atypical pathogens on intravenous antibiotic duration in hospitalized adults with lower respiratory tract infection : a randomized clinical trial. Clin Microbiol Infect 25 : 1415-1421, 2019
 
15) Saarela E, Tapiainen T, Kauppila J et al : Impact of multiplex respiratory virus testing on antimicrobial consumption in adults in acute care : a randomized clinical trial. Clin Microbiol Infect 26 : 506-511, 2020
PubMed
16) Purendki V, Huttner B, Marti C et al : Accuracy of comprehensive PCR analysis of nasopharyngeal and oropharyngeal swabs for CT-scan-confirmed pneumonia in elderly patients : a prospective cohort study. Clin Microbiol Infect 25 : 1114-1119, 2019
 
17) van Someren Greve F, Juffermans NP, Bos LDJ : Respiratory viruses in invasively ventilated critically ill patients-a prospective multicenter observational study. Crit Care Med 46 : 29-36, 2018
PubMed
18) Centers for Disease Control and Prevention : Influenza antiviral medications : summary for clinicians. May 6, 2021 https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm
 
19) Hayden FG, Sugaya N, Hirotsu N et al : Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 379 : 913-923, 2018
PubMed
P.6 掲載の参考文献
20) Ison MG, Portsmouth S, Yoshida Y et al : Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2) : a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 20 : 1204-1214, 2020
PubMed
21) Uehara T, Hayden FG, Kawaguchi K et al : Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility : impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis 221 : 346-355, 2020
PubMed
22) 日本感染症学会 : 日本感染症学会提言「抗インフルエンザ薬の使用について」. (2019年10月24日) http://www.kansensho.or.jp/modules/guidelines/index.php?content_id=37
 
P.7 掲載の参考文献
23) Ikematsu H, Hayden FG, Kawaguchi K et al : Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med 384 : 309-320, 2020
 
24) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会 : 成人肺炎診療ガイドライン 2017. 日本呼吸器学会, 2017
 
25) Centers for Disease Control and Prevention : Interim guidance for routine and influenza immunization services during the COVID-19 pandemic. June 4, 2021 https://www.cdc.gov/vaccines/pandemicguidance/index.html
 
26) 日本感染症学会 : 日本感染症学会提言「今冬のインフルエンザとCOVID-19に備えて」. 2020年8月3日 http://www.kansensho.or.jp/uploads/files/guidelines/2008_teigen_influenza_covid19.pdf
 
27) Piroth L, Cottenet J, Mariet AS et al : Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza : a nationwide, population-based retrospective cohort study. Lancet Respir Med 9 : 251-259, 2021
PubMed
28) Tolksdorf, K, Buda S, Schuler et al : Influenza-associated pneumonia as reference to assess seriousness of coronavirus disease (COVID-19). Euro Surveill 25 : 2000258, 2020
PubMed
29) Pagliano P, Sellitto C, Conti V et al : Characteristics of viral pneumonia in the COVID-19 era : an update. Infection, 2021 [online ahead of print]
 
P.8 掲載の参考文献
30) Sakamoto H, Ishikane M, Ueda P : Seasonal influenza activity during the SARS-CoV-2 outbreak in Japan. JAMA 323 : 1969-1971, 2020
PubMed
31) Australian Government Department of Health : Australian Influenza Surveillance report No.07, 2021 https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-surveilozflu-flucurr.htm/$File/flu-07-2021.pdf
 
P.9 掲載の参考文献
1) National Institutes of Health : Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2021
 
2) Bhimraj A, Morgan RL, Shumaker AH et al : Infectious diseases society of America Guidelines on the Treatment and Management of Patients with COVID-19. 2021
 
3) World Health Organization : Therapeutics and COVID-19 : living guideline. 2021
 
4) 診療の手引き検討委員会 : 新型コロナウイルス感染症診療の手引き 第5.1版. 2021
 
5) 日本感染症学会 : COVID-19に対する薬物治療の考え方 第7版. 2021
 
P.10 掲載の参考文献
6) 日本版敗血症診療ガイドライン2020特別委員会COVID-19対策タスクフォース : COVID-19薬物療法に関するRapid/Living recommendations 第3.2版. 2021
 
7) 病原体検査の指針検討委員会 : 新型コロナウイルス感染症 (COVID-19) 病原体検査の指針 第4版. 2021
 
8) Zhu N, Zhang D, Wang W et al : A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382 (8) : 727-733, 2020
 
9) Mahdy MAA, Younis W, Ewaida Z : An overview of SARS-CoV-2 and animal infection. Front Vet Sci 7 : 596391, 2020
PubMed
10) Hu B, Guo H, Zhou P et al : Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19 (3) : 141-154, 2021
 
P.11 掲載の参考文献
11) Lopes-Pacheco M, Silva PL, Cruz FF et al : Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies. Front Physiol 12 : 593223, 2021
PubMed
12) van Doremalen N, Bushmaker T, Morris DH et al : Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 382 (16) : 1564-1567, 2020
PubMed
13) Echternach M, Gantner S, Peters G et al : Impulse dispersion of aerosols during singing and speaking : A potential COVID-19 transmission pathway. Am J Respir Crit Care Med 202 (11) : 1584-1587, 2020
PubMed
14) Endo A, Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group ; Abbott S, Kucharski AJ et al : Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China. Wellcome Open Res 5 : 67, 2020
 
15) Vakili K, Fathi M, Hajiesmaeili M et al : Neurological symptoms, comorbidities, and complications of COVID-19 : A literature review and meta-analysis of observational studies. Eur Neurol 84 (5) : 307-324, 2021
PubMed
16) Wu Z, McGoogan JM : Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China : Summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 323 (13) : 1239-1242, 2020
 
P.12 掲載の参考文献
17) Zheng Z, Peng F, Xu B et al : Risk factors of critical & mortal COVID-19 cases : A systematic literature review and meta-analysis. J Infect 81 (2) : e16-e25, 2020
 
P.14 掲載の参考文献
18) Spinner CD, Gottlieb RL, Criner GJ et al : Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19 : A randomized clinical trial. JAMA 324 (11) : 1048-1057, 2020
PubMed
19) Goldman JD, Lye DCB, Hui DS et al : Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 383 (19) : 1827-1837, 2020
PubMed
20) RECOVERY Collaborative Group, Horby P, Lim WS et al : Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384 (8) : 693-704, 2021
 
21) Stebbing J, Phelan A, Griffin I et al : COVID-19 : combining antiviral and antiinflammatory treatments. Lancet Infect Dis 20 (4) : 400-402, 2020
PubMed
22) Kalil AC, Patterson TF, Mehta AK et al : Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 384 (9) : 795-807, 2021
PubMed
23) RECOVERY Collaborative Group : Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial. Lancet 397 (10285) : 1637-1645, 2021
 
P.15 掲載の参考文献
24) REMAP-CAP Investigators, Gordon AC, Mouncey PR et al : Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 384 (16) : 1491-1502, 2021
PubMed
25) Doi Y, Hibino M, Hase R et al : A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother 64 (12) : e01897-20, 2020
 
P.16 掲載の参考文献
26) Lescure FX, Honda H, Fowler RA et al : Sarilumab in patients admitted to hospital with severe or critical COVID-19 : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9 (5) : 522-532, 2021
PubMed
27) Lang FM, Lee KM, Teijaro JR et al : GMC-SF-based treatments in COVID-19 : reconciling opposing therapeutic approaches. Nat Rev Immunol 20 (8) : 507-514, 2020
 
28) WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S et al : Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19 : A meta-analysis. JAMA 324 (13) : 1330-1341, 2020
 
P.17 掲載の参考文献
29) Sheikh A, McMenamin J, Taylor B et al ; Public Health Scotland and the EAVE II Collaborators : SARS-CoV-2 Delta VOC in Scotland : demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397 (10293) : 2461-2462, 2021
PubMed
30) Abu-Raddad LJ, Chemaitelly H, Butt AA ; National Study Group for COVID-19 Vaccination : Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 385 (2) : 187-189, 2021
 
31) Haas EJ, Angulo FJ, McLaughlin JM et al : Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel : an observational study using national surveillance data. Lancet 397 (10287) : 1819-1829, 2021
PubMed
32) Wang P, Casner RG, Nair MS et al : Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe 29 (5) : 747-751.e744, 2021
 
33) Allen H, Vusirikala A, Flannagan J et al : Increased household transmission of COVID-19 cases associated with SARS-CoV-2 Variant of Concern B.1.617.2 : a national case-control study. Public Health England, 2021
 
P.18 掲載の参考文献
1) Nagano H, Takada D, Shin JH et al : Hospitalization of mild cases of community-acquired pneumonia decreased more than severe cases during the COVID-19 pandemic. Int J Infect Dis 106 : 323-328, 2021
PubMed
2) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会 : 成人肺炎診療ガイドライン 2017. 日本呼吸器学会, 2017
 
3) Metlay JP, Waterer GW, Long AC et al : Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 200 : e45-e67, 2019
 
P.19 掲載の参考文献
4) Loubet P, Tubiana S, Claessens YE et al : Community-acquired pneumonia in the emergency department : an algorithm to facilitate diagnosis and guide chest CT scan indication. Clin Microbiol Infect 26 : 382.e381-382.e387, 2020
 
5) Ebell MH, Chupp H, Cai X et al : Accuracy of signs and symptoms for the diagnosis of community-acquired pneumonia : A meta-analysis. Acad Emerg Med 27 : 541-553, 2020
PubMed
6) Shoar S, Musher DM : Etiology of community-acquired pneumonia in adults : a systematic review. Pneumonia (Nathan) 12 : 11, 2020
PubMed
7) Wu X, Li Y, Zhang M et al : Etiology of severe community-acquired pneumonia in adults based on metagenomic next-generation sequencing : A prospective multicenter study. Infect Dis Ther 9 : 1003-1015, 2020
 
8) Sangla F, Legouis D, Marti PE et al : One year after ICU admission for severe community-acquired pneumonia of bacterial, viral or unidentified etiology. What are the outcomes? PloS one 15 : e0243762, 2020
PubMed
P.20 掲載の参考文献
9) Ogawa H, Kitsios GD, Iwata M et al : Sputum gram stain for bacterial pathogen diagnosis in community-acquired pneumonia : A systematic review and bayesian meta-analysis of diagnostic accuracy and yield. Clin Infect Dis 71 : 499-513, 2020
PubMed
10) Burgmeijer EH, Duijkers R, Lutter R et al : Plasma cytokine profile on admission related to aetiology in community-acquired pneumonia. Clin Respir J 13 : 605-613, 2019
PubMed
11) Zhang X, Liu B, Liu Y et al : Efficacy of the quick sequential organ failure assessment for predicting clinical outcomes among community-acquired pneumonia patients presenting in the emergency department. BMC Infect Dis 20 : 316, 2020
PubMed
P.21 掲載の参考文献
12) Spagnolello O, Ceccarelli G, Borrazzo C et al : qSOFA as a new community-acquired pneumonia severity score in the emergency setting. Emerg Med J, 2020 [online ahead of print]
 
13) Kesselmeier M, Pletz MW, Blankenstein AL et al : Validation of the qSOFA score compared to the CRB-65 score for risk prediction in community-acquired pneumonia. Clin Microbiol Infect, 2020 [online ahead of print]
 
14) Ma CM, Wang N, Su QW et al : The performance of CURB-65 and PSI for predicting in-hospital mortality of community-acquired pneumonia in patients with type 2 diabetes compared with the non-diabetic population. Diabetes Metab Syndr Obes 14 : 1359-1366, 2021
PubMed
15) Marin-Corral J, Pascual-Guardia S, Amati F et al : Aspiration risk factors, microbiology, and empiric antibiotics for patients hospitalized with community-acquired pneumonia. Chest 159 : 58-72, 2021
PubMed
16) Uranga A, Artaraz A, Bilbao A et al : Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia. BMC Pulm Med 20 : 261, 2020
 
P.22 掲載の参考文献
17) Kimura T, Ito M, Onozawa S : Switching from intravenous to oral antibiotics in hospitalized patients with community-acquired pneumonia : A real-world analysis 2010-2018. J Infect Chemother 26 : 706-714, 2020
PubMed
18) Wittermans E, Vestjens SMT, Bos WJW et al : The extent of microbiological testing is associated with alteration of antibiotic therapy in adults with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 38 : 1359-1366, 2019
PubMed
19) Sando E, Suzuki M, Ishida M et al : Definitive and indeterminate pseudomonas aeruginosa infection in adults with community-acquired pneumonia : A prospective observational study. Ann Am Thorac Soc 18 (9) : 1475-1481, 2021
PubMed
20) Ceccato A, Mendez R, Ewig S et al : Validation of a prediction score for drug-resistant microorganisms in community-acquired pneumonia. Ann Am Thorac Soc 18 : 257-265, 2021
PubMed
P.23 掲載の参考文献
21) Ito A, Ishida T, Tachibana H et al : Azithromycin combination therapy for community-acquired pneumonia : propensity score analysis. Sci Rep 9 : 18406, 2019
PubMed
22) Povoa P, Coelho L, Salluh J : When should we use corticosteroids in severe community-acquired pneumonia? Curr Opin Infect Dis 34 : 169-174, 2021
PubMed
23) Wittermans E, Vestjens SM, Spoorenberg SM et al : Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia : A randomised clinical trial. Eur Respir J, 2021 [online ahead of print]
 
P.24 掲載の参考文献
24) Raess N, Schuetz P, Cesana-Nigro N et al : Influence of prednisone on inflammatory biomarkers in community-acquired pneumonia : Secondary analysis of a randomized trial. J Clin Pharmacol, 2021 [online ahead of print]
 
25) Pereira JM, Laszczynska O, Azevedo A et al : Early prediction of treatment failure in severe community-acquired pneumonia : The PRoFeSs score. J Crit Care 53 : 38-45, 2019
 
26) Luo Q, He X, Zheng Y et al : Elevated progranulin as a novel biomarker to predict poor prognosis in community-acquired pneumonia. J Infect 80 : 167-173, 2020
PubMed
27) Tsuchiya K, Suzuki Y, Yoshimura K et al : Macrophage mannose receptor CD206 predicts prognosis in community-acquired pneumonia. Sci Rep 9 : 18750, 2019
PubMed
28) Liu HY, Xiang HX, Xiang Y et al : The associations of serum S100A9 with the severity and prognosis in patients with community-acquired pneumonia : a prospective cohort study. BMC Infect Dis 21 : 327, 2021
PubMed
29) Wang JL, Chen X, Xu Y et al : The associations of serum IL-37 with the severity and prognosis in patients with community-acquired pneumonia : A retrospective cohort study. Front Immunol 12 : 636896, 2021
 
30) Akiyama Y, Ishiguro T, Uozumi R et al : Specific pathogens as predictors of poor long-term prognosis after hospital discharge for community-acquired pneumonia. Respir Med 176 : 106279, 2021
PubMed
P.26 掲載の参考文献
1) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会 : 成人肺炎診療ガイドライン 2017. 日本呼吸器学会, 2017
 
2) Miyashita N, Horita N, Higa F et al : Validation of a diagnostic score model for the prediction of Legionella pneumophila pneumonia. J Infect Chemother 25 : 407-412, 2019
PubMed
3) Jones BE, Herman DD, Dela Cruz CS et al : Summary for Clinicians : Clinical practice guideline for the diagnosis and treatment of community-acquired pneumonia. Ann Am Thorac Soc 17 : 133-138, 2020
PubMed
4) Pletz MW, Blasi F, Chalmers JD et al : International perspective on the new 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline : A critical appraisal by a global expert panel. Chest 158 : 1912-1918, 2020
 
P.27 掲載の参考文献
5) Lei JH, Xu Y, Jiang YF et al : Clustering cases of Chlamydia psittaci pneumonia in COVID-19 screening ward staff. Clin Infect Dis, 2020 [online ahead of print]
 
6) 厚生労働省/国立感染症研究所 : Infectious diseases weekly report Japan 23 (26) : 14, 2021
 
7) Caeiro Alves F, Aguiar R, Pessegueiro P et al : Thrombotic microangiopathy associated with Mycoplasma pneumoniae infection. BMJ Case Rep 2018 : bcr-2017-222582, 2018
 
8) Amode R, Ingen-Housz-Oro S, Ortonne N et al : Clinical and histologic features of Mycoplasma pneumoniae-related erythema multiforme : A single-center series of 33 cases compared with 100 cases induced by other causes. J Am Acad Dermatol 79 : 110-117, 2018
PubMed
9) Saraya T, Ohkuma K, Tsukahara Y et al : Correlation between clinical features, high-resolution computed tomography findings, and a visual scoring system in patients with pneumonia due to Mycoplasma pneumoniae. Respir Investig 56 : 320-325, 2018
 
10) Nakanishi M, Nakashima K, Takeshita M et al : Ability of high-resolution computed tomography to distinguish Mycoplasma pneumoniae pneumonia from other bacterial pneumonia : Significance of lateral bronchial lesions, less air bronchogram, and no peripheral predominance. Respir Investig 58 : 169-176, 2020
PubMed
P.28 掲載の参考文献
11) Xue G, Zhao H, Yan C et al : Evaluation of the CARDS toxin and its fragment for the serodiagnosis of Mycoplasma pneumoniae infections. Eur J Clin Microbiol Infect Dis 40 : 1705-1711, 2021
 
12) Tashiro M, Fushimi K, Kawano K et al : Comparison of efficacy of antimicrobial agents among hospitalized patients with Mycoplasma pneumoniae pneumonia in Japan during large epidemics of macrolide-resistant M. pneumoniae infections : A nationwide observational study. Clin Infect Dis 65 : 1837-1842, 2017
PubMed
13) Tashiro M, Fushimi K, Kawano K et al : Adjunctive corticosteroid therapy for inpatients with Mycoplasma pneumoniae pneumonia. BMC Pulm Med 17 : 219, 2017
PubMed
14) Baheerathan A, Ross Russell A, Bremner F et al : A rare case of bilateral optic neuritis and Guillain-Barre syndrome post Mycoplasma pneumoniae infection. Neuroophthalmology 41 : 41-47, 2017
 
15) Kenri T, Suzuki M, Sekizuka T et al : Periodic genotype shifts in clinically prevalent Mycoplasma pneumoniae strains in Japan. Front Cell Infect Microbiol 10 : 385, 2020
PubMed
16) Zha L, Shen J, Tefsen B et al : Clinical features and outcomes of adult COVID-19 patients co-infected with Mycoplasma pneumoniae. J Infect 81 : e12-e15, 2020
PubMed
17) Yamasaki K, Kawanami T, Yatera K et al : Significance of anaerobes and oral bacteria in community-acquired pneumonia. PLoS One 8 : e63103, 2013
PubMed
18) Noguchi S, Mukae H, Kawanami T et al : Bacteriological assessment of healthcare-associated pneumonia using a clone library analysis. PLoS One 10 : e0124697, 2015
PubMed
19) Noguchi S, Yatera K, Kawanami T et al : Frequency of detection of Chlamydophila pneumoniae using bronchoalveolar lavage fluid in patients with community-onset pneumonia. Respir Investig 55 : 357-364, 2017
PubMed
P.29 掲載の参考文献
20) Ma L, Wang W, Le Grange JM et al : Coinfection of SARS-CoV-2 and Other Respiratory Pathogens. Infect Drug Resist 13 : 3045-3053, 2020
PubMed
21) De Francesco MA, Poiesi C, Gargiulo F et al : Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features. J Infect 82 : e4-e7, 2021
PubMed
22) Gu L, Liu W, Ru M et al : The application of metagenomic next-generation sequencing in diagnosing Chlamydia psittaci pneumonia : a report of five cases. BMC Pulm Med 20 : 65, 2020
 
P.30 掲載の参考文献
23) Ito A, Ishida T, Washio Y et al : Legionella pneumonia due to non-Legionella pneumophila serogroup 1 : usefulness of the six-point scoring system. BMC Pulm Med 17 : 211, 2017
PubMed
24) Muyldermans A, Descheemaeker P, Boel A et al : What is the risk of missing legionellosis relying on urinary antigen testing solely? A retrospective Belgian multicenter study. Eur J Clin Microbiol Infect Dis 39 : 729-734, 2020
PubMed
25) Jasper AS, Musuuza JS, Tischendorf JS et al : Are Fluoroquinolones or Macrolides better for treating Legionella Pneumonia? A systematic review and meta-analysis. Clin Infect Dis 72 : 1979-1989, 2021
PubMed
P.31 掲載の参考文献
1) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会 : 成人肺炎診療ガイドライン 2017. pp1-175, 日本呼吸器学会, 2017
 
2) Mandell LA, Niederman MS : Aspiration pneumonia. N Engl J Med 380 : 651-663, 2019
PubMed
3) Santos JMLG, Ribeiro O, Jesus LMT et al : Interventions to prevent aspiration pneumonia in older adults : An updated systematic review. J Speech Lang Hear Res 64 : 464-480, 2021
PubMed
P.32 掲載の参考文献
4) Yoshimatsu Y, Tobino K, Ko Y et al : Careful history taking detects initially unknown underlying causes of aspiration pneumonia. Geriatr Gerontol Int 20 : 785-790, 2020
PubMed
5) Ryu AJ, Navin PJ, Hu X et al : Aspiration can occur in the absence of subjective or demonstrable swallowing difficulties and manifest a broad spectrum of clinicoradiologic presentations. Chest 156 (6) : 1160-1166, 2019
PubMed
6) Okazaki T, Ebihara S, Mori T et al : Association between sarcopenia and pneumonia in older people. Geriatr Gerontol Int 20 (1) : 7-13, 2020
PubMed
7) Fujishima I, Fujiu-Kurachi M, Arai H et al : Sarcopenia and dysphagia : Position paper by four professional organizations. Geriatr Gerontol Int 19 : 91-97, 2019
 
P.33 掲載の参考文献
8) Marin-Corral J, Pascual-Guardia S, Amati F et al : Aspiration risk factors, microbiology, and empiric antibiotics for patients hospitalized with community-acquired pneumonia. Chest 159 (1) : 58-72, 2021
PubMed
9) Otsuji K, Fukuda K, Ogawa M et al : Dynamics of microbiota during mechanical ventilation in aspiration pneumonia. BMC Pulm Med 19 : 260, 2019
 
10) 千田一嘉 : 誤嚥性肺炎の人生の最終段階における医療・ケアとACP (特集 ますます増える誤嚥性肺炎診療の最前線). 日医師会誌 149 : 2173-2177, 2021
 
11) 日本医師会生命倫理懇談会 : 終末期医療に関するガイドライン (改訂版). 2019
 
12) Asai N, Suematsu H, Ohashi W et al : Ceftriaxone versus tazobactam/piperacillin and carbapenems in the treatment of aspiration pneumonia : A propensity score matching analysis. J Infect Chemother, 2021 [online ahead of print]
 
P.34 掲載の参考文献
13) Hasegawa S, Shiraishi A, Yaegashi M et al : Ceftriaxone versus ampicillin/sulbactam for the treatment of aspiration-associated pneumonia in adults. J Comp Eff Res 8 (15) : 1275-1284, 2019
PubMed
14) 三木誠, 三笠桂一, 門田淳一他 : 市中肺炎患者におけるlascufloxacin注射剤とlevofloxacin注射剤の第III相二重盲検比較試験. 日化療会誌 69 : 255-269, 2021
 
15) 三木誠, 三笠桂一, 門田淳一他 : 慢性呼吸器病変の二次感染, 誤嚥性肺炎および肺膿瘍患者におけるlascufloxacin注射剤の一般臨床試験. 日化療会誌 69 : 270-285, 2021
 
16) 三木誠, 三笠桂一, 門田淳一他 : 市中肺炎患者におけるlascufloxacinとlevofloxacinの第III相二重盲検比較試験. 日化療会誌 68 (S-1) 41-54, 2020
 
17) Aga M, Naganuma T, Serizawa Y et al : Association of early antibiotic therapy and in-hospital mortality in adult mild-tomoderate acute aspiration pneumonitis : a cohort study. Intern Emerg Med, 2021 [online ahead of print
 
P.35 掲載の参考文献
18) Maeda K, Murotani K, Kamoshita S et al : Nutritional management in inpatients with aspiration pneumonia : a cohort medical claims database study. Arch Gerontol Geriatr 95 : 104398, 2021
PubMed
19) Australian and New Zealand Society for Geriatric Medicine Position Statement : Dysphagia and aspiration in older people. Australas J Ageing 39 : 85, 2020
PubMed
20) 日本老年医学会, 日本在宅医学会, 国立長寿医療研究センター : 高齢者在宅医療・介護サービスガイドライン 2019. ライフ・サイエンス, 2019
 
P.36 掲載の参考文献
1) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編 : 成人肺炎診療ガイドライン 2017. 日本呼吸器学会, 2017
 
P.37 掲載の参考文献
2) Givens JL, Jones RN, Shaffer ML et al : Survival and comfort after treatment of pneumonia in advanced dementia. Arch Intern Med 170 (13) : 1102-1107, 2010
PubMed
P.38 掲載の参考文献
3) Del Rio-Pertuz G, Gutierrez JF, Triana AJ et al : Usefulness of sputum gram stain for etiologic diagnosis in community-acquired pneumonia : a systematic review and meta-analysis. BMC Infect Dis 19 (1) : 403, 2019
 
4) Fernando SM, Tran A, Cheng W et al : Diagnosis of ventilator-associated pneumonia in critically ill adult patients-a systematic review and meta-analysis. Intensive Care Med 46 (6) : 1170-1179, 2020
PubMed
P.39 掲載の参考文献
5) Akata K, Yatera K, Yamasaki K et al : The significance of oral streptococci in patients with pneumonia with risk factors for aspiration : the bacterial floral analysis of 16S ribosomal RNA gene using bronchoalveolar lavage fluid. BMC Pulm Med 16 (1) : 79, 2016
PubMed
6) Kawanami T, Yatera K, Yamasaki K et al : Clinical impact of methicillin-resistant staphylococcus aureus on bacterial pneumonia : cultivation and 16S ribosomal RNA gene analysis of bronchoalveolar lavage fluid. BMC Infect Dis 16 : 155, 2016
PubMed
7) Monard C, Pehlivan J, Auger G et al : Multicenter evaluation of a syndromic rapid multiplex PCR test for early adaptation of antimicrobial therapy in adult patients with pneumonia. Crit Care 24 (1) : 434, 2020
PubMed
8) Morikawa K, Okada F, Ando Y et al : Meticillin-resistant Staphylococcus aureus and meticillin-susceptible S. aureus pneumonia : comparison of clinical and thin-section CT findings. Br J Radiol 85 (1014) : e168-e175, 2012
 
P.40 掲載の参考文献
9) Wussler D, Kozhuharov N, Tavares Oliveira M et al : Clinical Utility of Procalcitonin in the Diagnosis of Pneumonia. Clin Chem 65 (12) : 1532-1542, 2019
PubMed
10) Kamat IS, Ramachandran V, Eswaran H et al : Procalcitonin to distinguish viral from bacterial pneumonia : A systematic review and meta analysis. Clin Infect Dis 70 (3) : 538-542, 2020
PubMed
11) Lam SW, Bauer SR, Fowler R et al : Systematic review and meta-analysis of procalcitonin-guidance versus usual care for antimicrobial management in critically ill patients : focus on subgroups based on antibiotic initiation, cessation, or mixed strategies. Crit Care Med 46 (5) : 684-690, 2018
PubMed
12) Maruyama T, Fujisawa T, Okuno M et al : A new strategy for healthcare-associated pneumonia : a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis 57 (10) : 1373-1383, 2013
PubMed
13) Kalil AC, Metersky ML, Klompas M et al : Management of adults with hospitalacquired and ventilator-associated pneumonia : 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63 (5) : e61-e111, 2016
 
P.41 掲載の参考文献
14) Howatt M, Klompas M, Kalil AC et al : Carbapenem antibiotics for the empiric treatment of nosocomial pneumonia : A systematic review and meta-analysis. Chest 159 (3) : 1041-1054, 2021
PubMed
15) Yang P, Chen Y, Jiang S et al : Association between antibiotic consumption and the rate of carbapenem resistant gramnegative bacteria from China based on 153 tertiary hospitals data in 2014. Antimicrob Resist Infect Control 7 : 137, 2018
 
16) Babich T, Naucler P, Valik JK et al : Ceftazidime, carbapenems, or piperacillin tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection : a multisite retrospective study. Clin Infect Dis 70 (11) : 2270-2280, 2020
PubMed
P.42 掲載の参考文献
17) Dragan V, Wei Y, Elligsen M et al : Prophylactic antimicrobial therapy for acute aspiration pneumonitis. Clin Infect Dis 67 (4) : 513-518, 2018
PubMed
18) Mandell LA, Niederman MS : Aspiration Pneumonia. N Engl J Med 380 (7) : 651-663, 2019
PubMed
19) Heffernan AJ, Sime FB, Lipman J et al : Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli : A systematic review. Int J Antimicrob Agents 53 (3) : 234-245, 2019
PubMed
P.43 掲載の参考文献
1) 疫学情報センター : 結核 https://www.jata.or.jp/rit/ekigaku/toukei/nenpou/
 
P.44 掲載の参考文献
2) Sakamoto H, Ishikane M, Ueda P : Seasonal influenza activity during the SARS-CoV-2 outbreak in Japan. Jama 323 (19) : 1969-1971, 2020
 
3) Lai CC, Yu WL : The COVID-19 pandemic and tuberculosis in Taiwan. J Infect 81 (2) : e159-e161, 2020
 
4) Komiya K, Yamasue M, Takahashi O et al : The COVID-19 pandemic and the true incidence of Tuberculosis in Japan. J Infect 81 (3) : e24-e25, 2020
 
5) WHO : Global Tuberculosis Report 2020 https://www.who.int/teams/global-tuberculosis-programme/tb-reports/globaltuberculosis-report-2020
 
6) Saunders MJ, Evans CA : COVID-19, tuberculosis and poverty : Preventing a perfect storm. Eur Respir J 56 (1) : 2001348, 2020
PubMed
P.45 掲載の参考文献
7) Al Zahrani K, Al Jahdali H, Poirier L et al : Yield of smear, culture and amplification tests from repeated sputum induction for the diagnosis of pulmonary tuberculosis. Int J Tuberc Lung Dis 5 (9) : 855-860, 2001
PubMed
8) Matsumoto H, Komiya K, Yamasue M et al : Features of active pulmonary tuberculosis without abnormal chest X-ray findings. Infect Dis (Lond) 52 (7) : 520-523, 2020
PubMed
9) Goto A, Komiya K, Kan T et al : Factors associated with atypical radiological findings of pulmonary tuberculosis. PLoS One 14 (7) : e0220346, 2019
 
10) Hogan CA, Puri L, Gore G et al : Impact of fluoroquinolone treatment on delay of tuberculosis diagnosis : A systematic review and meta-analysis. J Clin Tuberc Other Mycobact Dis 6 : 1-7, 2017
PubMed
11) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会 : 成人肺炎診療ガイドライン 2017. 日本呼吸器学会, 2017
 
12) Fujishima N, Komiya K, Matsunaga N et al : A pitfall of treatment with tosufloxacin for pneumonia that might be lung tuberculosis. Intern Med 58 (2) : 263-266, 2019
PubMed
13) Kan T, Komiya K, Honjo K et al : Impact of additional antibiotics on in-hospital mortality in tuberculosis isolated general bacteria : A propensity score analysis. J Infect Chemother 25 (9) : 714-719, 2019
PubMed
P.46 掲載の参考文献
14) Wang M, Fitzgerald JM, Richardson K et al : Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic? Int J Tuberc Lung Dis 15 (8) : 1062-1068, 2011
PubMed
15) 日本結核病学会 : 結核診療ガイド. 2018
 
16) 日本結核病学会 : 「結核医療の基準」の改定-2018年. Kekkaku 93 (1) : 61-68, 2018
 
P.47 掲載の参考文献
17) 鈴木純子 : 結核の治療 : 初回治療と主要薬剤の副作用. 呼吸器内科 37 (5) : 471-477, 2020
 
18) Dorman SE, Nahid P, Kurbatova EV et al : Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med 384 (18) : 1705-1718, 2021
 
19) Bagheri N, Montazeri H : On BCG vaccine protection from COVID-19 : A review. SN Compr Clin Med, 2021 [online ahead of print]
 
P.48 掲載の参考文献
20) Escobar LE, Molina-Cruz A, Barillas-Mury C : BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A 117 (30) : 17720-17726, 2020
PubMed
21) Wickramasinghe D, Wickramasinghe N, Kamburugamuwa SA et al : Correlation between immunity from BCG and the morbidity and mortality of COVID-19. Trop Dis Travel Med Vaccines 6 : 17, 2020
PubMed
22) Kumar A, Misra S, Verma V et al : Global impact of environmental temperature and BCG vaccination coverage on the transmissibility and fatality rate of COVID-19. PLoS One 15 (10) : e0240710, 2020
 
23) Szigeti R, Kellermayer D, Trakimas G et al : BCG epidemiology supports its protection against COVID-19? A word of caution. PLoS One 15 (10) : e0240203, 2020
 
24) Hensel J, McAndrews KM, McGrail DJ et al : Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses. Sci Rep 10 (1) : 18377, 2020
 
25) Okada M, Kita Y, Hashimoto S et al : Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis. Hum Vaccin Immunother 13 (2) : 298-305, 2017
PubMed
26) Yamasue M, Komiya K, Usagawa Y et al : Factors associated with false negative interferon-γ release assay results in patients with tuberculosis : A systematic review with meta-analysis. Sci Rep 10 (1) : 1607, 2020
 
27) Zhou G, Luo Q, Luo S et al : Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection : A systematic review and meta-analysis. Lancet Infect Dis 20 (12) : 1457-1469, 2020
 
P.49 掲載の参考文献
28) 加藤誠也 : 潜在性結核感染症の治療. 呼吸器内科 37 (5) : 520-525, 2020
 
29) Menzies D, Adjobimey M, Ruslami R et al : Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med 379 (5) : 440-453, 2018
 
P.51 掲載の参考文献
1) Moon SM, Jhun BW, Baek SY et al : Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. Respir Med 151 : 1-7, 2019
PubMed
2) Kim OH, Chong YP, Shim TS et al : Redevelopment after spontaneous sputum conversion in noncavitary nodular bronchiectatic Mycobacterium avium complex lung disease. J Infect Chemother 27 (8) : 1156-1161, 2021
PubMed
3) Daley CL, Iaccarino JM, Lange C et al : Treatment of Nontuberculous Mycobacterial Pulmonary Disease : An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 71 (4) : 905-913, 2020
PubMed
4) Han DW, Jo KW, Kim OH et al : Cavity formation and its predictors in noncavitary nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Respir Med 179 : 106340, 2021
PubMed
5) Kang HR, Hwang EJ, Kim SA et al : Clinical implications of size of cavities in patients with nontuberculous mycobacterial pulmonary disease : A single-center cohort study. Open Forum Infect Dis 8 (3) : ofab087, 2021
 
6) Oshitani Y, Kitada S, Edahiro R et al : Characteristic chest CT findings for progressive cavities in Mycobacterium avium complex pulmonary disease : a retrospective cohort study. Respir Res 21 (1) : 10, 2020
PubMed
P.52 掲載の参考文献
7) Griffith DE, Eagle G, Thomson R et al : Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Respir Crit Care Med 198 (12) : 1559-1569, 2018
 
8) Griffith DE, Thomson R, Flume PA et al : Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease : Sustainability and durability of culture conversion and safety of long-term exposure. Chest, 2021 [online ahead of print]
 
9) Winthrop KL, Flume PA, Thomson R et al : Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease : A 12-month open-label extension clinical trial. Ann Am Thorac Soc 18 (7) : 1147-1157, 2021
PubMed
P.53 掲載の参考文献
10) Hoy SM : Amikacin liposome inhalation suspension in refractory Mycobacterium avium complex lung disease : A profile of its use. Clin Drug Investig 41 (4) : 405-412, 2021
PubMed
11) Kim HJ, Lee JS, Kwak N et al : Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease. BMC Pulm Med 19 (1) : 212, 2019
 
12) Morimoto K, Izumi K, Ato M et al : Actual practice of standard treatment for pulmonary nontuberculous mycobacteriosis in Japan. Respir Med 158 : 67-69, 2019
PubMed
13) Furuuchi K, Morimoto K, Kurashima A et al : Treatment duration and disease recurrence following the successful treatment of patients with Mycobacterium avium complex lung disease. Chest 157 (6) : 1442-1445, 2020
PubMed
P.54 掲載の参考文献
14) Park YE, Chong YP, Kim YJ et al : Outcome of shorter treatment duration in non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease. J Thorac Dis 12 (3) : 338-348, 2020
PubMed
15) Jhun BW, Moon SM, Jeon K et al : Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease : a 15-year follow-up study. Eur Respir J 55 (1) : 1900798, 2020
PubMed
16) Kim HJ, Kwak N, Hong H et al : BACES Score for predicting mortality in nontuberculous mycobacterial pulmonary disease. Am J Respir Crit Care Med 203 (2) : 230-236, 2021
PubMed
17) Wang PH, Pan SW, Shu CC et al : Clinical course and risk factors of mortality in Mycobacterium avium complex lung disease without initial treatment. Respir Med 171 : 106070, 2020
PubMed
18) Lee H, Myung W, Lee EM et al : Mortality and prognostic factors of nontuberculous mycobacterial infection in Korea : A population-based comparative study. Clin Infect Dis 72 (10) : e610-e619, 2021
 
19) Nishiuchi Y, Maekura R, Kitada S et al : The recovery of Mycobacterium aviumintracellulare complex (MAC) from the residential bathrooms of patients with pulmonary MAC. Clin Infect Dis 45 (3) : 347-351, 2007
PubMed
20) Nishiuchi Y, Iwamoto T, Maruyama F : Infection sources of a common nontuberculous mycobacterial pathogen, Mycobacterium avium complex. Front Med (Lausanne) 4 : 27, 2017
PubMed
21) Nishiuchi Y, Tamura A, Kitada S et al : Mycobacterium avium complex organisms predominantly colonize in the bathtub inlets of patients' bathrooms. Jpn J Infect Dis 62 (3) : 182-186, 2009
PubMed
P.55 掲載の参考文献
22) Arikawa K, Ichijo T, Nakajima S et al : Genetic relatedness of Mycobacterium avium subsp. hominissuis isolates from bathrooms of healthy volunteers, rivers, and soils in Japan with human clinical isolates from different geographical areas. Infect Genet Evol 74 : 103923, 2019
PubMed
23) Morimoto K, Aono A, Murase Y et al : Prevention of aerosol isolation of nontuberculous mycobacterium from the patient's bathroom. ERJ Open Res 4 (3) : 2018
PubMed
P.57 掲載の参考文献
1) Strickland AB, Shi M : Mechanisms of fungal dissemination. Cell Mol Life Sci 78 : 3219-3238, 2021
PubMed
2) Donnelly JP, Chen SC, Kauffman CA et al : Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 71 : 1367-1376, 2020
 
3) 深在性真菌症のガイドライン作成委員会編 : 深在性真菌症の診断・治療ガイドライン 2014. 協和企画, 2014
 
4) 日本医真菌学会クリプトコックス症の診断・治療ガイドライン作成委員会編 : クリプトコックス症の診断・治療ガイドライン 2019. 日本医真菌学会, 2019
 
5) Linder KA, Kauffman CA, Miceli MH : Performance of Aspergillus galactomannan lateral flow assay on bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis. J Fungi (Basel) 6 : 297, 2020
PubMed
6) Forsberg K, Woodworth K, Walters M et al : Candida auris : the recent emergence of a multidrug-resistant fungal pathogen. Med Mycol 57 : 1-12, 2019
PubMed
7) Goto N, Futamura K, Okada M et al : Management of Pneumocystis jirovecii Pneumonia in Kidney Transplantation to Prevent Further Outbreak. Clin Med Insights Circ Respir Pulm Med 9 : 81-90, 2015
PubMed
8) Richardson MD : Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 56 : 5-11, 2005
 
9) Casadevall A : Fungal diseases in the 21st century : the near and far horizons. Pathog Immun 3 : 183-196, 2018
PubMed
10) van Rhijn N, Bromley M : The Consequences of our changing environment on life threatening and debilitating fungal diseases in humans. J Fungi (Basel) 7 : 367, 2021
PubMed
11) Bongomin F, Gago S, Oladele RO et al : Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel) 3 : 57, 2017
PubMed
P.58 掲載の参考文献
12) Benedict K, Jackson BR, Chiller T et al : Estimation of direct healthcare costs of fungal diseases in the United States. Clin Infect Dis 68 : 1791-1797, 2019
PubMed
13) Wiederhold NP, Verweij PE : Aspergillus fumigatus and pan-azole resistance : who should be concerned? Curr Opin Infect Dis 33 : 290-297, 2020
PubMed
14) Ciociola T, Giovati L, Conti S et al : Antiinfective antibody-derived peptides active against endogenous and exogenous fungi. Microorganisms 9 : 143, 2021
PubMed
15) Bassetti M, Vena A, Bouza E et al : Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections : are the MICs useful for clinicians? Clin Microbiol Infect 26 : 1024-1033, 2020
PubMed
16) Xu Y, Chen M, Zhu J et al : Aspergillus species in lower respiratory tract of hospitalized patients from Shanghai, China : Species diversity and emerging azole resistance. Infect Drug Resist 13 : 4663-4672, 2020
 
P.59 掲載の参考文献
17) Latge JP, Chamilos G : Aspergillus fumigatus and Aspergillosis in 2019. Clin Microbiol Rev 33 : e00140-18, 2019
PubMed
18) Maitre T, Cottenet J, Godet C et al : Chronic pulmonary aspergillosis : prevalence, favouring pulmonary diseases and prognosis. Eur Respir J 21 : 2003345, 2021
 
19) Lestrade PPA, Buil JB, van der Beek MT et al : Paradoxal trends in azole-resistant Aspergillus fumigatus in a national multicenter surveillance program, the Netherlands, 2013-2018. Emerg Infect Dis 26 : 1447-1455, 2020
 
20) Tsuchido Y, Tanaka M, Nakano S et al : Prospective multicenter surveillance of clinically isolated Aspergillus species revealed azole-resistant Aspergillus fumigatus isolates with TR34/L98H mutation in the Kyoto and Shiga regions of Japan. Med Mycol 57 : 997-1003, 2019
PubMed
21) Macedo D, Leonardelli F, Gamarra S et al : Emergence of triazole resistance in Aspergillus spp. in Latin America. Curr Fungal Infect Rep 19 : 1-11, 2021
 
22) Cadena J, Thompson GR 3rd, Patterson TF : Aspergillosis : Epidemiology, diagnosis, and treatment. Infect Dis Clin North Am 35 : 415-434, 2021
PubMed
23) Fekkar A, Poignon C, Blaize M et al : Fungal infection during COVID-19 : Does Aspergillus mean secondary invasive aspergillosis? Am J Respir Crit Care Med 202 : 902-903, 2020
PubMed
24) Wall G, Lopez-Ribot JL : Current antimycotics, new prospects, and future approaches to antifungal therapy. Antibiotics (Basel) 9 : 445, 2020
 
P.60 掲載の参考文献
25) Lestrade PPA, Meis JF, Melchers WJG et al : Triazole resistance in Aspergillus fumigatus : recent insights and challenges for patient management. Clin Microbiol Infect 25 : 799-806, 2019
PubMed
26) Bassetti M, Azoulay E, Kullberg BJ et al : EORTC/MSGERC Definitions of Invasive Fungal Diseases : Summary of Activities of the Intensive Care Unit Working Group. Clin Infect Dis 72 : S121-S127, 2021
 
27) Arastehfar A, Carvalho A, van de Veerdonk F et al : COVID-19 associated pulmonary aspergillosis (CAPA) -from immunology to treatment. J Fungi (Basel) 6 : 91, 2020
PubMed
28) Buchanan KL, Murphy JW : What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis 4 : 71-83, 1998
PubMed
29) Shoham S, Levitz SM : The immune response to fungal infections. Br J Haematol 129 : 569-582, 2005
PubMed
P.61 掲載の参考文献
30) Denham ST, Brown JCS : Mechanisms of pulmonary escape and dissemination by Cryptococcus neoformans. J Fungi 4 : 25, 2018
PubMed
31) 河手-堀内絵理子, 石黒卓, 大楠美佐子 他 : Cryptococcus gattiiによる肺クリプトコッカス症の1例. 日呼吸会誌 9 : 355-359, 2020
 
32) Firacative C, Meyer W, Castaneda E : Cryptococcus neoformans and Cryptococcus gattii Species Complexes in Latin America : A map of molecular types, genotypic diversity, and antifungal susceptibility as reported by the Latin American Cryptococcal Study Group. J Fungi (Basel) 7 : 282, 2021
 
33) Woo YH, Martinez LR : Cryptococcus neoformans-astrocyte interactions : effect on fungal blood brain barrier disruption, brain invasion, and meningitis progression. Crit Rev Microbiol 47 : 206-223, 2021
PubMed
34) Yang B, Lee H, Lee T et al : The use of surgery in a real-world clinic to diagnose and treat pulmonary cryptococcosis in immunocompetent patients. J Thorac Dis 11 : 1251-1260, 2019
 
P.62 掲載の参考文献
35) Catherinot E, Lanternier F, Bougnoux ME et al : Pneumocystis jirovecii pneumonia. Infect Dis Clin North Am 24 : 107-138, 2010
PubMed
36) Nakashima K, Aoshima M, Ohkuni Y et al : Loop-mediated isothermal amplification method for diagnosing Pneumocystis pneumonia in HIVuninfected immunocompromised patients with pulmonary infiltrates. J Infect Chemother 20 (12) : 757-761, 2014
PubMed
37) Del Corpo O, Butler-Laporte G, Sheppard DC et al : Diagnostic accuracy of serum (1-3) -β-D-glucan for Pneumocystis jirovecii pneumonia : a systematic review and meta-analysis. Clin Microbiol Infect 26 : 1137-1143, 2020
 
P.63 掲載の参考文献
38) Brockhurst MA, Harrison F, Veening J-W et al : Assessing evolutionary risks of resistance for new antimicrobial therapies. Nat Ecol Evol 3 : 515-517, 2019
PubMed
P.64 掲載の参考文献
1) Liu JW, Chen YH, Lee WS et al : Randomized noninferiority trial of Cefoperazone-Sulbactam versus Cefepime in the treatment of hospital-acquired and healthcare-associated pneumonia. Antimicrob Agents Chemother 63 : e00023-19, 2019
PubMed
P.65 掲載の参考文献
2) Miyazaki T, Nakamura S, Hashiguchi K et al : The efficacy and safety of sitafloxacin and garenoxacin for the treatment of pneumonia in elderly patients : A randomized, multicenter, open-label trial. J Infect Chemother 25 : 886-893, 2019
 
3) Yamagata A, Ito A, Nakanishi Y et al : Prognostic factors in nursing and healthcare-associated pneumonia. J Infect Chemother 26 : 563-569, 2020
PubMed
4) Ebihara T, Miyamoto T, Kozaki K : Prognostic factors of 90-day mortality in older people with healthcare-associated pneumonia. Geriatr Gerontol Int 20 : 1036-1043, 2020
PubMed
5) Asai N, Watanabe H, Shiota A et al : Efficacy and accuracy of qSOFA and SOFA scores as prognostic tools for community-acquired and healthcare-associated pneumonia. Int J Infect Dis 84 : 89-96, 2019
PubMed
P.66 掲載の参考文献
6) Ito A, Ishida T, Tokumasu H et al : Evaluation of pneumonia severity scoring systems in nursing and healthcare-associated pneumonia for predicting prognosis : A prospective, cohort study. J Infect Chemother 26 : 372-378, 2020
PubMed
7) Noguchi S, Yatera K, Naito K et al : Utility of the quick sequential organ failure assessment in Japanese patients with nursing- and healthcare-associated pneumonia. Geriatr Gerontol Int 19 : 177-183, 2019
 
8) Ito A, Ishida T, Tachibana H et al : Is antipseudomonal antibiotic treatment needed for all nursing and healthcare-associated pneumonia patients at risk for antimicrobial resistance? J Glob Antimicrob Resist 22 : 441-447, 2020
PubMed
P.67 掲載の参考文献
9) 小泉健 : 超高齢社会における肺炎入院患者の診療アウトカム～地域病院での肺炎治療の現状. 新潟医学会誌 133 : 109-113, 2019
 
10) 朝野和典 : 成人肺炎診療ガイドライン2017による高齢者肺炎診療の現状と課題. 日本臨床 78 : 570-576, 2020
Medical*Online
11) 佐々木篤志, 清水秀文, 伊藤幸祐他 : 医療・介護関連肺炎により入院した超高齢患者の意思決定と転帰に関する調査. 日呼ケアリハ会誌 29 : 287-291, 2020
 
12) 厚生労働省人生の最終段階における医療の普及・啓発の在り方に関する検討会 : 人生の終段階における医療に関する意識調査報告書. 平成30年3月
 

II章 閉塞性肺疾患

P.70 掲載の参考文献
1) Rabe KF, Martinez FJ, Ferguson GT et al : A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD : The ETHOS study protocol. Respir Med 158 : 59-66, 2019
 
P.71 掲載の参考文献
2) Rabe KF, Martinez FJ, Ferguson GT et al : Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 383 (1) : 35-48, 2020
PubMed
3) Lipson DA, Criner GJ, Lomas DA : Single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 379 (6) : 592-593, 2018
PubMed
4) Lipson DA, Crim C, Criner GJ et al : Reduction in all-cause mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 201 (12) : 1508-1516, 2020
PubMed
5) Halpin DMG, Criner GJ, Dransfield MT et al : Triple versus dual combination therapy in chronic obstructive pulmonary disease in Asian countries : Analysis of the IMPACT Trial. Pulm Ther 7 (1) : 101-118, 2021
PubMed
6) Suissa S, Dell'Aniello S, Ernst P : Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD. Chest 157 (4) : 846-855, 2020
PubMed
7) Kato M, Tomii K, Hashimoto K et al : The IMPACT Study-Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD : Efficacy and safety in a Japanese population. Int J Chron Obstruct Pulmon Dis 14 : 2849-2861, 2019
 
8) 日本呼吸器学会COPDガイドライン第5版作成委員会 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン 第5版 2018. メディカルレビュー社, 2018
 
9) Hashimoto S, Sorimachi R, Ichinose M et al : Asthma and chronic obstructive pulmonary disease overlap according to the Japanese respiratory society diagnostic criteria : The prospective, observational ACO Japan cohort study. Adv Ther 38 (2) : 1168-1184, 2021
 
10) Matsunaga K, Kuwahira I, Hanaoka M et al : An official JRS statement : The principles of fractional exhaled nitric oxide (FeNO) measurement and interpretation of the results in clinical practice. Respir Investig 59 (1) : 34-52, 2021
PubMed
11) Global Initiative for Chronic Obstructive Lung Disease : 2021 GOLD Reports. https://goldcopd.org/2021-gold-reports/
 
P.72 掲載の参考文献
12) Harries TH, Rowland V, Corrigan CJ et al : Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies : systematic review and meta-analysis. Respir Res 21 (1), 2020
 
13) Mammen MJ, Lloyd DR, Kumar S et al : Triple therapy versus dual or monotherapy with long-acting bronchodilators for chronic obstructive pulmonary disease. A systematic review and meta-analysis. Ann Am Thorac Soc 17 (10) : 1308-1318, 2020
PubMed
14) Nici L, Mammen MJ, Charbek E et al : Pharmacologic management of chronic obstructive pulmonary disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 201 (9) : e56-e69, 2020
 
15) Pascoe S, Barnes N, Brusselle G et al : Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease : analysis of the IMPACT trial. Lancet Respir Med 7 (9) : 745-756, 2019
PubMed
16) Pavord ID, Chanez P, Criner GJ et al : Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med 377 (17) : 1613-1629, 2017
PubMed
P.73 掲載の参考文献
17) Pavord I, Chapman K, Bafadhel M et al : Mepolizumab for eosinophil-associated COPD : Analysis of METREX and METREO. Int J Chron Obstruct Pulmon Dis 16 : 1755-1770, 2021
PubMed
18) Criner GJ, Celli BR, Brightling CE et al : Benralizumab for the prevention of COPD exacerbations. N Engl J Med 381 (11) : 1023-1034, 2019
PubMed
19) Criner GJ, Celli BR, Singh D et al : Predicting response to benralizumab in chronic obstructive pulmonary disease : analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med 8 (2) : 158-170, 2020
PubMed
20) Dobler CC, Morrow AS, Beuschel B et al : Pharmacologic therapies in patients with exacerbation of chronic obstructive pulmonary disease : A systematic review with meta-analysis. Ann Intern Med 172 (6) : 413-422, 2020
PubMed
21) Sivapalan P, Lapperre TS, Janner J et al : Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP) : a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med 7 (8) : 699-709, 2019
 
P.74 掲載の参考文献
22) Phillips JE : Inhaled Phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases. Front Pharmacol 11 : 259, 2020
PubMed
23) Singh D, Beeh KM, Colgan B et al : Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD. Respir Res 20 (1), 2019
 
24) Vermeersch K, Gabrovska M, Aumann J et al : Azithromycin during acute chronic obstructive pulmonary disease exacerbations requiring hospitalization (BACE). A multicenter, randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 200 (7) : 857-868, 2019
 
P.75 掲載の参考文献
25) Dransfield MT, Voelker H, Bhatt SP et al : Metoprolol for the prevention of acute exacerbations of COPD. N Engl J Med 381 (24) : 2304-2314, 2019
PubMed
26) Mcdonald VM, Fingleton J, Agusti A et al : Treatable traits : a new paradigm for 21st century management of chronic airway diseases : Treatable Traits Down Under International Workshop report. Eur Respir J 53 (5) : 1802058, 2019
PubMed
27) Mathioudakis AG, Janssens W, Sivapalan P et al : Acute exacerbations of chronic obstructive pulmonary disease : in search of diagnostic biomarkers and treatable traits. Thorax 75 (6) : 520-527, 2020
PubMed
28) Mcdonald VM, Osadnik CR, Gibson PG : Treatable traits in acute exacerbations of chronic airway diseases. Chron Respir Dis 16 : 147997311986795, 2019
PubMed
P.77 掲載の参考文献
1) 日本呼吸ケア・リハビリテーション学会, 日本呼吸理学療法学会, 日本呼吸器学会 : 呼吸リハビリテーションに関するステートメント. 日呼吸ケアリハ会誌 27 : 95-114, 2018
 
2) F Reis L, Guimaraes FS, Lopes AJ et al : Long-term pulmonary rehabilitation progressively reduces hospitalizations and mortality in a cohort of patients with severe and very severe copd : a 5-year follow up. Eur J Phys Rehabil Med, 2021 [online ahead of print]
 
3) Damm K, Lingner H, Schmidt K et al : Preferences of patients with asthma or COPD for treatments in pulmonary rehabilitation. Health Econ Rev 17 : 14, 2021
PubMed
4) Holland AE, Cox NS, Houchen-Wolloff L et al : Defining modern pulmonary rehabilitation. An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc 18 (5) : e12-e29, 2021
 
P.78 掲載の参考文献
5) Garcia Aymerich J : Physical activity and COPD development. Time to advocate. Thorax 74 (9) : 831-832, 2019
PubMed
6) Hansen GM, Marott JL, Holtermann A et al : Midlife cardiorespiratory fitness and the long-term risk of chronic obstructive pulmonary disease. Thorax 4 (9) : 843-848, 2019
 
7) Zhang Y, Zhao X : Effects of the health belief model-based intervention on anxiety, depression, and quality of life in chronic obstructive pulmonary disease. Neuroimmunomodulation 28 (3) : 129-136, 2021
PubMed
8) Roberts NJ, Kidd L, Kirkwood K et al : How is the education component of pulmonary rehabilitation delivered in practice? Is it patient-centred? Clin Respir J 15 (7) : 835-842, 2021
 
P.79 掲載の参考文献
9) Aldhahir AM, Aldabayan YS, Alqahtani JS et al : A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation : a pilot study. ERJ Open Res 7 (1) : 00077-2021, 2021
PubMed
10) Sanchez-Nieto JM, Fernandez-Munoz I, Carrillo-Alcaraz A : Effectiveness of Non-Presential Individualized Exercise Training PrOgram (NIETO) in lower limb physical performance in advanced COPD. J Clin Med 10 (5) : 1010, 2021
PubMed
P.80 掲載の参考文献
11) Gloeckl R, Schneeberger T, Leitl D et al : Whole-body vibration training versus conventional balance training in patients with severe COPD-a randomized, controlled trial. Respir Res 22 (1) : 138, 2021
PubMed
12) Gonzalez-Montesinos JL, Fernandez-Santos JR, Vaz-Pardal C et al : Effects of a rehabilitation programme using a nasal inspiratory restriction device in COPD. Int J Environ Res Public Health 18 (8) : 4207, 2021
 
13) Liu X, Fu C, Hu W et al : The effect of Tai Chi on the pulmonary rehabilitation of chronic obstructive pulmonary disease : a systematic review and meta-analysis. Ann Palliat Med 10 (4) : 3763-3782, 2021
 
14) Dong X, Wang X, Jia N et al : A comparison between Qigong exercise and cycle ergometer exercise for the rehabilitation of chronic obstructive pulmonary disease : A pilot randomized controlled trial (CONSORT). Medicine (Baltimore) 100 (21) : e26010, 2021
 
15) Lindenauer PK, Stefan MS, Pekow PS et al : Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among medicare beneficiaries. JAMA 323 (18) : 1813-1823, 2020
PubMed
P.81 掲載の参考文献
16) Vitacca M, Ambrosino N, Belli S et al : The severity of acute exacerbations of COPD and the effectiveness of pulmonary rehabilitation. Respir Med 184 : 106465, 2021
PubMed
17) Kjargaard JL, Juhl CB, Lange P et al : Early pulmonary rehabilitation after acute exacerbation of COPD : a randomised controlled trial. ERJ Open Res 6 (1) : 00173-2019, 2020
PubMed
18) Kjargaard J, Juhl CB, Lange P et al : Adherence to early pulmonary rehabilitation after COPD exacerbation and risk of hospital readmission : a secondary analysis of the COPD-EXA-REHAB study. BMJ Open Respir Res 7 (1) : e000582, 2020
 
19) Barbosa MT, Sousa CS, Morais-Almeida M et al : Telemedicine in COPD : An overview by topics. COPD 17 (5) : 601-617, 2020
PubMed
20) Nolan CM, Kaliaraju D, Jones SE et al : Home versus outpatient pulmonary rehabilitation in COPD : a propensity-matched cohort study. Thorax 74 (10) : 996-998, 2019
PubMed
P.82 掲載の参考文献
21) Lu Y, Li P, Li N et al : Effects of home-based breathing exercises in subjects with COPD. Respir Care 65 (3) : 377-387, 2020
 
22) Li Y, Qian H, Yu K et al : Nonadherence in home-based pulmonary rehabilitation program for COPD patients. Can Respir J 2020 : 5146765, 2020
 
23) Burge AT, Holland AE, McDonald CF et al : Home-based pulmonary rehabilitation for COPD using minimal resources : An economic analysis. Respirology 25 (2) : 183-190, 2020
PubMed
24) Rutkowski S : Management challenges in chronic obstructive pulmonary disease in the COVID-19 pandemic : Telehealth and virtual reality. J Clin Med 10 (6) : 1261, 2021
PubMed
P.84 掲載の参考文献
1) Finch S, Shoemark A, Dicker AJ et al : Pregnancy zone protein is associated with airway infection, neutrophil extracellular trap formation, and disease severity in bronchiectasis. Am J Respir Crit Care Med 200 : 992-1001, 2019
PubMed
2) Oriano M, Gramegna A, Terranova L et al : Sputum neutrophil elastase associates with microbiota and Pseudomonas aeruginosa in bronchiectasis. Eur Respir J 56 : 2000769, 2020
PubMed
3) Ramsey KA, Chen ACH, Radicioni G et al : Airway mucus hyperconcentration in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 201 : 661-670, 2020
PubMed
4) Ringshausen FC, Rademacher J, Pink I et al : Increasing bronchiectasis prevalence in Germany, 2009-2017 : a population-based cohort study. Eur Respir J 54 : 1900499, 2019
PubMed
5) Choi H, Yang B, Nam H et al : Population-based prevalence of bronchiectasis and associated comorbidities in South Korea. Eur Respir J 54 : 1900194, 2019
PubMed
P.85 掲載の参考文献
6) Kim SH, Jung YJ, Ko MS et al : Prevalence of asymptomatic bronchiectasis and associations among the health screening population in South Korea. ERJ Open Res 7 : 00188-2021, 2021
PubMed
7) Shoemark A, Cant E, Carreto L et al : A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation. Eur Respir J 53 : 1900303, 2019
PubMed
8) Keir HR, Shoemark A, Dicker AJ et al : Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis : an international, observational, multicohort study. Lancet Respir Med, 2021 [online ahead of print]
 
9) Dicker AJ, Lonergan M, Keir HR et al : The sputum microbiome and clinical outcomes in patients with bronchiectasis : a prospective observational study. Lancet Respir Med, 2021 [online ahead of print]
 
P.86 掲載の参考文献
10) Sibila O, Perea L, Canto E et al : Antimicrobial peptides, disease severity and exacerbations in bronchiectasis. Thorax 74 : 835-842, 2019
PubMed
11) Huang JT, Kuzmanova E, Dicker AJ et al : Serum desmosine is associated with long-term all-cause and cardiovascular mortality in bronchiectasis. Am J Respir Crit Care Med 202 : 897-899, 2020
PubMed
12) Alcaraz-Serrano V, Gimeno-Santos E, Scioscia G et al : Association between physical activity and risk of hospitalisation in bronchiectasis. Eur Respir J 55 : 1902138, 2020
 
13) Gao YH, Ado Leyah H, Finch S et al : Relationship between symptoms, exacerbations, and treatment response in bronchiectasis. Am J Respir Crit Care Med 201 : 1499-1507, 2020
 
14) Crichton ML, Dudgeon EK, Shoemark A et al : Validation of the Bronchiectasis Impact Measure (BIM) : a novel patientreported outcome measure. Eur Respir J 57 : 2003156, 2021
 
15) Spinou A, Siegert RJ, Guan WJ et al : The development and validation of the Bronchiectasis Health Questionnaire. Eur Respir J 49 : 1601532, 2017
PubMed
16) Polverino E, Goeminne PC, McDonnell MJ et al : European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 50 : 1700629, 2017
PubMed
17) Laska IF, Crichton ML, Shoemark A et al : The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults : a systematic review and meta-analysis. Lancet Respir Med 7 : 855-869, 2019
PubMed
P.87 掲載の参考文献
18) Barker AF, O'Donnell AE, Flume P et al : Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2) : two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2 : 738-749, 2014
PubMed
19) Crichton ML, Lonergan M, Barker A et al : Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis : a post hoc analysis of the AIR-BX studies. Eur Respir J 56 : 2000608, 2020
PubMed
20) Sibila O, Laserna E, Shoemark A et al : Airway bacterial load and inhaled antibiotic response in bronchiectasis. Am J Respir Crit Care Med 200 : 33-41, 2019
PubMed
21) Haworth CS, Bilton D, Chalmers JD et al : Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Psudomonas aeruginosa (ORBIT-3 and ORBIT-4) : two phase 3, randomised controlled trials. Lancet Respir Med 7 : 213-226, 2019
 
22) Chalmers JD, Cipolla D, Thompson B et al : Changes in respiratory symptoms during 48-weel treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis : results from the ORBIT-3 and -4 studies. Eur Respir J 56 : 2000110, 2020
 
23) Chalmers JD, Boersma W, Lonergan M et al : Long-term macrolide antibiotics for the treatment of bronchiectasis in adults : an individual participant data meta-analysis. Lancet Respir Med 7 : 845-854, 2019
PubMed
24) Henkle E, Curtis JR, Chen L et al : Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. Eur Respir J 54 : 1801896, 2019
PubMed
25) Aliberti S, Sotgiu G, Blasi F et al : Blood eosinophils predict inhaled fluticasone response in bronchiectasis. Eur Respir J 56 : 2000453, 2020
PubMed
26) Aliberti S, Sotgiu G, Martinez Garcia MA : Blood eosinophils do not predict inhaled budesonide response in bronchiectasis. Eur Respir J 56 : 2002210, 2020
 
P.88 掲載の参考文献
27) Chalmers JD, Haworth CS, Metersky ML et al : Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med 383 : 2127-2137, 2020
PubMed
P.90 掲載の参考文献
1) 日本呼吸器学会 咳嗽・喀痰の診療ガイドライン2019作成委員会編 : 咳嗽・喀痰の診療ガイドライン. メディカルレビュー社, pp56-58, 2019
 
P.91 掲載の参考文献
2) Langton Hewer SC, Smyth AR : Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 4 (4) : CD004197, 2017
 
P.92 掲載の参考文献
3) Weng D, Wu Q, Chen XQ et al : Azithromycin treats diffuse panbronchiolitis by targeting T cells via inhibition of mTOR pathway. Biomed Pharmacother 110 : 440-448, 2019
 
P.93 掲載の参考文献
4) Yamakawa H, Takemura T, Sato S et al : The usefulness of a transbronchial lung cryobiopsy for diffuse bronchiolitis. Intern Med 60 (9) : 1457-1462, 2021
PubMed
5) Sirol Aflah Syazatul S, Piciucchi S, Tomassetti S et al : Cryobiopsy in the diagnosis of bronchiolitis : a retrospective analysis of twenty-three consecutive patients. Sci Rep 10 (1) : 10906, 2020
PubMed
6) Keicho N, Hijikata M, Morimoto K et al : Primary ciliary dyskinesia caused by a large homozygous deletion including exons 1-4 of DRC1 in Japanese patients with recurrent sinopulmonary infection. Mol Genet Genomic Med 8 (1) : e1033, 2020
 
P.94 掲載の参考文献
7) Inaba A, Furuhata M, Morimoto K et al : Primary ciliary dyskinesia in Japan : systematic review and meta-analysis. BMC Pulm Med 19 (1) : 135, 2019
 
8) Middleton PG, Mall MA, Dievinek P et al : Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele. N Engl J Med 381 (19) : 1809-1819, 2019
 
9) Shibata S, Ajiro M, Hagiwara M : Mechanism-based personalized medicine for cystic fibrosis by suppressing pseudo exon inclusion. Cell Chem Biol 27 (12) : 1472-1482. e1476, 2020
 
10) Nichols DP, Odem-Davis K, Cogen JD et al : Pulmonary outcomes associated with long-term azithromycin therapy in cystic fibrosis. Am J Respir Crit Care Med 201 (4) : 430-437, 2020
PubMed
11) Weinberger M, Lesser D : Diffuse panbronchiolitis : A progressive fatal lung disease that is curable with azithromycin, but only if diagnosed! Pediatr Pulmonol 54 (4) : 457-462, 2019
PubMed

III章 間質性肺疾患

P.97 掲載の参考文献
1) Drake TM, Docherty AB, Harrison EM et al : Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study. Am J Respir Crit Care Med 2020 : 1656-1665, 2020
PubMed
2) Umemura Y, Mitsuyama Y, Minami K et al : Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by Coronavirus disease 2019 : An interventional study. Int J Infect Dis 108 : 454-460, 2021
PubMed
3) Wong AW, Fidler L, Marcoux V et al : Practical consideration for the diagnosis and treatment of fibrotic interstitial lung disease during of the coronavirus disease 2019 pandemic. CHEST 158 : 1069-1078, 2020
PubMed
4) Troy LK, Grainge C, Corte TJ et al : Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE) : a prospective, comparative study. Lancet Respir Med 8 : 171-181, 2020
PubMed
P.98 掲載の参考文献
5) Cooper WA, Mahar A, Myers JL et al : Cryobiopsy for identification of usual interstitial pneumonia and other interstitial lung disease features. Further lessons from COLDICE, a prospective multicenter clinical trial. Am J Respir Crit Care Med 203 : 1656-1665, 2021
 
6) Hetzel J, Wells AU, Costabel U et al : Transbrochial cryobiopsy increases diagnostic confidence in interstitial lung disease : a prospective multicenter trial. Eur Respir J 56 : 1901520, 2020
 
7) 冨岡洋海, 坂東政司, 近藤康博 : びまん性肺疾患のmultidisciplinary discussion診断に関するアンケート調査結果. 日呼吸誌 10 (2) : 97-101, 2021
 
8) Hatabu H, Hunninghake GM, Richeldi L et al : Interstitial lung abnormalities detected incidentally on CT : a position paper from Fleischner Society. Lancet Respir Med 8 : 726-737, 2020
 
P.99 掲載の参考文献
9) Hino T, Lee KS, Yoo H et al : Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP). Eur J Radiol Open 8 : 100336, 2021
PubMed
10) Sgalla G, Lo Greco E, Calvello M et al : Disease progression across the spectrum of idiopathic pulmonary fibrosis : a multicenter study. Respirology 25 : 1144-1151, 2020
PubMed
11) Flaherty KR, Wells AU, Cottin V et al : Nintedanib in progressive fibrosing interstitial lung disease. N Engl J Med 381 : 1718-1727, 2019
PubMed
P.100 掲載の参考文献
12) Wells A, Flaherty KR, Brown KK et al : Nintedanib in progressive fibrosing interstitial lung disease-subgroup analysis by interstitial lung diseases diagnosis in the INBUILD trial : a randomized, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 8 : 453-460, 2020
 
13) Maher TM, Corte TJ, Fischer A et al : Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease : a double-blind, randomized, placebo-controlled, phase 2 trial. Lancet Respir Med 8 : 147-157, 2020
PubMed
14) Behr J, Prasse A, Kreuter M et al : Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIFE) : a double-blind, randomized, placebo-controlled, phase 2b trial. Lancet Respir Med 9 : 476-486, 2021
 
15) Song JW, Ogura T, Inoue Y et al : Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis : results from INPULSIS-ON. Respirology 25 : 410-416, 2020
PubMed
P.101 掲載の参考文献
16) Behr J, Prasse A, Writz H et al : Survival and course of lung function in the presence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis : long term results of the INSIGHTS-IPF registry. Eur Respir J 56 : 1902279, 2020
 
17) Leuschner G, Klotsche J, Kreuter M et al : Idiopathic pulmonary fibrosis in elderly patients : analysis of the INSIGHTS-IPF observational study. Front Med 7 : 601279, 2020
PubMed
18) Kang J, Han M, Song JW et al : Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis : a propensity score matching analysis. Sci Rep 24 : 15620, 2020
 
P.102 掲載の参考文献
19) Belhassen M, Dalton F, Nolin M et al : Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. Respir Res 22 : 135, 2021
PubMed
20) Hisata S, Bando M, Homma S et al : Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis : a multicenter retrospective observational study in Japan. Respir Investig, 2021 [online ahead of print]
 
21) Richeldi L, Fernandez Perez ER, Costabel U et al : Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE) : a phase 2, randomized, double-blind, placebo-controlled trial. Lancet Respir Med 8 : 25-33, 2020
PubMed
P.103 掲載の参考文献
22) Kreuter M, Polke M, Walsh SLF et al : Acute exacerbation of idiopathic pulmonary fibrosis : international survey and call for harmonization. Eur Respir J 55 : 1901760, 2020
 
23) Suzuki T, Hozumi H, Miyashita K et al : Prognostic classification in acute exacerbation of idiopathic pulmonary fibrosis : a multicenter retrospective cohort study. Sci Rep 11 : 9120, 2021
PubMed
24) Moor CC, Mostard RML, Grutters JC et al : Home Monitoring in Patients with idiopathic pulmonary fibrosis. A randomized controlled trial. Am J Respir Crit Care Med 202 : 393-401, 2020
 
25) 井上義一, 滝沢綾子, Birring SS : 間質性肺疾患に関する簡易健康状態質問表KBILD日本語版の開発. 日呼吸誌 8 (6) : 386-390, 2019
 
P.104 掲載の参考文献
1) Konishi K et al. Am J Respir Crit Care Med 180 (2) : 167-175, 2009
PubMed
2) Wootton SC et al. Am J Respir Crit Care Med 183 (12) : 1698e702, 2011
PubMed
P.105 掲載の参考文献
3) Saraya T, Kimura H, Kurai D et al : Clinical significance of respiratory virus detection in patients with acute exacerbation of interstitial lung diseases. Respir Med 136 : 88-92, 2018
PubMed
4) Drake TM, Docherty AB, Harrison EM et al ; ISARIC4C Investigators : Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study. Am J Respir Crit Care Med 202 (12) : 1656e65, 2020
PubMed
5) Kondoh Y, Kataoka K, Ando M et al : COVID-19 and acute exacerbation of interstitial lung disease. Respir Investig 59 (5) : 675-678, 2021
PubMed
6) D'Alessandro-Gabazza CN, Kobayashi T, Yasuma T et al : A Staphylococcus proapoptotic peptide induces acute exacerbation of pulmonary fibrosis. Nat Commun 11 (1) : 1539, 2020
PubMed
P.106 掲載の参考文献
7) Ryu C, Sun H, Gulati M et al : Extracellular mitochondrial DNA is generated by fibroblasts and predicts death in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 196 (12) : 1571-1581, 2017
 
8) Sakamoto K, Furukawa T, Yamano Y : Serum mitochondrial DNA predicts the risk of acute exacerbation and progression of idiopathic pulmonary fibrosis. Eur Respir J 57 (1) : 2001346, 2021
PubMed
9) Newton CA, Oldham JM, Ley B et al : Telomere length and genetic variant associations with interstitial lung disease progression and survival. Eur Respir J 53 (4) : 1801641, 2019
PubMed
10) Ley B, Liu S, Elicker BM et al : Telomere length in patients with unclassifiable interstitial lung disease : a cohort study. Eur Respir J 56 (2) : 2000268, 2020
PubMed
P.107 掲載の参考文献
11) Tomos I, Karakatsani A, Manali ED et al : Telomere length across different UIP fibrotic-Interstitial Lung Diseases : a prospective Greek case-control study. Pulmonology, 2020 [online ahead of print]
 
12) Suzuki A, Kondoh Y, Brown KK et al : Acute exacerbations of fibrotic interstitial lung diseases. Respirology 25 (5) : 525-534, 2020
PubMed
13) Murohashi K, Hara Y, Saigusa Y et al : Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute or subacute idiopathic interstitial pneumonias and acute exacerbation of collagen vascular diseases-related interstitial pneumonia. J Thorac Dis 11 : 2448-2457, 2019
PubMed
14) Enomoto N, Oyama Y, Enomoto Y et al : Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis. Chron Respir Dis 16 : 1479972318809476, 2019
PubMed
15) Enomoto N, Naoi H, Aono Y et al : Acute exacerbation of unclassifiable idiopathic interstitial pneumonia : comparison with idiopathic pulmonary fibrosis. Ther Adv Respir Dis 14 : 1753466620935774, 2020
PubMed
16) Miyashita K, Kono M, Saito G et al : Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis. Clin Respir J 15 (3) : 336-344, 2021
PubMed
17) Cao M, Sheng J, Qiu X et al : Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases : a population-based study. BMC Pulm Med 19 : 215, 2019
 
18) Salonen J, Purokivi M, Bloigu R et al : Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases. BMJ Open Respir Res 7 (1) : e000563, 2020
 
19) Alhamad EH, Cal JG, Alrajhi NN et al : Acute exacerbation in interstitial lung disease. Ann Thorac Med 16 (2) : 178-187, 2021
PubMed
P.108 掲載の参考文献
20) Kreuter M, Koegler H, Trampisch M et al : Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF) : insights from the INPULSIS(R) trials. Respir Res 20 (1) : 71, 2019
 
21) Arai T, Tachibana K, Sugimoto C et al : High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias. Respirology 22 (7) : 1363-1370, 2017
PubMed
22) Jang HJ, Yong SH, Leem AY et al : Corticosteroid responsiveness in patients with acute exacerbation of interstitial lung disease admitted to the emergency department. Sci Rep 11 (1) : 5762, 2021
 
23) Farrand E, Vittinghoff E, Ley B et al : Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF. Respirology 25 (6) : 629-635, 2020
PubMed
24) Kreuter M, Polke M, Walsh SLF et al : Acute exacerbation of idiopathic pulmonary fibrosis : international survey and call for harmonisation. Eur Respir J 55 (4) : 1901760, 2020
PubMed
P.109 掲載の参考文献
25) Hozumi H, Hasegawa H, Miyashita K et al : Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis : A propensity score-matched analysis. Respirology 24 (8) : 792-798, 2019
PubMed
26) Naccache JM, Jouneau S, Didier M et al : Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med, 2021 [online ahead of print]
 
27) Yamazaki R, Nishiyama O, Saeki S et al : The utility of the Japanese Association for Acute Medicine DIC scoring system for predicting survival in acute exacerbation of fibrosing idiopathic interstitial pneumonia. PLoS One 14 (8) : e0212810, 2019
 
P.110 掲載の参考文献
28) Arai T, Kida H, Ogata Y et al ; Osaka Acute Exacerbation of Interstitial Pneumonia Research Group : Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias. Respirology 24 (7) : 658-666, 2019
 
29) Kondoh Y, Azuma A, Inoue Y et al : Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis. A randomized, double-blind placebo-controlled trial. Am J Respir Crit Care Med 201 (9) : 1110-1119, 2020
PubMed
30) Kang J, Han M, Song JW : Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis : a propensity score matching analysis. Sci Rep 10 (1) : 15620, 2020
 
P.111 掲載の参考文献
31) Dotan Y, Vaidy A, Shapiro WB et al : Effect of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Lung Transplantation Outcome. Chest 154 (4) : 818-826, 2018
PubMed
32) Chizinga M, Machuca TN, Shahmohammadi A et al : Lung transplantation for acute exacerbation of interstitial lung disease. Thorax, 2021 [online ahead of print]
 

IV章 肺胞性肺疾患

P.114 掲載の参考文献
1) 井上義一, 平成22～23年度厚生労働省科学研究費補助金難治性疾患克服研究事業肺胞蛋白症の難治化要因の解明, 診断, 治療, 管理の標準化と指針の確立研究班 : 肺胞蛋白症の診断, 治療, 管理の指針. 2012
 
2) Salvaterra E, Campo I : Pulmonary alveolar proteinosis : from classification to therapy. Breathe (Sheffield, England) 16 (2) : 200018, 2020
 
3) Suzuki T, Sakagami T, Rubin BK et al : Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 205 (12) : 2703-2710, 2008
PubMed
4) Tanaka T, Motoi N, Tsuchihashi Y et al : Adult-onset hereditary pulmonary alveolar proteinosis caused by a single-base deletion in CSF2RB. J Med Genet 48 (3) : 205-209, 2011
PubMed
5) Brasch F, Birzele J, Ochs M et al : Surfactant proteins in pulmonary alveolar proteinosis in adults. Eur Respir J 24 (3) : 426-435, 2004
PubMed
P.115 掲載の参考文献
6) Nogee LM, Garnier G, Dietz HC et al : A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 93 (4) : 1860-1863, 1994
PubMed
7) Mildenberger E, deMello DE, Lin Z et al : Focal congenital alveolar proteinosis associated with abnormal surfactant protein B messenger RNA. Chest 119 (2) : 645-647, 2001
PubMed
8) Yokota T, Matsumura Y, Ban N et al : Heterozygous ABCA3 mutation associated with non-fatal evolution of respiratory distress. Eur J Pediatr 167 (6) : 691-693, 2008
PubMed
9) Iwatani N, Mabe H, Devriendt K et al : Deletion of NKX2.1 gene encoding thyroid transcription factor-1 in two siblings with hypothyroidism and respiratory failure. J Pediatr 137 (2) : 272-276, 2000
PubMed
10) Sakaue S, Yamaguchi E, Inoue Y et al : Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis. Nat Commun 12 (1) : 1032, 2021
PubMed
11) Uchida K, Nakata K, Carey B et al : Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. J Immunol Methods 402 (1-2) : 57-70, 2014
 
12) Ito M, Nakagome K, Ohta H et al : Elderly-onset hereditary pulmonary alveolar proteinosis and its cytokine profile. BMC Pulm Med 17 (1) : 40, 2017
PubMed
P.116 掲載の参考文献
13) Kusakabe Y, Uchida K, Hiruma T et al : A standardized blood test for the routine clinical diagnosis of impaired GM-CSF signaling using flow cytometry. J Immunol Methods 413 : 1-11, 2014
PubMed
14) Inoue Y, Trapnell BC, Tazawa R et al : Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 177 (7) : 752-762, 2008
PubMed
15) Campo I, Luisetti M, Griese M et al : Whole lung lavage therapy for pulmonary alveolar proteinosis : a global survey of current practices and procedures. Orphanet J Rare Dis 11 (1) : 115, 2016
PubMed
P.117 掲載の参考文献
16) Tashiro T, Tomita Y, Inaba M et al : Severe pulmonary alveolar proteinosis with respiratory failure treated by intrapulmonary percussive ventilation. Respirol case reports 8 (9) : e00676, 2020
 
17) Sheng G, Chen P, Wei Y et al : Better approach for autoimmune pulmonary alveolar proteinosis treatment : inhaled or subcutaneous granulocyte-macrophage colony-stimulating factor : a meta-analyses. Respir Res 19 (1) : 163, 2018
 
18) Tazawa R, Ueda T, Abe M et al : Inhaled GM-CSF for pulmonary alveolar proteinosis. N Engl J Med 381 (10) : 923-932, 2019
PubMed
19) Trapnell BC, Inoue Y, Bonella F et al : Inhaled molgramostim therapy in autoimmune pulmonary alveolar proteinosis. N Engl J Med 383 (17) : 1635-1644, 2020
PubMed
P.118 掲載の参考文献
20) McCarthy C, Lee E, Bridges JP et al : Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis. Nat Commun 9 (1) : 3127, 2018
PubMed
21) Shi S, Wang R, Chen L et al : Long-term follow-up and successful treatment of pulmonary alveolar proteinosis without hypercholesterolemia with statin therapy : a case report. J Int Med Res 49 (4) : 3000605211010046, 2021
 
22) Dupin C, Hurtado M, Cazes A et al : Pioglitazone in pulmonary alveolar proteinosis : promising first clinical experience. Respir Med Res 78 : 100756, 2020
PubMed
P.119 掲載の参考文献
23) Soyez B, Borie R, Menard C et al : Rituximab for auto-immune alveolar proteinosis, a real life cohort study. Respir Res 19 (1) : 74, 2018
 
24) Kavuru MS, Malur A, Marshall I et al : An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J 38 (6) : 1361-1367, 2011
PubMed
25) Ioachimescu OC, Sieber S, Kotch A : Idiopathic pulmonary haemosiderosis revisited. Eur Respir J 24 (1) : 162-170, 2004
PubMed
26) Saha BK : Idiopathic pulmonary hemosiderosis : A state of the art review. Respir Med 176 : 106234, 2021
PubMed
P.120 掲載の参考文献
27) Stainer A, Rice A, Devaraj A et al : Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults. BMC Pulm Med 19 (1) : 185, 2019
 
28) Saha BK, Chong WH, Milman NT : Differentiation of idiopathic pulmonary hemosiderosis from rheumatologic and autoimmune diseases causing diffuse alveolar hemorrhage : establishing a diagnostic approach. Clin Rheumatol, 2021 [online ahead of print]
 
29) Sethi GR, Singhal KK, Puri AS et al : Benefit of gluten-free diet in idiopathic pulmonary hemosiderosis in association with celiac disease. Pediatr Pulmonol 46 (3) : 302-305, 2011
PubMed
30) Alimi A, Taytard J, Abou Taam R et al : Pulmonary hemosiderosis in children with Down syndrome : a national experience. Orphanet J Rare Dis 13 (1) : 60, 2018
PubMed
31) Yang CT, Chiang BL, Wang LC : Aggressive corticosteroid treatment in childhood idiopathic pulmonary hemosiderosis with better outcome. J Formos Med Assoc 120 (2) : 838-846, 2021
PubMed
32) Calabrese F, Giacometti C, Rea F et al : Recurrence of idiopathic pulmonary hemosiderosis in a young adult patient after bilateral single-lung transplantation. Transplantation 74 (11) : 1643-1645, 2002
 
33) Ross B, Halloran K, Adam B et al : Disease recurrence after lung transplantation for idiopathic pulmonary hemosiderosis. Respir Med Case Rep 30 : 101128, 2020
PubMed

V章 肺循環障害に起因する肺疾患

P.122 掲載の参考文献
1) Simonneau G, Montani D, Celermajer DS et al : Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53 (1) : 1801913, 2019
PubMed
2) Kovacs G, Berghold A, Scheidl S et al : Pulmonary arterial pressure during rest and exercise in healthy subjects : a systematic review. Eur Respir J 34 (4) : 888-894, 2009
PubMed
P.123 掲載の参考文献
3) Maron BA, Hess E, Maddox TM et al : Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort : Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation 133 (13) : 1240-1248, 2016
 
4) Galie N, McLaughlin VV, Rubin LJ et al : An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J 53 (1) : 1802148, 2019
PubMed
5) 日本循環器学会, 日本肺高血圧・肺循環学会, 日本呼吸器学会他 : 肺高血圧症治療ガイドライン (2017年改訂版) https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_fukuda_h.pdf
 
P.128 掲載の参考文献
1) Konstantinides SV, Meyer G, Becattini C et al : 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Repiratory Society. Eur Heart J 41 (4) : 543-603, 2020
 
2) 伊藤正明, 池田正孝, 石橋宏之他 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2017_ito_h.pdf
 
3) Barco S, Schmidtmann I, Ageno W et al : Early discharge and home treatment of patients with low-risk pulmonary embolismwith the oral factor Xa inhibitor rivaroxaban : an international multicentre single-arm clinical trial. Eur Heart J 41 : 509-518, 2020
 
P.129 掲載の参考文献
4) Agnelli G, Becattini C, Meyer G et al : Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382 : 1599-1607, 2020
PubMed
5) Giustozzi M, Agnelli G, Del Toro-Cervera J et al : Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer : A systematic review and meta-analysis. Thromb Haemost 120 : 1128-1136, 2020
 
6) Di Nisio M, van Es N, Carrier M et al : Extended treatment with edoxaban in cancer patients with venous thromboembolism : A post-hoc analysis of the Hokusai-VTE Cancer study J Thromb Haemost 17 : 1866-1874, 2019
PubMed
7) Yamashita Y, Murata K, Morimoto T et al : Clinical outcomes of patients with pulmonary embolism versus deep vein thrombosis : From the COMMAND VTE Registry Thromb Res 184 : 50-57, 2019
PubMed
8) Yamashita Y, Morimoto T, Amano H et al : Validation of simplified PESI score or identification of low-risk patients with pulmonary embolism : From the COMMAND VTE Registry. Eur Heart J Acute Cardiovasc Care 9 : 262-270, 2020
PubMed
P.130 掲載の参考文献
9) Yamashita Y, Morimoto T, Amano H et al : Usefulness of simplified pulmonary embolism severity index score for identification of patients with low-risk pulmonary embolism and active cancer : From the COMMAND VTE Registry. CHEST 157 : 636-644, 2020
PubMed
10) Sakamoto J, Yamashita Y, Morimoto T et al : Cancer-associated venous thromboembolism in the real world - From the COMMAND VTE Registry. Circ J 83 : 2271-2281, 2019
PubMed
11) Nishimoto Y, Yamashita Y, Kim K et al : Risk factors for major bleeding during anticoagulation therapy in cancer-associated venous thromboembolism - From the COMMAND VTE Registry. Circ J 84 : 2006-2014, 2020
PubMed
12) Oi M, Yamashita Y, Toyufuku M et al : D-dimer levels at diagnosis and long-term clinical outcomes in venous thromboembolism : from the COMMAND VTE Registry. J Thromb Thrombolysis 49 : 551-561, 2020
 
13) Ohashi Y, Ikeda M, Kunitoh H et al : Venous thromboembolism in cancer patients : report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn J Clin Oncol 50 (11) : 1246-1253, 2020
PubMed
P.131 掲載の参考文献
14) Malas MB, Naazie IN, Elsayed N et al : Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality : A systematic review and meta-analysis. EClinical Medicine 29 : 100639, 2020
 
15) Iba T, Levy JH, Levi M et al : Coagulopathy in COVID-19. J Thromb Haemost 18 (9) : 2103-2109, 2020
PubMed
16) Zhou F, Yu T, Du R et al : Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study. Lancet 395 (10229) : 1054-1062, 2020
 
17) Tang N, Bai H, Chen X et al : Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18 : 1094-1099, 2020
 
18) Moores LK, Tritschler T, Brosnahan S et al : Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019 ; CHEST Guideline and Expert Panel Report. CHEST 158 (3) : 1143-1163, 2020
 
19) Paranjpe I, Fuster V, Lala A et al : Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 76 : 122-124, 2020
PubMed
20) Lemos ACB, do Espirito Santo DA, Salvetti MC et al : Therapeutic versus prophylactic anticoagulation for severe COVID-19 : a randomized phase II clinical trial (HESACOVID). Thromb Res 196 : 359-366, 2020
PubMed
21) INSPIRATION Investigators ; Sadeghipour P, Talasaz AH, Rashidi F et al : Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit : The INSPIRATION Randomized Clinical Trial. JAMA 325 (16) : 1620-1630, 2021
PubMed
22) Al-Samkari H, Gupta S, Leaf RK et al : Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19. Ann Intern Med 174 (5) : 622-632, 2021
PubMed
23) 日本静脈学会, 肺塞栓症研究会, 日本血管外科学会, 日本脈管学会 : 新型コロナウイルス感染症 (COVID-19) における静脈血栓塞栓症予防の診療指針. 2021年4月5日版 (Version 2.0) https://js-phlebology.jp/?p=3481
 
P.132 掲載の参考文献
24) Yamashita Y, Hara N, Obana O et al : Clinical features of venous thromboembolism in patients with coronavirus disease 2019 (COVID-19) in Japan-A Case Series Study-. Cir J 85 : 309-313, 2021132
 
25) Fujiwara S, Nakajima M, Haszynski RH et al : Prevalence of thromboembolic events and status of prophylactic anticoagulant therapy in hospitalized patients with COVID-19 in Japan. J Infect Chemother 27 : 869-875, 2021
 
26) Horiuchi H, Morishita E, Urano T et al ; Questionnaire-survey Joint Team on The COVID-19-related thrombosis : COVID-19-related thrombosis in Japan : Final report of a questionnaire-based survey in 2020. J Atheroroscler Thromb 28 : 406-416, 2021
 
27) Yamashita Y, Maruyama Y, Satokawa H et al : Incidence and clinical features of venous thromboembolism in hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan. Circ J, 2021 [online ahead of print]
 
28) Barco S, Russo M, Vicaut E et al : Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Clin Res Cardiol 108 (7) : 772-778, 2019
PubMed
P.133 掲載の参考文献
29) Zoppellaro G, Badawy MR, Squizzato A et al : Balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension-A systematic review and meta-analysis. Circ J 83 : 1660-1667, 2019
PubMed
30) Tanabe N, Fukuda K, Matsubara H et al : Selexipag for chronic thromboembolic pulmonary hypertension in Japanese patients-A double-blind, randomized, placebo-controlled, multicenter phase II study-. Circ J 84 : 1866-1874, 2020
PubMed
31) Tanabe N, Ogo T, Hatano M et al : Safety and effectiveness of riociguat for chronic thromboembolic pulmonary hypertension in real-world clinical practice : interim data from post-marketing surveillance in Japan. Pulm Circ 10 (3) : 2045894020938986, 2020
PubMed
32) Kalra R, Duval S, Thenappan T et al : Comparison of balloon pulmonary angioplasty and pulmonary vasodilators for inoperable chronic thromboembolic pulmonary hypertension : A systematic review and meta-analysis. Sci Rep 10 : 8870, 2020
PubMed
33) Kawakami T, Matsubara H, Abe K et al : Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension : protocol for the MR BPA study. BMJ Open 10 (2) : e028831, 2020
 

VI章 アレルギー性肺疾患

P.136 掲載の参考文献
1) 厚生労働省 : 人口動態統計 (確定数の概況) https://www.mhlw.go.jp/toukei/list/81-1a.html
 
P.137 掲載の参考文献
2) Nagase H, Adachi M, Matsunaga K et al : Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int 69 (1) : 53-60, 2020
PubMed
3) Gon Y, Ohyanagi N, Kobayashi A : The association between control level and self-reported treatment adherence across different treatment types in Japanese asthma patients. Respir Investig 59 (4) : 454-463, 2021
PubMed
4) 日本アレルギー学会喘息ガイドライン専門部委員会監 : 喘息予防・管理ガイドライン 2018. 協和企画, 2018
 
5) 日本アレルギー学会監 : アレルギー総合ガイドライン 2019. 協和企画, 2019
 
P.138 掲載の参考文献
6) Clarridge K, Chin S, Eworuke E et al : A Boxed Warning for Montelukast : The FDA Perspective. J Allergy Clin Immunol Pract 9 (7) : 2638-2641, 2021
PubMed
7) Global Initiative for Asthma (GINA) : Global strategy for asthma management and prevention : NHLBI/WHO Workshop report : National Heart, Lung and Blood Institute. National Institutes of Health, updated 20 Dec 2020 http://www.ginasthma.com
 
8) Papi A, Fabbri LM, Kerstjens HAM et al : Inhaled long-acting muscarinic antagonists in asthma - A narrative review. Eur J Intern Med 85 : 14-22, 2021
PubMed
P.139 掲載の参考文献
9) 日本呼吸器学会難治性喘息診断と治療の手引き2019作成委員会編 : 難治性喘息診断と治療の手引き 2019. メディカルレビュー社, 2018
 
10) Matsunaga K, Adachi M, Nagase H et al : Association of low-dosage systemic corticosteroid use with disease burden in asthma. NPJ Prim Care Respir Med 30 : 35, 2020
PubMed
11) Sullivan PW, Ghushchyan VH, Globe G et al : Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol 141 : 110-116, 2018
PubMed
12) Ekstrom M, Nwaru BI, Hasvold P et al : Oral corticosteroid use, morbidity and mortality in asthma : A nationwide prospective cohort study in Sweden. Allergy 74 : 2181-2190, 2019
PubMed
P.140 掲載の参考文献
13) 日本呼吸器学会喘息とCOPDオーバーラップ診断と治療の手引き2018作成委員会編 : 喘息とCOPD のオーバーラップ (ACO) 診断の治療と手引き 2018. メディカルレビュー社, 2017
 
14) Global Strategy for the Diagnosis, Management and Prevention of COPD 2020 https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf
 
15) Kerstjens HAM, Maspero J, Chapman KR et al : Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twicedaily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM) : a randomised, double-blind, controlled phase 3 study. Lancet Respir Med 8 : 1000-1012, 2020
PubMed
16) Lee LA, Bailes Z, Barnes N et al : Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN) : a double-blind, randomised, phase 3A trial. Lancet Respir Med 9 : 69-84, 2021
 
17) Gessner C, Kornmann O, Maspero J et al : Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate oncedaily versus salmeterol/fluticasone twicedaily plus tiotropium once-daily in patients with uncontrolled asthma : A randomised, Phase IIIb, non-inferiority study (ARGON). Respir Med 170 : 106021, 2020
 
P.141 掲載の参考文献
18) Humbert M, Taille C, Mala L et al ; STELLAIR investigators : Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count : the STELLAIR study. Eur Respir J 51 (5) : 1702523, 2018
PubMed
19) Khurana S, Brusselle GG, Bel EH et al : Long-term safety and clinical benefit of Mepolizumab in patients with the most severe eosinophilic asthma : The COSMEX Study. Clin Ther 41 : 2041-2056, 2019
PubMed
20) Ohta K, Adachi M, Tohda Y et al : Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma. Allergol Int 67 : 266-272, 2018
PubMed
21) Castro M, Corren J, Pavord ID et al : Dupilumab Efficacy and Safety in Moderateto-Severe Uncontrolled Asthma. N Engl J Med 78 : 2486-2496, 2018
 
22) Dupin C, Belhadi D, Guilleminault L et al : Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clun Exp Allergy 50 : 789-798, 2020
 
23) Wenzel SE : Severe Adult Asthmas : Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes. Am J Respir Crit Care Med 203 (7) : 809-821, 2021
PubMed
P.142 掲載の参考文献
24) Chaudhuri R, Rubin A, Sumino K et al : Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+) : a follow-up of three randomised controlled trials. Lancet Respir Med 9 : 457-466, 2021
PubMed
25) Sugiyama H, Iikura M, Hojo M et al : Treatment for intractable asthma ; bronchial thermoplasty. Glob Health Med 1 : 95-100, 2019
PubMed
26) Salem I, Gras D, Joubert P et al : Persistent reduction of mucin production after bronchial thermoplasty in severe asthma. Am J Respir Crit Care Med 199 : 536-538, 2019
 
27) U.S. Department of Health and Human Services : National Heart, Lung, and Blood Institute : National Asthma Education and Prevention Program. Expert Panel Report 4 (EPR-4) : Guidelines for the Diagnosis and Management of Asthma. 2021
 
P.143 掲載の参考文献
28) Vultaggio A, Agache I, Akdis CA et al : Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic : An EAACI statement. Allergy 75 : 2764-2774, 2020
PubMed
P.144 掲載の参考文献
1) 日本呼吸器学会 咳嗽・喀痰の診療ガイドライン2019作成委員会 : 咳嗽・喀痰の診療ガイドライン 2019. メディカルレビュー社, 2019
 
2) Morice AH, Millqvist E, Bieksiene K et al : ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J 55 : 1901136, 2020
PubMed
P.145 掲載の参考文献
3) Zhang Q, Luo W, Zhan W et al : Nonasthmatic eosinophilic bronchitis is characterized by proximal airway eosinophilic inflammation as compared with classic asthma and cough variant asthma. Clin Exp Allergy, 2021 [online ahead of print]
 
4) Sugawara H, Saito A, Yokoyama S et al : Comparison of therapeutic effects of inhaled corticosteroids on three subtypes of cough variant asthma as classified by the impulse oscillometry system. Respir Res 20 : 41, 2019
PubMed
5) Ohkura N, Fujimura M, Hara J et al : Methacholine-induced cough as an indicator of bronchodilator-responsive cough. Pulm Pharmacol Ther 64 : 101962, 2020
PubMed
6) Fukuhara A, Saito J, Birring SS et al : Clinical characteristics of cough frequency patterns in patients with and without asthma. J Allergy Clin Immunol Pract 8 : 654-661, 2020
PubMed
7) Cote A, Russell RJ, Boulet LP et al : Managing chronic cough due to asthma and NAEB in adults and adolescents : CHEST guideline and expert panel report. Chest 158 : 68-96, 2020
 
P.146 掲載の参考文献
8) Matsumoto H, Izuhara Y, Niimi A et al : Risks and cough-aggravating factors in prolonged cough. Epidemiological observations from the Nagahama Cohort Study. Ann Am Thorac Soc 14 : 698-705, 2017
PubMed
9) Tajiri T, Kawachi H, Yoshida H et al : The causes of acute cough : a tertiary-care hospital study in Japan. J Asthma, 2021 [online ahead of print]
 
10) Chen LC, Zeng GS, Wu LL et al : Diagnostic value of FeNO and MMEF for predicting cough variant asthma in chronic cough patients with or without allergic rhinitis. J Asthma 58 : 326-333, 2021
PubMed
P.147 掲載の参考文献
11) Lin J, Wang Z, Qiu C et al : A multicenter, prospective, observational study on montelukast monotherapy or montelukast-based combinations treating cough variant asthma. J Thorac Dis 12 : 6573-6585, 2021
 
12) Colak Y, Afzal S, Lange P et al : Role and impact of chronic cough in individuals with asthma from the general population. J Allergy Clin Immunol Pract 7 : 1783-1792e8, 2019
PubMed
13) Kanemitsu Y, Matsumoto H, Oguma T et al : Independent factors contributing to daytime and nighttime asthmatic cough refractory to inhaled corticosteroids. J Investig Allergol Clin Immunol 29 : 30-39, 2019
PubMed
14) Fukumitsu K, Kanemitsu Y, Asano T et al : Tiotropium attenuates refractory cough and capsaicin cough reflex sensitivity in patients with asthma. J Allergy Clin Immunol Pract 6 : 1613-1620. e2, 2018
 
P.148 掲載の参考文献
15) Kanemitsu Y, Fukumitsu K, Kurokawa R et al : Increased capsaicin sensitivity in patients with severe asthma is associated with worse clinical outcome. Am J Respir Crit Care Med 201 : 1068-1077, 2020
PubMed
16) Yamamura K, Hara J, Ohkura N et al : Increased cough receptor sensitivity to capsaicin predicts a positive bronchial thermoplasty response : A single-center retrospective study. J Bronchology Interv Pulmonol 26 : 137-141, 2019
PubMed
17) Zeiger RS, Schatz M, Butler RK et al : Burden of specialist-diagnosed chronic cough in adults. J Allergy Clin Immunol Pract 8 : 1645-1657. e7, 2020
 
18) Johansson H, Johannessen A, Holm M et al : Prevalence, progression and impact of chronic cough on employment in Northern Europe. Eur Respir J 57 : 2003344, 2021
PubMed
19) Kubo T, Tobe K, Okuyama K et al : Disease burden and quality of life of patients with chronic cough in Japan : a population-based cross-sectional survey. BMJ Open Respir Res 8 : e000764, 2021
PubMed
20) Kang SY, Song WJ, Won HK et al : Cough persistence in adults with chronic cough : A 4-year retrospective cohort study. Allergol Int 69 : 588-593, 2020
PubMed
21) Latti AM, Pekkanen J, Koskela HO : Persistence of chronic cough in a community-based population. ERJ Open Res 6 : 00229-2019, 2020
 
P.149 掲載の参考文献
22) Shapiro CO, Proskocil BJ, Oppegard LJ et al : Airway sensory nerve density is increased in chronic cough. Am J Respir Crit Care Med 203 : 348-355, 2021
PubMed
23) Smith JA, Kitt MM, Morice AH et al : Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough : a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med 8 : 775-785, 2020
PubMed
24) Smith J, Morice A, McGarvey L et al : Objective cough frequency with Gefapixant in chronic cough : A pooled analysis of two phase 3 randomized, controlled clinical trials (COUGH-1 and COUGH-2). Am J Respir Crit Care Med 203 : A2353, 2021
 
25) Morice AH, Birring SS, Smith JA et al : Characterization of patients with refractory or unexplained chronic cough participating in a phase 2 clinical trial of the P2X3-Receptor Antagonist Gefapixant. Lung 199 : 121-129, 2021
 
P.150 掲載の参考文献
26) Morice A, Smith JA, McGarvey L et al : Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough : a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J, 2021 [online ahead of print]
 
27) Smith J, Allman D, Badri H et al : The neurokinin-1 receptor antagonist orvepitant is a novel antitussive therapy for chronic refractory cough : Results from a phase 2 pilot study (VOLCANO-1). Chest 157 : 111-118, 2020
PubMed
28) Cho PSP, Fletcher HV, Turner RD et al : Impaired cough suppression in chronic refractory cough. Eur Respir J 53 : 1802203, 2019
PubMed
29) Yang J, Crawley B, Dehom S et al : Chronic Refractory Cough : Objective improvement with aerodynamic-focused. J Voice 35 : 324.e9-324.e13, 2021
 
30) Mohammed S, Steer J, Ellis J et al : Nonpharmacological cough control therapy for chronic refractory cough and cough associated with underlying lung disease. ERJ Open Res 6 : 00243-2019, 2020
PubMed
P.151 掲載の参考文献
1) 長瀬洋之 : アレルギー疾患の分子標的治療の展望. 日職業・環境アレルギー会誌 23 (1) : 26, 2015
Medical*Online
P.152 掲載の参考文献
2) Ueki S, Hebisawa A, Kitani M et al : Allergic bronchopulmonary aspergillosis-A luminal hypereosinophilic disease with extracellular trap cell death. Front Immunol 9 : 2346, 2018
PubMed
P.153 掲載の参考文献
3) 「アレルギー性気管支肺真菌症」研究班 : アレルギー性気管支肺真菌症の診療の手引き. 医学書院, 2019
 
4) Agarwal R, Aggarwal AN, Dhooria S et al : A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J 47 (2) : 490-498, 2016
PubMed
5) Agarwal R, Dhooria S, Singh Sehgal I et al : A randomized trial of itraconazole vs prednisolone in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Chest 153 (3) : 656-664, 2018
PubMed
6) Tillie-Leblond I, Germaud P, Leroyer C et al : Allergic bronchopulmonary aspergillosis and omalizumab. Allergy 66 (9) : 1254-1256, 2011
PubMed
7) Voskamp AL, Gillman A, Symons K et al : Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract 3 (2) : 192-199, 2015
PubMed
P.154 掲載の参考文献
8) Dunican EM, Elicker BM, Gierada DS et al : Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest 128 (3) : 997-1009, 2018
PubMed
9) Tolebeyan A, Mohammadi O, Vaezi Z et al : Mepolizumab as possible treatment for allergic bronchopulmonary aspergillosis : A review of eight cases. Cureus 12 (8) : e9684, 2020
 
10) Dhariwal J, Hearn AP, Kavanagh JE et al : Real-world effectiveness of anti-IL-5/5R therapy in severe atopic eosinophilic asthma with fungal sensitization. J Allergy Clin Immunol Pract 9 (6) : 2315-2320.e1, 2021
 
11) Matsuura H, Fujiwara K, Omori H et al : Successful treatment with benralizumab for allergic bronchopulmonary aspergillosis that developed after disastrous heavy rainfall in Western Japan. Intern Med 60 (9) : 1443-1450, 2021
PubMed
12) Tsubouchi K, Arimura-Omori M, Inoue S et al : A case of allergic bronchopulmonary aspergillosis with marked peripheral blood eosinophilia successfully treated with benralizumab. Respir Med Case Rep 32 : 101339, 2021
 
13) Ramonell RP, Lee FE, Swenson C et al : Dupilumab treatment for allergic bronchopulmonary aspergillosis : A case series. J Allergy Clin Immunol Pract 8 (2) : 742-743, 2020
 
14) Mummler C, Kemmerich B, Behr J et al : Differential response to biologics in a patient with severe asthma and ABPA : a role for dupilumab? Allergy Asthma Clin Immunol 16 : 55, 2020
 
15) Tashiro H, Takahashi K, Kurihara Y et al : Efficacy of dupilumab and biomarkers for systemic corticosteroid naive allergic bronchopulmonary mycosis. Allergol Int 70 (1) : 145-147, 2021
PubMed
16) Corren J, Castro M, O'Riordan T et al : Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract 8 (2) : 516-526, 2020
 
17) 好酸球性多発血管炎性肉芽腫症 (EGPA). "抗リン脂質抗体症候群・好酸球性多発血管炎性肉芽腫症・結節性多発動脈炎・リウマトイド血管炎の治療の手引き 2020" 針谷正祥編. 診断と治療社, pp39-50, 2021
 
P.155 掲載の参考文献
18) Wechsler ME, Akuthota P, Jayne D et al : Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376 (20) : 1921-1932, 2017
 
19) Basta F, Mazzuca C, Nucera E et al : Omalizumab in eosinophilic granulomatosis with polyangiitis : friend or foe? A systematic literature review. Clin Exp Rheumatol 38 Suppl 124 (2) : 214-220, 2020
PubMed
20) Detoraki A, Di Capua L, Varricchi G et al : Omalizumab in patients with eosinophilic granulomatosis with polyangiitis : a 36-month follow-up study. J Asthma 53 (2) : 201-206, 2016
PubMed
21) Wechsler ME, Wong DA, Miller MK et al : Churg-strauss syndrome in patients treated with omalizumab. Chest 136 (2) : 507-518, 2009
PubMed
22) Nanzer AM, Dhariwal J, Kavanagh J et al : Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis. ERJ Open Res 6 (4) : 00451-2020, 2020
PubMed
23) Guntur VP, Manka LA, Denson JL et al : Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract 9 (3) : 1186-1193.e1, 2021
 
24) Chica-Guzman MV, Morillo-Guerrero R, Carron-Herrero A et al : Eosinophilic granulomatosis with polyangiitis successfully treated with benralizumab. Ann Allergy Asthma Immunol 125 (2) : 228-230, 2020
PubMed
25) Takenaka K, Minami T, Yoshihashi Y et al : Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis. Allergol Int 68 (4) : 539-540, 2019
PubMed
26) Miyata Y, Inoue H, Homma T et al : Efficacy of benralizumab and clinical course of IgG4 in eosinophilic granulomatosis with polyangiitis. J Investig Allergol Clin Immunol 31 (4) : 346-348, 2021
PubMed
27) Matucci A, Bormioli S, Bercich L et al : Effect of dupilumab treatment in a severe asthma patient with EGPA. J Allergy Clin Immunol Pract, 2021 [online ahead of print]
 
P.156 掲載の参考文献
28) Suzuki Y, Suda T : Eosinophilic pneumonia : A review of the previous literature, causes, diagnosis, and management. Allergol Int 68 (4) : 413-419, 2019
PubMed
29) Kisling A, Jones J, Hixson C et al : Mepolizumab : an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance. Drugs Context 9 : 2020-5-3, 2020
PubMed
30) Shimizu Y, Kurosawa M, Sutoh Y et al : Long-term treatment with anti-interleukin 5 antibodies in a patient with chronic eosinophilic pneumonia. J Investig Allergol Clin Immunol 30 (2) : 154-155, 2020
 
31) Isomoto K, Baba T, Sekine A et al : Promising effects of benralizumab on chronic eosinophilic pneumonia. Intern Med 59 (9) : 1195-1198, 2020
PubMed
32) Yazawa S, Toyoshima M, Koda K et al : Benralizumab as initial treatment for chronic eosinophilic pneumonia. Allergol Int 70 (1) : 140-142, 2021
PubMed
33) Brenard E, Pilette C, Dahlqvist C et al : Real-life study of mepolizumab in idiopathic chronic eosinophilic pneumonia. Lung 198 (2) : 355-360, 2020
PubMed
34) Kaya H, Gumus S, Ucar E et al : Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia. Chest 142 (2) : 513-516, 2012
PubMed
35) Fowler C, Hoover W : Dupilumab for chronic eosinophilic pneumonia. Pediatr Pulmonol 55 (12) : 3229-3230, 2020
PubMed
36) Menzella F, Montanari G, Patricelli G et al : A case of chronic eosinophilic pneumonia in a patient treated with dupilumab. Ther Clin Risk Manag 15 : 869-875, 2019
 
37) Tomyo F, Sugimoto N, Kawamoto M et al : Anti-interleukin 5 antibody is effective for not only severe asthma and eosinophilic pneumonia but also eosinophilic bronchiolitis. Respirol Case Rep 7 (2) : e00397, 2019
PubMed
38) Takeshita Y, Nobuyama S, Kanetsuna Y et al : Eosinophilic bronchiolitis successfully treated with mepolizumab. J Allergy Clin Immunol Pract 8 (3) : 1159-1161.e1, 2020
 
39) Takano T, Inutsuka Y, Nakamura S et al : Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection. Respirol Case Rep 9 (8) : e00810, 2021
 
P.157 掲載の参考文献
40) Roufosse F, Kahn JE, Rothenberg ME et al : Efficacy and safety of mepolizumab in hypereosinophilic syndrome : A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol 146 (6) : 1397-1405, 2020
 
41) Fujii K, Takahashi H, Hayakawa N et al : Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab. Respirol Case Rep 8 (8) : e00665, 2020
 
42) Wieser JK, Kuehn GJ, Prezzano JC et al : Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment. JAAD Case Rep 6 (4) : 292-295, 2020
 
P.158 掲載の参考文献
1) Furusawa H, Cardwell JH, Okamoto T et al : Chronic hypersensitivity pneumonitis, an interstitial lung disease with distinct molecular signatures. Am J Respir Crit Care Med 202 : 1430-1444, 2020
PubMed
P.159 掲載の参考文献
2) Ley B, Torgerson DG, Oldham JM et al : Rare protein-altering telomere-related gene variants in patients with chronic hypersensitivity pneumonitis. Am J Respir Crit Care Med 200 : 1154-1163, 2019
PubMed
3) Fernandez Perez ER, Sprunger DB, Ratanawatkul P et al : Increasing hypersensitivity pneumonitis-related mortality in the United States from 1988 to 2016. Am J Respir Crit Care Med 199 : 1284-1287, 2019
PubMed
4) Raghu G, Remy-Jardin M, Ryerson CJ et al : Diagnosis of hypersensitivity pneumonitis in adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 202 : e36-e69, 2020
PubMed
P.160 掲載の参考文献
5) Chami HA, Diaz-Mendoza J, Chua A et al : Transbronchial biopsy and cryobiopsy in the diagnosis of hypersensitivity pneumonitis among patients with interstitial lung disease. Ann Am Thorac Soc 18 : 148-161, 2021
PubMed
6) Patolia S, Tamae Kakazu M, Chami HA et al : Bronchoalveolar lavage lymphocytes in the diagnosis of hypersensitivity pneumonitis among patients with interstitial lung disease. Ann Am Thorac Soc 17 : 1455-1467, 2020
PubMed
7) Adderley N, Humphreys CJ, Barnes H et al : Bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis : a systematic review and meta-analysis. Eur Respir J 56 : 2000206, 2020
PubMed
8) Fernandez Perez ER, Travis WD, Lynch DA et al : Diagnosis and Evaluation of Hypersensitivity Pneumonitis : CHEST Guideline and Expert Panel Report. Chest 160 (2) : e97-e156, 2021
 
P.161 掲載の参考文献
9) Barnett J, Molyneaux PL, Rawal B et al : Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis. Eur Respir J 54 : 1900531, 2019
PubMed
10) Barnes H, Morisset J, Molyneaux P et al : A systematically derived exposure assessment instrument for chronic hypersensitivity pneumonitis. Chest 157 : 1506-1512, 2020
PubMed
11) Shirai T, Tanino Y, Nikaido T et al : Screening and diagnosis of acute and chronic bird-related hypersensitivity pneumonitis by serum IgG and IgA antibodies to bird antigens with Immuno-CAP(R). Allergol Int 70 : 208-214, 2021
 
P.162 掲載の参考文献
12) Onishi Y, Kawamura T, Higashino T et al : Clinical features of chronic summertype hypersensitivity pneumonitis and proposition of diagnostic criteria. Respir Investig 58 : 59-67, 2020
PubMed
13) De Sadeleer LJ, Hermans F, De Dycker E et al : Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort : a single-centre cohort study. J Clin Med 8 : 14, 2019
 
14) Terras Alexandre A, Martins N, Raimundo S et al : Impact of azathioprine use in chronic hypersensitivity pneumonitis patients. Pulm Pharmacol Ther 60 : 101878, 2020
PubMed
15) Fiddler CA, Simler N, Thillai M et al : Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis-A single-centre experience. Clin Respir J 13 : 791-794, 2019
PubMed
P.163 掲載の参考文献
16) Noh S, Yadav R, Li M et al : Use of leflunomide in patients with chronic hypersensitivity pneumonitis. BMC Pulm Med 20 : 199, 2020
PubMed
17) Ferreira M, Borie R, Crestani B et al : Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP) : A retrospective, multicentric, observational study. Respir Med 172 : 106146, 2020
PubMed
18) Flaherty KR, Wells AU, Cottin V et al : Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381 : 1718-1727, 2019
PubMed
19) Wells AU, Flaherty KR, Brown KK et al : Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial : a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 8 : 453-460, 2020
 
20) Behr J, Prasse A, Kreuter M et al : Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF) : a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 9 : 476-486, 2021
PubMed
21) Tzilas V, Tzouvelekis A, Bouros E et al : Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis : a 3-year real-life observational study. ERJ Open Res 6 : 00152-2020, 2020
PubMed
P.164 掲載の参考文献
22) Alberti ML, Malet Ruiz JM, Fernandez ME et al : Comparative survival analysis between idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Pulmonology 26 : 3-9, 2020
PubMed
23) Nasser M, Larrieu S, Si-Mohamed S et al : Progressive fibrosing interstitial lung disease : a clinical cohort (the PROGRESS study). Eur Respir J 57 : 2002718, 2021
 
24) Salisbury ML, Gu T, Murray S et al : Hypersensitivity pneumonitis : Radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory. Chest 155 : 699-711, 2019
PubMed
25) Nukui Y, Miyazaki Y, Masuo M et al : Periostin as a predictor of prognosis in chronic bird-related hypersensitivity pneumonitis. Allergol Int 68 : 363-369, 2019
PubMed
26) Nukui Y, Yamana T, Masuo M et al : Serum CXCL9 and CCL17 as biomarkers of declining pulmonary function in chronic bird-related hypersensitivity pneumonitis. PLoS One 14 : e0220462, 2019
PubMed
P.165 掲載の参考文献
27) Hanzawa S, Tateishi T, Ishizuka M et al : Changes in serum KL-6 levels during short-term strict antigen avoidance are associated with the prognosis of patients with fibrotic hypersensitivity pneumonitis caused by avian antigens. Respir Investig 58 : 457-464, 2020
PubMed

VII章 全身性疾患と肺病変

P.168 掲載の参考文献
1) Hoffmann-Vold AM, Fretheim H, Halse AK et al : Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am J Respir Crit Care Med 200 : 1258-1266, 2019
 
P.169 掲載の参考文献
2) Hoffmann-Vold AM, Allanore Y, Alves M et al : Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 80 : 219-227, 2021
PubMed
3) Wu W, Jordan S, Graf N et al : Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann Rheum Dis 78 : 648-656, 2019
PubMed
4) Nihtyanova SI, Sari A, Harvey JC et al : Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis Rheumatol 72 : 465-476, 2020
PubMed
5) Elhai M, Hoffmann-Vold AM, Avouac J et al : Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol 71 : 972-982, 2019
PubMed
6) Volkmann ER, Tashkin DP, Kuwana M et al : Progression of interstitial lung disease in systemic sclerosis : the importance of pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis Rheumatol 71 : 2059-2067, 2019
 
7) Volkmann ER, Tashkin DP, Sim M et al : Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann Rheum Dis 78 : 122-130, 2019
PubMed
9) Seibold JR, Maher TM, Highland KB et al : Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease : data from the SENSCIS trial. Ann Rheum Dis 79 : 1478-1484, 2020
PubMed
10) Highland KB, Distler O, Kuwana M et al : Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate : subgroup analysis of the SENSCIS trial. Lancet Respir Med 9 : 96-106, 2021
PubMed
11) Kuwana M, Ogura T, Makino S et al : Nintedanib in patients with systemic sclerosis associated interstitial lung disease : A Japanese population analysis of the SENSCIS trial. Mod Rheumatol 31 : 141-150, 2021
PubMed
12) Azuma A, Chung L, Behera D et al : Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease : subgroup analysis of the SENSCIS trial. Respir Invest 59 : 252-259, 2021
PubMed
13) Maher TM, Mayes MD, Kreuter M et al : Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease : Further analyses of a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 73 : 671-676, 2021
PubMed
14) Kuwana M, Allanore Y, Denton CP et al : Nintedanib in patients with systemic sclerosis-associated interstitial lung disease : subgroup analyses by autoantibody status and skin score. Arthritis Rheumatol, 2021 [online ahead of print]
 
15) Khanna D, Lin CJF, Furst DE et al : Tocilizumab in systemic sclerosis : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8 : 963-974, 2020
PubMed
170
 
P.171 掲載の参考文献
16) Roofeh D, Lin CJF, Goldin J et al : Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol 73 : 1301-1310, 2021
PubMed
17) Elhai M, Boubaya M, Distler O et al : Outcome of systemic sclerosis patients treated with rituximab in contemporary practice : a prospective cohort study. Ann Rheum Dis 8 : 979-987, 2019
 
18) Ebata S, Yoshizaki A, Oba K et al : Safety and efficacy of rituximab in systemic sclerosis (DESIRES) : a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 3 : E489-E497, 2021
PubMed
19) Goswami R, Ray A, Chatterjee M et al : Rituximab in the treatment of systemic sclerosis related interstitial lung disease : a systematic review and meta-analysis. Rheumatology (Oxford) 60 : 557-567, 2021
PubMed
P.172 掲載の参考文献
20) Sato S, Masui K, Nishina N et al : Initial predictors of poor survival in myositis-associated interstitial lung disease : a multicentre cohort of 497 patients. Rheumatology (Oxford) 57 : 1212-1221, 2018
PubMed
21) Kaneko Y, Nunokawa T, Taniguchi Y et al : Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease : a large-scale multicentre cohort study. Rheumatology (Oxford) 59 : 112-119, 2020
PubMed
22) Kaieda S, Gono T, Masui K et al : Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease. PLoS One 15 (6) : e0234523, 2020
 
23) Gono T, Masui K, Nishina N et al : Risk prediction modeling based on a combination of initial serum biomarkers in myositis-associated interstitial lung disease. Arthritis Rheumatol 73 : 677-686, 2021
PubMed
P.173 掲載の参考文献
24) Takei R, Yamano Y, Kataoka K et al : Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease. Respir Investig 58 : 83-90, 2020
 
25) Hozumi H, Fujisawa T, Nakashima R et al : Efficacy of glucocorticoids and calcineurin inhibitors for anti-aminoacyl-tRNA synthetase antibody-positive polymyositis/dermatomyositis-associated interstitial lung disease : A propensity score-matched analysis. J Rheumatol 46 : 509-517, 2019
PubMed
26) Takada K, Katada Y, Ito S et al : Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis : a single-arm clinical trial. Rheumatology (Oxford) 59 : 1084-1093, 2020
 
27) Fujisawa T, Hozumi H, Kamiya Y et al : Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD : A randomized, open-label trial. Respirology 26 : 370-377, 2021
PubMed
28) Langlois V, Gillibert A, Uzunhan Y et al : Rituximab and cyclophosphamide in antisynthetase syndrome-related interstitial lung disease : An observational retrospective study. J Rheumatol 47 : 1678-1686, 2020
PubMed
29) Tsuji H, Nakashima R, Hosono Y et al : Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 72 : 488-498, 2020
PubMed
30) Chen Z, Wang X, Ye S : Tofacitinib in Amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med 381 : 291-293, 2019
 
31) Takanashi S, Kaneko Y, Takeuchi T : Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis : A literature review. Mod Rheumatol, 2021 [online ahead of print]
 
P.174 掲載の参考文献
32) Abe Y, Kusaoi M, Tada K et al : Successful treatment of anti-MDA5 antibodypositive refractory interstitial lung disease with plasma exchange therapy. Rheumatology (Oxford) 59 : 767-771, 2020
PubMed
33) Shirakashi M, Nakashima R, Tsuji H et al : Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford) 59 : 3284-3292, 2020
PubMed
P.175 掲載の参考文献
1) 厚生労働科学研究費補助金・難治性疾患等政策研究事業編 : ANCA関連血管炎 診療ガイドライン 2017. 診断と治療社, 2017
 
2) 厚生労働科学研究費補助金・難治性疾患等政策研究事業針谷正祥編 : 抗リン脂質抗体症候群・好酸球性多発血管炎性肉芽腫症・結節性多発動脈炎・リウマトイド血管炎の治療の手引き 2020. 診断と治療社, 2021
 
3) Chung SA, Langford CA, Maz M et al : 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 73 (8) : 1366-1383, 2021
PubMed
P.176 掲載の参考文献
4) Flaherty KR, Wells AU, Cottin V et al : Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381 (18) : 1718-1727, 2019
PubMed
5) Sada KE, Yamamura M, Harigai M et al : Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 16 (2) : R101, 2014
 
6) 坂東政司 : MPO-ANCA陽性間質性肺炎 診断・治療. 日本臨牀 76 (増刊号6) : 290-296, 2018
Medical*Online
P.177 掲載の参考文献
7) Mukherjee M, Thomas SR, Radford K et al : Sputum antineutrophil cytoplasmic antibodies in serum antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis. Am J Respir Crit Care Med 199 (2) : 158-170, 2019
PubMed
8) Suzuki A, Sakamoto S, Kurosaki A et al : Chest high-resolution CT findings of microscopic polyangiitis : A Japanese first nationwide prospective cohort study. AJR Am J Roentgenol 213 (1) : 104-114, 2019
PubMed
P.178 掲載の参考文献
9) Hosoda C, Baba T, Hagiwara E et al : Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis. Respirology 21 (5) : 920-926, 2016
PubMed
10) Neel A, Espitia-Thibault A, Arrigoni PP et al : Bronchiectasis is highly prevalent in anti-MPO ANCA-associated vasculitis and is associated with a distinct disease presentation. Semin Arthritis Rheum 48 (1) : 70-76, 2018
PubMed
11) Lhote R, Chilles M, Groh M et al : Spectrum and prognosis of antineutrophil cytoplasmic antibody-associated vasculitisrelated bronchiectasis : Data from 61 patients. J Rheumatol 47 (10) : 1522-1531, 2020
PubMed
12) Ono N, Inoue Y, Miyamura T et al : The association of airway comorbidities with the clinical phenotypes and outcomes of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis. J Rheumatol 48 (3) : 417-425, 2021
PubMed
P.180 掲載の参考文献
13) Walsh M, Merkel PA, Jayne DRW : Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382 (7) : 622-631, 2020
PubMed
14) Klemmer PJ, Chalermskulrat W, Reif MS et al : Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 42 (6) : 1149-1153, 2003
PubMed
P.181 掲載の参考文献
15) Jayne DRW, Merkel PA, Schall TJ et al ; ADVOCATE Study Group : Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384 (7) : 599-609, 2021
 
P.182 掲載の参考文献
16) Wells AU, Flaherty KR, Brown KK et al : Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial : a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 8 (5) : 453-460, 2020
 
P.183 掲載の参考文献
17) Bettiol A, Urban ML, Dagna L et al : Mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA) : a European multicenter observational study. Arthritis Rheumatol, 2021 [online ahead of print]
 
P.184 掲載の参考文献
18) Hirayama K, Kobayashi M, Usui J et al : Pulmonary involvements of anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan. Nephrol Dial Transplant 30 (Suppl 1) : i83-i93, 2015
 
19) Hozumi H, Kono M, Hasegawa H et al : Clinical significance of interstitial lung disease and its acute exacerbation in microscopic polyangiitis. Chest 159 (6) : 2334-2345, 2021
PubMed
P.186 掲載の参考文献
1) Baughman RP, Teirstein AS, Judson MA et al ; Case Control Etiologic Study of Sarcoidosis (ACCESS) research group : Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164 : 1885-1889, 2001
 
2) Douglas JG, Middleton WG, Gaddie J et al : Sarcoidosis : a disorder commoner in non-smokers? Thorax 41 : 787-791, 1986
PubMed
3) Hattori T, Konno S, Shijubo N et al : Increased prevalence of cigarette smoking in Japanese patients with sarcoidosis. Respirology 18 : 1152-1157, 2013
PubMed
4) Te HS, Perlman DM, Shenoy C et al : Clinical characteristics and organ system involvement in sarcoidosis : comparison of the University of Minnesota Cohort with other cohorts. BMC Pulm Med 20 : 155, 2020
PubMed
5) Hattori T, Konno S, Shijubo N et al : Nationwide survey on the organ-specific prevalence and its interaction with sarcoidosis in Japan. Sci Rep 8 : 9440, 2018
PubMed
6) Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 160 : 736-755, 1999
 
P.187 掲載の参考文献
7) Yamanouchi Y, Sawahata M, Sakamoto N et al : Characteristics of 68 patients with clinically proven sarcoidosis based on the Japan Society of Sarcoidosis and Other Granulomatous Disorders 2015 criteria. Respir Investig 58 : 102-109, 2020
 
8) Isobe M, Tezuka D : Isolated cardiac sarcoidosis : clinical characteristics, diagnosis and treatment. Int J Cardiol 182 : 132-140, 2015
PubMed
9) 日本循環器学会他 : 2016年版心臓サルコイドーシスの診療ガイドライン. 2017
 
10) Kawai H, Sarai M, Kato Y et al : Diagnosis of isolated cardiac sarcoidosis based on new guidelines. ESC Heart Fail 7 : 2662-2671, 2020
PubMed
P.188 掲載の参考文献
11) Nakajima T, Yasufuku K, Kurosu K et al : The role of EBUS-TBNA for the diagnosis of sarcoidosis--comparisons with other bronchoscopic diagnostic modalities. Respir Med 103 : 1796-1800, 2009
PubMed
12) Belhomme N, Jouneau S, Bouzille G et al : Role of serum immunoglobulins for predicting sarcoidosis outcome : A cohort study. PLoS One 13 : e0193122, 2018
PubMed
13) Thillai M, Atkins CP, Crawshaw A et al : BTS Clinical Statement on pulmonary sarcoidosis. Thorax 76 : 4-20, 2021
PubMed
P.189 掲載の参考文献
14) Judson MA, Baughman RP, Costabel U et al : The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids : a retrospective analysis from a randomized clinical trial. Respir Med 108 : 189-194, 2014
PubMed
15) Pietinalho A, Ohmichi M, Lofroos AB et al : The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsyproven cases. Sarcoidosis Vasc Diffuse Lung Dis 17 : 158-166, 2000
PubMed
16) Hattori T, Konno S, Shijubo N et al : Resolution rate of pulmonary sarcoidosis and its related factors in a Japanese population. Respirology 22 : 1604-1608, 2017
 

VIII章 じん肺

P.192 掲載の参考文献
1) Qi XM, Luo Y, Song MY et al : Pneumoconiosis : current status and future prospects. Chin Med J (Engl) 134 : 898-907, 2021
PubMed
2) Suganuma N, Natori Y, Kurosawa H et al : Update of occupational lung disease. J Occup Health 61 : 10-18, 2019
PubMed
P.193 掲載の参考文献
3) Martinez Gonzalez C, Casan Clara P, Prieto Fernandez A et al : Berylliosis : A granulomatosis to remind us of the importance of occupational history. Arch Bronconeumol (Engl Ed) 56 : 470-471, 2020
PubMed
4) Sener MU, Simsek C, Ozkara S et al : Comparison of the International Classification of High-resolution Computed Tomography for occupational and environmental respiratory diseases with the International Labor Organization International Classification of Radiographs of Pneumoconiosis. Ind Health 57 : 495-502, 2019
PubMed
5) Nogami S, J-P NA, Nogami M et al : Radiographic diagnosis of Pneumoconioses by AIR Pneumo-trained physicians : Comparison with low-dose thin-slice computed tomography. J Occup Health 62 : e12141, 2020
PubMed
6) Wang X, Yu J, Zhu Q et al : Potential of deep learning in assessing pneumoconiosis depicted on digital chest radiography. Occup Environ Med 77 : 597-602, 2020
 
7) Masanori A : Imaging diagnosis of classical and new pneumoconiosis : predominant reticular HRCT pattern. Insights Imaging 12 : 33, 2021
PubMed
P.194 掲載の参考文献
8) Ehrlich R, Akugizibwe P, Siegfried N et al : The association between silica exposure, silicosis and tuberculosis : a systematic review and meta-analysis. BMC Public Health 21 : 953, 2021
PubMed
9) Kurth L, Laney AS, Blackley DJ et al : Prevalence of spirometry-defined airflow obstruction in never-smoking working US coal miners by pneumoconiosis status. Occup Environ Med 77 : 265-267, 2020
PubMed
10) An J, Song M, Chang B : Asbestosis mimicking metastatic lung cancer : Case report. Medicina (Kaunas) 57 : 402, 2021
PubMed
11) Zhao H, Xie Y, Wang J et al : Pulmonary rehabilitation can improve the functional capacity and quality of life for pneumoconiosis patients : A systematic review and meta-analysis. Biomed Res Int 2020 : 6174936, 2020
PubMed
12) Nakano M, Hirata M, Hamasaki M et al : Indium kinetics in an indium exposed worker before and after bilateral lung transplantation. J Occup Health 62 : e12165, 2020
 
P.195 掲載の参考文献
13) Krefft S, Wolff J, Rose C : Silicosis : An update and guide for clinicians. Clin Chest Med 41 : 709-722, 2020
PubMed
14) 堀口高彦, 広瀬正裕, 近藤えり子 : 珪肺. 呼吸器内科 38 : 137-141, 2020
 
15) Ulvestad B, Ulvestad M, Skaugset NP et al : Pulmonary function and high-resolution computed tomography in outdoor rock drillers exposed to crystalline silica. Occup Environ Med 77 : 611-616, 2020
PubMed
16) Al Badri FM, Adams S : Domestic mixed-dust pneumoconiosis : A case report and literature review. Respir Med Case Rep 29 : 100985, 2019
PubMed
P.196 掲載の参考文献
17) Hall NB, Blackley DJ, Halldin CN et al : Current review of pneumoconiosis among US coal miners. Curr Environ Health Rep Sep 6 (3) : 137-147, 2019
PubMed
18) Musk AW, de Klerk N, Reid A et al : Asbestos-related diseases. Int J Tuberc Lung Dis 24 : 562-567, 2020
PubMed
19) 四十坊典晴 : 石綿関連肺・胸膜疾患 (中皮腫を除く). 呼吸器内科 38 : 104-110, 2020
 
20) Barnikel M, Million PM, Knoop H et al : The natural course of lung function decline in asbestos exposed subjects with pleural plaques and asbestosis. Respir Med 154 : 82-85, 2019
PubMed
21) Riccelli MG, Goldoni M, Poli D et al : Welding fumes, a risk factor for lung diseases. Int J Environ Res Public Health 17 : 2552, 2020
 
22)田村猛夏 : 溶接工肺. 呼吸器内科 38 : 131-136, 2020
 
P.197 掲載の参考文献
23) Yamamoto Y, Tsujino K, Urasaki K et al : Arc-welders' pneumoconiosis with atypical radiological and bronchoalveolar lavage fluid findings : A case report. Respir Med Case Rep 29 : 101023, 2020
PubMed
24) Koksal D, Karcioglu O, Babaoglu E et al : The contribution of bronchoalveolar lavage in the diagnosis of welder's lung in a patient with pulmonary fibrosis. Arch Environ Occup Health 75 : 56-59, 2020
 
25) 森山寛史, 高田俊範 : 超硬合金肺. 呼吸器内科 38 : 142-148, 2020
 
26) Chiba Y, Kido T, Tahara M et al : Hard metal lung disease with favorable response to corticosteroid treatment : A case report and literature review. Tohoku J Exp Med 247 : 51-58, 2019
PubMed
27) 天田敦子, 長南達也 : インジウム肺の発生と臨床. 呼吸器内科 38 : 149-156, 2020
 
P.198 掲載の参考文献
28) Oyman EK, Hatman EA, Karagul DA et al : A current example of historical cases : Occupational pulmonary aluminosis. Turk Thorac J 22 : 83-85, 2021
 
29) MacMurdo MG, Mroz MM, Culver DA et al : Chronic beryllium disease : Update on a moving target. Chest 158 : 2458-2466, 2020
PubMed
30) Greaves SA, Atif SM, Fontenot AP : Adaptive immunity in pulmonary sarcoidosis and chronic beryllium disease. Front Immunol 11 : 474, 2020
PubMed

IX章 医原性肺疾患

P.200 掲載の参考文献
1) 日本呼吸器学会薬剤性肺障害の診断・治療の手引き第2版作成委員会編 : 薬剤性肺障害の診断・治療の手引き 第2版. メディカルレビュー社, 2018
 
P.201 掲載の参考文献
2) Johkoh T, Lee KS, Nishino M et al : Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors : A position paper from the fleischner society. Chest 159 : 1107-1125, 2021
PubMed
3) Noonan SA, Sachs PB, Camidge DR : Transient asymptomatic pulmonary opacities occurring during osimertinib treatment. J Thorac Oncol 11 : 2253-2258, 2016
PubMed
4) Lee H, Lee HY, Sun JM et al : Transient asymptomatic pulmonary opacities during osimertinib treatment and its clinical implication. J Thorac Oncol 13 : 1106-1112, 2018
 
5) Ciccarese F, Piccinino A, Brocchi S et al : Expected and non-expected immune-related adverse events detectable by CT. Eur J Radiol 138 : 109617, 2021
PubMed
P.202 掲載の参考文献
6) Gemma A, Kusumoto M, Sakai F et al : Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with osimertinib in Japan. J Thorac Oncol 15 : 1893-1906, 2020
PubMed
P.203 掲載の参考文献
7) Kiriu T, Tamura D, Tachihara M et al : Successful osimertinib rechallenge with steroid therapy after osimertinib-induced interstitial lung disease. Intern Med 57 : 91-95, 2018
PubMed
8) Bickert C, Kahnert K, Kauffmann-Guerrero D et al : Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis : three case studies. Ther Adv Med Oncol 13 : 17588359211018028, 2021
PubMed
9) Kodama H, Wakuda K, Yabe M et al : Retrospective analysis of osimertinib rechallenge after osimertinib-induced interstitial lung disease in patients with EGFRmutant non-small cell lung carcinoma. Invest New Drugs 39 : 571-577, 2021
PubMed
10) Gemma A, Kusumoto M, Kurihara Y et al : Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib. J Thorac Oncol 14 : 672-682, 2019
PubMed
11) Masuda N, Ohe Y, Gemma A et al : Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan. Cancer Sci 110 : 1401-1407, 2019
 
12) Nishio M, Yoshida T, Kumagai T et al : Brigatinib in Japanese patients with ALK-positive NSCLC previously treated with alectinib and other tyrosine kinase inhibitors : Outcomes of the phase 2 J-ALTA Trial. J Thorac Oncol 16 : 452-463, 2021
 
P.204 掲載の参考文献
13) Ng TL, Narasimhan N, Gupta N et al : Early-onset pulmonary events associated with brigatinib use in advanced NSCLC. J Thorac Oncol 15 : 1190-1199, 2020
PubMed
14) 小野薬品工業 : オプジーボ点滴静注20 mg, 100 mg, 240 mg 切除不能な進行・再発の非小細胞肺癌 全例調査 特定使用成績調査結果報告書. 2020年11月
 
15) 小野薬品工業 : オプジーボ点滴静注20mg, 100 mg, 240 mg 根治不能又は転移性の腎細胞癌 全例調査 特定使用成績調査結果報告書. 2021年2月
 
16) Baba T, Sakai F, Kato T et al : Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma. Future Oncol 15 : 1911-1920, 2019
PubMed
17) Saito Y, Sasaki S, Oikado K et al : Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer. Cancer Sci 112 : 1495-1505, 2021
PubMed
18) Sata M, Sasaki S, Oikado K et al : Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer. Cancer Sci 112 : 1506-1513, 2021
PubMed
19) MSD : キイトルーダ点滴静注20 mg, 100 mg 使用成績調査 (非小細胞肺癌) 最終報告書. 2020年9月
 
P.205 掲載の参考文献
20) Tamura K, Tsurutani J, Takahashi S et al : Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine : a dose-expansion, phase 1 study. Lancet Oncol 20 : 816-826, 2019
PubMed
21) Modi S, Saura C, Yamashita T et al : Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382 : 610-621, 2020
PubMed
22) Kumagai K, Aida T, Tsuchiya Y et al : Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci 2020 111 : 4636-4645, 2020
PubMed
23) Imatoh T, Ushiki A, Ota M et al : Association of HLA-DRB1*04 : 05 allele with drug-induced interstitial lung disease in Japanese population. Pharmacogenomics J 20 : 823-830, 2020
PubMed
P.206 掲載の参考文献
1) Hanania AN, Mainwaring W, Ghebre YT et al : Radiation-induced lung injury : Assessment and management. Chest 156 : 150-162, 2019
PubMed
2) Kasmann L, Dietrich A, Staab-Weijnitz CA et al : Radiation-induced lung toxicity-cellular and molecular mechanisms of pathogenesis, management, and literature review. Radiat Oncol 15 : 214, 2020
PubMed
3) Roy S, Salerno KE, Citrin DE : Biology of radiation-induced lung injury. Semin Radiat Oncol 31 : 155-161, 2021
PubMed
P.207 掲載の参考文献
4) Shaverdian N, Shepherd AF, Rimner A et al : Need for caution in the diagnosis of radiation pneumonitis during the COVID-19 pandemic. Adv Radiat Oncol 5 : 617-620, 2020
PubMed
P.208 掲載の参考文献
5) Palma DA, Senan S, Tsujino K et al : Predicting radiation pneumonitis after chemoradiation therapy for lung cancer : an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 85 : 444-450, 2013
PubMed
6) Marks LB, Bentzen SM, Deasy JO et al : Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 76 : S70-S76, 2010
PubMed
P.209 掲載の参考文献
7) Sasaki T, Seto T, Yamanaka T et al A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer : WJOG5008L. Br J Cancer 119 : 675-682, 2018
PubMed
8) Bradley JD, Hu C, Komaki RR et al : Long-term results of NRG oncology RTOG 0617 : Standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol 38 : 706-714, 2020
PubMed
9) Tomita N, Okuda K, Ogawa Y et al : Relationship between radiation doses to heart substructures and radiation pneumonitis in patients with thymic epithelial tumors. Sci Rep 10 : 11191, 2020
PubMed
10) Huang EX, Hope AJ, Lindsay PE et al : Heart irradiation as a risk factor for radiation pneumonitis. Acta Oncol 50 : 51-60, 2011
PubMed
11) Vogelius IR, Bentzen SM : A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol 51 : 975-983, 2012
PubMed
12) Kong FM, Wang S : Nondosimetric risk factors for radiation-induced lung toxicity. Semin Radiat Oncol 25 : 100-109, 2015
PubMed
13) Sliwinska-Mosson M, Wadowska K, Trembecki L et al : Markers useful in monitoring radiation-induced lung injury in lung cancer patients : A review. J Pers Med 10 : 72, 2020
PubMed
14) Kashihara T, Nakayama Y, Ito K et al : Usefulness of simple original interstitial lung abnormality scores for predicting radiation pneumonitis requiring steroidal treatment after definitive radiation therapy for patients with locally advanced non-small cell lung cancer. Adv Radiat Oncol 6 : 100606, 2021
PubMed
15) Hagiwara Y, Nakayama Y, Kudo S et al : Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease. J Radiat Res 61 : 563-574, 2020
PubMed
P.210 掲載の参考文献
16) Keffer S, Guy CL, Weiss E : Fatal radiation pneumonitis : Literature review and case series. Adv Radiat Oncol 5 : 238-249, 2020
PubMed
P.211 掲載の参考文献
17) Yom SS, Liao Z, Liu HH et al : Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68 : 94-102, 2007
PubMed
18) Chun SG, Hu C, Choy H et al : Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer : A secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol 35 : 56-62, 2017
PubMed
19) Tsukita Y, Yamamoto T, Mayahara H et al : Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer : A multi-center retrospective study. Radiother Oncol 160 : 266-272, 2021
PubMed
20) Liao Z, Lee JJ, Komaki R et al : Bayesian Adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. J Clin Oncol 36 : 1813-1822, 2018
PubMed
21) Kim H, Pyo H, Noh JM et al : Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis : comparison between X-ray and proton therapy. Radiat Oncol 14 : 19, 2019
 
22) Turkkan G, Willems Y, Hendriks LEL et al : Idiopathic pulmonary fibrosis : Current knowledge, future perspectives and its importance in radiation oncology. Radiother Oncol 155 : 269-277, 2021
PubMed
23) Antonia SJ, Villegas A, Daniel D et al : Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377 : 1919-1929, 2017
PubMed
P.212 掲載の参考文献
24) Shaverdian N, Beattie J, Thor M et al : Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors. Ann Oncol 31 : 1719-1724, 2020
PubMed
25) Saito G, Oya Y, Taniguchi Y et al : Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON). Lung Cancer 161 : 86-93, 2021
PubMed
26) Shintani T, Kishi N, Matsuo Y et al : Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab. Clin Lung Cancer, 2021 [online ahead of print]
 
27) Geng Y, Zhang Q, Feng S et al : Safety and efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer : a systematic review and meta-analysis. Cancer Med 10 : 1222-1239, 2021
 
28) Tian S, Switchenko JM, Buchwald ZS et al : Lung stereotactic body radiation therapy and concurrent immunotherapy : A multicenter safety and toxicity analysis. Int J Radiat Oncol Biol Phys 108 : 304-313, 2020
PubMed
29) Riviere P, Sumner W, Cornell M et al : Radiation recall pneumonitis after treatment with checkpoint blockade immunotherapy : A case series and review of literature. Front Oncol 11 : 662954, 2021
PubMed
P.213 掲載の参考文献
30) Rahi MS, Parekh J, Pednekar P et al : Radiation-induced lung injury-current perspectives and management. Clin Pract 11 : 410-429, 2021
PubMed
31) Sio TT, Atherton PJ, Pederson LD et al : Daily lisinopril vs placebo for prevention of chemoradiation-induced pulmonary distress in patients with lung cancer (Alliance MC1221) : A pilot double-blind randomized trial. Int J Radiat Oncol Biol Phys 103 : 686-696, 2019
PubMed

X章 胸膜の疾患

P.216 掲載の参考文献
1) Zha L, Kitamura Y, Kitamura T et al : Population-based cohort study on health effects of asbestos exposure in Japan. Cancer Sci 110 (3) : 1076-1084, 2019
PubMed
P.217 掲載の参考文献
2) Siddiqui MT, Schmitt F, Churg A et al : Proceedings of the American Society of Cytopathology companion session at the 2019 United states and Canadian Academy of Pathology Annual meeting. Part 2 : effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma. J Am Soc Cytopathol 8 (6) : 352-361, 2019
PubMed
3) Chapel DB, Schulte JJ, Berg K et al : MTAP Immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Mod Pathol 33 (2) : 245-254, 2020
PubMed
4) Berg KB, Churg AM, Cheung S et al : Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens. Cancer Cytopathol 128 (2) : 126-132, 2020
PubMed
5) Hatem L, McIntire PJ, He B et al : The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology. Diagn Cytopathol 47 (3) : 160-165, 2019
PubMed
6) Nicholson AG, Sauter JL, Nowak AK et al : EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma : towards a more multidisciplinary approach. J Thorac Oncol 15 (1) : 29-49, 2020
PubMed
7) Erber R, Warth A, Muley T et al : BAP1 loss is a useful adjunct to distinguish malignant mesothelioma including the adenomatoid-like variant from benign adenomatoid tumors. Appl Immunohistochem Mol Morphol 28 (1) : 67-73, 2020
PubMed
P.218 掲載の参考文献
8) Shiroshita A, Kurosaki M, Takeshita M et al : Medical thoracoscopy, computed tomography-guided biopsy, and ultrasound-guided biopsy for malignant pleural mesothelioma : A systematic review. Anticancer Research 41 : 2217-2225, 2021
PubMed
9) Wei1 Y, Shen K, Lv T et al : Comparison between closed pleural biopsy and medical thoracoscopy for the diagnosis of undiagnosed exudative pleural effusions : a systematic review and meta-analysis. Transl Lung Cancer Res 9 (3) : 446-458, 2020
 
10) Bayman N, Appel W, Ashcroft L : Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma : An open-label, multicenter, phase III randomized trial. J Clin Oncol 37 (14) : 1200-1208, 2019
 
11) Lee CC, Soon YY, Vellayappan B et al : Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma : A systematic review and meta-analysis of randomized trials. Crit Rev Oncol Hematol 160 : 103278, 2021
PubMed
P.219 掲載の参考文献
12) Gao R, Wang F, Wang Z et al : Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma An updated meta-analysis. Medicine 98 : 14 (e14979), 2019
 
13) Vandenhoeck J, van Meerbeeck JP, Fransen E et al : DNA methylation as a diagnostic biomarker for malignant mesothelioma : A systematic review and meta-analysis. J Thorac Oncol 31, 2021
 
14) Cantinia L, Peccia F, Murrone A et al : Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma : A single center experience with systematic review and meta-analysis. Lung Cancer 146 : 318-326, 2020
 
15) Brosseau S, Danel C, Scherpereel A et al : Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype : A series of 214 cases from the Bio-MAPS Cohort. Clin Lung Cancer 20 (5) : e564-e575, 2019
PubMed
P.220 掲載の参考文献
16) Murphy DJ, Mak SM, Mallia A et al : Loco-regional staging of malignant pleural mesothelioma by integrated 18F-FDG PET/MRI. Eur J Radiol 115 : 46-52, 2019
PubMed
17) Lopci E, Novellis P, Testori A et al : Invivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma. Nucl Med Commun 40 (11) : 1179-1186, 2019
 
18) Lombard A, Mistry H, Chapman SC et al : Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models : Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed. Eur J Pharm Sci 161 : 105781, 2021
PubMed
19) Armato SG 3rd, Nowak AK : Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1). J Thorac Oncol 13 (7) : 1012-1021, 2018
PubMed
20) Li F, Ahmad M, Qayyum F et al : Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma. Eur Radiol 29 (6) : 2981-2988, 2019
PubMed
21) Toreyin ZN, Ghosh M, Goksel O et al : Exhaled breath analysis in diagnosis of malignant pleural mesothelioma : Systematic review. Int J Environ Res Public Health 17 (3) : 1110, 2020
PubMed
22) Catino A, de Gennaro G, Di Gilio A et al : Breath analysis : A systematic review of volatile organic compounds (VOCs) in diagnostic and therapeutic management of pleural mesothelioma. Cancers 11 (6) : 831, 2019
PubMed
P.221 掲載の参考文献
23) Baas P, Scherpereel A, Nowak AK et al : First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743) : a multicentre, randomised, open-label, phase 3 trial. Lancet 397 (10272) : 375-386, 2021
PubMed
24) Disselhorst MJ, Quispel-Janssen J, Lalezari F et al : Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE) : results of a prospective, single-arm, phase 2 trial. Lancet Respir Med 7 (3) : 260-270, 2019
PubMed
25) Scherpereel A, Mazieres J, Greillier L et al : Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2) : a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 20 (2) : 239-253, 2019
PubMed
26) Haakensen VD, Nowak AK, Ellingsen EB et al : NIPU : a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. J Transl Med 19 (1) : 232, 2021
 
27) Yap TA, Nakagawa K, Fujimoto N et al : Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med 9 (6) : 613-621, 2021
PubMed
28) Popat S, Curioni-Fontecedro A, Dafni U et al : A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma : the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol 31 (12) : 1734-1745, 2020
PubMed
P.222 掲載の参考文献
29) Nakano T, Kuribayashi K, Kondo M et al : Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma : A Japanese safety study. Asia Pac J Clin Oncol 17 (3) : 264-272, 2021
PubMed
30) Eberst G, Anota A, Scherpereel A et al : Health-related quality of life impact from adding bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. Clin Cancer Res 25 (19) : 5759-5765, 2019
 
31) de Gooijer CJ, van der Noort V, Stigt JA et al : Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19) : an investigator-initiated, randomised, open-label, phase 2 trial. Lancet Respir Med 9 (6) : 585-592, 2021
PubMed
32) Nowak AK, Lesterhuis WJ, Kok PS et al : Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM) : a multicentre, single-arm, phase 2 trial with a safety runin. Lancet Oncol 21 (9) : 1213-1223, 2020
 
33) Hassan R, Alley E, Kindler H et al : Clinical response of live-attenuated, Listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma. Clin Cancer Res 25 (19) : 5787-5798, 2019
 
34) Riesterer O, Ciernik IF, Stahel RA et al : Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. Radiother Oncol 138 : 121-125, 2019
PubMed
35) Cho BCJ, Donahoe L, Bradbury PA et al : Surgery for malignant pleural mesothelioma after radiotherapy (SMART) : final results from a single-centre, phase 2 trial. Lancet Oncol 22 (2) : 190-197, 2021
PubMed
P.223 掲載の参考文献
36) Trovo M, Relevant A, Polesel J et al : Radical hemithoracic radiotherapy versus palliative radiotherapy in non-metastatic malignant pleural mesothelioma : Results from a phase 3 randomized clinical trial. Int J Radiat Oncol Biol Phys 109 (5) : 1368-1376, 2021
PubMed
37) Predina JD, Newton AD, Corbett C et al : A clinical trial of TumorGlow to identify residual disease during pleurectomy and decortication. Ann Thorac Surg 107 (1) : 224-232, 2019
 
38) Jarvinen T, Paajanen J, Ilonen I et al : Hyperthermic intrathoracic chemoperfusion for malignant pleural mesothelioma : Systematic review and meta-analysis. Cancers 13 : 3637, 2021
PubMed
39) Markowiak T, Kerner N, Neu R et al : Adequate nephroprotection reduces renal complications after hyperthermic intrathoracic chemotherapy. J Surg Oncol 120 (7) : 1220-1226, 2019
PubMed
40) Ceresoli GL, Aerts JG, Dziadziuszko R et al : Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR) : a multicentre, singlearm phase 2 trial. Lancet Oncol 20 (12) : 1702-1709, 2019
PubMed
P.224 掲載の参考文献
1) Morales-Rull JL, Bielsa S, Conde-Martel A et al : Pleural effusions in acute decompensated heart failure : Prevalence and prognostic implications. Eur J Intern Med 52 : 49-53, 2018
PubMed
P.225 掲載の参考文献
2) Tsujimoto N et al. PLoS One 10 (6) : e0130141, 2015
 
3) Lin FC et al. J Ultrasound Med 20 (12) : 1341-1345, 2001
PubMed
4) Lai YF et al. Thorax 64 : 806-809, 2009
PubMed
5) Asciak R, Hassan M, Mercer RM et al : Prospective analysis of the predictive value of sonographic pleural fluid echogenicity for the diagnosis of exudative effusion. Respiration 97 (5) : 451-456, 2019
PubMed
6) Shkolnik B, Judson MA, Austin A et al : Diagnostic accuracy of thoracic ultrasonography to differentiate transudative from exudative pleural effusion. Chest 158 (2) : 692-697, 2020
PubMed
P.226 掲載の参考文献
7) Davies HE et al. Thorax 65 : ii41-ii53, 2010
PubMed
8) Lentz RJ, Shojaee S, Grosu HB et al : The impact of gravity vs suction-driven therapeutic thoracentesis on pressure-related complications : The GRAVITAS Multicenter Randomized Controlled Trial. Chest 157 (3) : 702-711, 2020
PubMed
9) Sagar AES, Landaeta MF, Adrianza AM et al : Complications following symptomlimited thoracentesis using suction. Eur Respir J 56 (5) : 1902356, 2020
PubMed
10) Light RW et al. Ann Intern Med 77 (4) : 507-513, 1972
PubMed
11) Gotsman I et al. Am J Med 111 (5) : 375-378, 2001
PubMed
12) Arnold DT, De Fonseka D, Perry S : Investigating unilateral pleural effusions : the role of cytology. Eur Respir J 52 (5) : 1801254, 2018
PubMed
13) Hassan M, Cargill T, Harries E et al : The microbiology of pleural infection in adults : a systematic review. Eur Respir J 54 (3) : 1900542, 2019
 
14) Hooper C et al. Thorax 65 (Suppl 2) : ii4-17, 2010
 
15) Sharma A, Agrawal A, Sindhwani G et al : Efficacy of procalcitonin and pentraxin-3 as early biomarkers for differential diagnosis of pleural effusions. Pleura Peritoneum 6 (2) : 83-90, 2021
PubMed
16) Wang CY et al. Eur J Clin Microbiol Infect Dis 30 (3) : 313-318, 2011
PubMed
17) Lin MC et al. Chest 136 (1) : 205-211, 2009
PubMed
P.227 掲載の参考文献
18) Kim SB, Shin B, Lee JH et al : Pleural fluid ADA activity in tuberculous pleurisy can be low in elderly, critically ill patients with multi-organ failure. BMC Pulm Med 20 (1) : 13, 2020
 
19) Nagayasu A, Kubo S, Nakano K et al : IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion. Intern Med 57 : 2251-2257, 2018
PubMed
20) Shimoda M, Tanaka Y, Morimoto K et al : A Case of Sjogren's syndrome with pleural effusion : Difficult to distinguish from tuberculous pleurisy because of a high adenosine deaminase level. Intern Med, 2021 [online ahead of print]
 
21) Beukes A, Shaw JA, Diacon AH et al : The utility of pleural fluid lactate dehydrogenase to adenosine deaminase ratio in pleural tuberculosis. Respiration 100 (1) : 59-63, 2021
PubMed
22) Wang J, Liu J, Xie X et al : The pleural fluid lactate dehydrogenase/adenosine deaminase ratio differentiates between tuberculous and parapneumonic pleural effusions. BMC Pulm Med 17 (1) : 168, 2017
 
23) Lee J, Yoo SS, Lee SY et al : Pleural fluid adenosine deaminase/serum C-reactive protein ratio for the differentiation of tuberculous and parapneumonic effusions with neutrophilic predominance and high adenosine deaminase levels. Infection 45 (1) : 59-65, 2017
 
24) Ren ZH, Xu L : Biomarkers of distinguishing neutrophil-predominant tuberculous pleural effusion from parapneumonic pleural effusion. Am J Med Sci 361 (4) : 469-478, 2021
PubMed
25) Shaw JA, Ahmed L, Koegelenberg CFN : Effusions related to TB. Eur Respir Monogr 87 : 172-192, 2020
 
26) Zhang M, Yan L, Lippi G et al : Pleural biomarkers in diagnostics of malignant pleural effusion : a narrative review. Transl Lung Cancer Res 10 (3) : 1557-1570, 2021
 
27) Saraya T, Ohkuma K, Koide T et al : A novel diagnostic method for distinguishing parapneumonic effusion and empyema from other diseases by using the pleural lactate dehydrogenase to adenosine deaminase ratio and carcinoembryonic antigen levels. Medicine (Baltimore) 98 (13) : 215003, 2019
 
28) Wang S, Tian S, Li Y et al : Development and validation of a novel scoring system developed from a nomogram to identify malignant pleural effusion. EBioMedicine 58 : 102924, 2020
 
P.228 掲載の参考文献
29) Lin L, Li S, Xiong Q et al : A retrospective study on the combined biomarkers and ratios in serum and pleural fluid to distinguish the multiple types of pleural effusion. BMC Pulm Med 21 (1) : 95, 2021
 
30) Anevlavis S, Varga C, Nam TH et al : Is there any role for thoracoscopy in the diagnosis of benign pleural effusions. Clin Respir J 13 (2) : 73-81, 2019
PubMed
31) Gong L, Huang G, Huang Y : Medical thoracoscopy for the management of exudative pleural effusion : A retrospective study. Risk Manag Healthc Policy 13 : 2845-2855, 2020
PubMed
32) Thomas M, Ibrahim WH, Raza T et al : Medical thoracoscopy for exudative pleural effusion : an eight-year experience from a country with a young population. BMC Pulm Med 17 (1) : 151, 2017
 
33)田尻智子, 河内寛明, 吉田寛他 : 当院における胸水細胞診陰性症例に対する局所麻酔下胸腔鏡検査の検討. 気管支学 41 : 569-573, 2019
Medical*Online
34) 矢嶋知佳, 蛸井浩行, 林宏紀他 : 治療経過中に大量胸水をきたし, 局所麻酔下胸腔鏡で初期悪化を確認した肺結核の1例. 日呼吸会誌 8 (2) : 97-101, 2019
 
35)田口禎浩, 梶原浩太郎, 兼定晴香他 : 胸膜病変のみを有したIgG4関連胸膜炎の1例. 日呼吸会誌 9 (2) : 118-122, 2020
 
36) Chen CH, Cheng WC, Wu BR et al : Feasibility and safety of pleuroscopic cryobiopsy of the pleura : A prospective study. Can Respir J 2018 : 6746470, 2018
PubMed
37) Nakai T, Matsumoto Y, Sasada S et al : Cryobiopsy during flex-rigid pleuroscopy : an emerging alternative biopsy method in malignant pleural mesothelioma. A comparative study of pathology. Jpn J Clin Oncol 49 (6) : 559-566, 2019
PubMed
P.229 掲載の参考文献
38) Rahman NM et al. Chest 145 (4) : 848-855, 2014
PubMed
39) Yamazaki A, Ito A, Ishida T et al : Polymicrobial etiology as a prognostic factor for empyema in addition to the renal, age, purulence, infection source, and dietary factors score. Respir Investig 57 (6) : 574-581, 2019
 
40) Corcoran JP, Psalidas I, Gerry S et al : Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection : the PILOT study. Eur Respir J 56 (5) : 2000130, 2020
 
41) Kho SS, Chan SK, Yong MC et al : Pleural fluid lactate as a point-of-care adjunct diagnostic aid to distinguish tuberculous and complicated parapneumonic pleural effusions during initial thoracentesis : Potential use in a tuberculosis endemic setting. Respir Investig 58 (5) : 367-375, 2020
 
42) Shen KR, Bribriesco A, Crabtree T et al : The American Association for Thoracic Surgery consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg 153 (6) : e129-e146, 2017
 
43) Rahman NM et al. Chest 137 (3) : 536-543, 2010
PubMed
44) Maskell NA et al. N Engl J Med 352 (9) : 865-874, 2005
PubMed
45) Rahman NM et al. N Engl J Med 365 (6) : 518-526, 2011
PubMed
P.230 掲載の参考文献
46) Bedat B, Plojoux J, Noel J et al : Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection. ERJ Open Res 5 (3) : 00084, 2019
PubMed
47) Kheir F, Thakore S, Mehta H et al : Intrapleural fibrinolytic therapy versus early medical thoracoscopy for treatment of pleural infection. Randomized controlled clinical trial. Ann Am Thorac Soc 17 (8) : 958-964, 2020
PubMed
48) Roper WH et al. Am Rev Tuberc 71 (5) : 616-634, 1955
PubMed
49) Sun F, Li L, Liao X et al : Adjunctive use of prednisolone in the treatment of free-flowing tuberculous pleural effusion : A retrospective cohort study. Respir Med 139 : 86-90, 2018
PubMed
50) Ryan H, Yoo J, Darsini P : Corticosteroids for tuberculous pleurisy. Cochrane Database Syst Rev 3 (3) : CD001876, 2017
 
51) Lai YF et al. Thorax 58 (2) : 149-151, 2003
PubMed
52) Muruganandan S, Azzopardi M, Thomas R et al : The Pleural Effusion And Symptom Evaluation (PLEASE) study of breath-lessness in patients with a symptomatic pleural effusion. Eur Respir J 55 (5) : 1900980, 2020
PubMed
P.231 掲載の参考文献
53) Chen B et al. Ann Thorac Cardiovasc Surg 21 (3) : 223-228, 2015
PubMed
54) Kumar A, Asaf BB, Lingaraju VC et al : Thoracoscopic decortication of stage III tuberculous empyema is effective and safe in selected cases. Ann Thorac Surg 104 (5) : 1688-1694, 2017
PubMed

XI章 呼吸不全と換気障害

P.234 掲載の参考文献
1) 日本呼吸器学会監, 睡眠時無呼吸症候群 (SAS) の診療ガイドライン作成委員会編 : 睡眠時無呼吸症候群 (SAS) の診療ガイドライン 2020. 2020
 
P.235 掲載の参考文献
2) Benjafield AV, Ayas NT, Eastwood PR et al : Estimation of the global prevalence and burden of obstructive sleep apnoea : a literature-based analysis. Lancet Respir Med 7 (8) : 687-698, 2019
PubMed
3) Young T, Palta M, Dempsey J et al : The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328 (17) : 1230-1235, 1993
PubMed
4) Peppard PE, Young T, Barnet JH et al : Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 177 (9) : 1006-1014, 2013
PubMed
5) Ip MS, Lam B, Lauder IJ et al : A community study of sleep-disordered breathing in middle-aged Chinese men in Hong Kong. Chest 119 (1) : 62-69, 2001
 
6) Horner RL : Motor control of the pharyngeal musculature and implications for the pathogenesis of obstructive sleep apnea. Sleep 19 (10) : 827-853, 1996
 
7) White DP : The pathogenesis of obstructive sleep apnea : advances in the past 100 years. Am J Respir Cell Mol Biol 34 (1) : 1-6, 2006
PubMed
8) Practice guidelines for the perioperative management of patients with obstructive sleep apnea : an updated report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Anesthesiology 120 (2) : 268-286, 2014
PubMed
P.236 掲載の参考文献
9) Kuna ST, Sant'Ambrogio G : Pathophysiology of upper airway closure during sleep. JAMA 266 (10) : 1384-1389, 1991
PubMed
10) White DP : Pathogenesis of obstructive and central sleep apnea. Am J Respir Crit Care Med 172 (11) : 1363-1370, 2005
PubMed
11) Younes M : Contributions of upper airway mechanics and control mechanisms to severity of obstructive apnea. Am J Respir Crit Care Med 168 (6) : 645-658, 2003
PubMed
12) Jordan AS, McSharry DG, Malhotra A : Adult obstructive sleep apnoea. Lancet 383 (9918) : 736-747, 2014
PubMed
13) Sankri-Tarbichi AG, Rowley JA, Badr MS : Expiratory pharyngeal narrowing during central hypocapnic hypopnea. Am J Respir Crit Care Med 179 (4) : 313-319, 2009
PubMed
14) Naughton M, Benard D, Tam A et al : Role of hyperventilation in the pathogenesis of central sleep apneas in patients with congestive heart failure. Am Rev Respir Dis 148 (2) : 330-338, 1993
PubMed
15) Xie A, Skatrud JB, Puleo DS et al : Apneahypopnea threshold for CO2 in patients with congestive heart failure. Am J Respir Crit Care Med 165 (9) : 1245-1250, 2002
PubMed
16) Tkacova R, Hall MJ, Liu PP et al : Left ventricular volume in patients with heart failure and Cheyne-Stokes respiration during sleep. Am J Respir Crit Care Med 156 (5) : 1549-1555, 1997
PubMed
P.237 掲載の参考文献
17) Javaheri S : A mechanism of central sleep apnea in patients with heart failure. N Engl J Med 341 (13) : 949-954, 1999
PubMed
18) Mortara A, Sleight P, Pinna GD et al : Association between hemodynamic impairment and Cheyne-Stokes respiration and periodic breathing in chronic stable congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 84 (8) : 900-904, 1999
PubMed
19) American Academy of Sleep Medicine : International Classification of Sleep Disorders. 3rd ed. Darien, IL : American Academy of Sleep Medicine, 2014
 
P.238 掲載の参考文献
20) Young T, Finn L, Peppard PE et al : Sleep disordered breathing and mortality : eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 31 (8) : 1071-1078, 2008
PubMed
21) Marin JM, Carrizo SJ, Vicente E et al : Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure : an observational study. Lancet 365 (9464) : 1046-1053, 2005
PubMed
P.240 掲載の参考文献
1) Jacobs SS, Krishnan JA, Lederer DJ et al : Home oxygen therapy for adults with chronic lung disease an Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 202 (10) : e121-e141, 2020
 
P.241 掲載の参考文献
2) Visca D, Mori L, Tsipouri V et al : Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx) : a prospective, open-label, mixedmethod, crossover randomised controlled trial. Lancet Respir Med 6 (10) : 759-770, 2018
PubMed
P.242 掲載の参考文献
3) Cani KC, Matte DL, Silva IJCS et al : Impact of home oxygen therapy on the level of physical activities in daily life in subjects with COPD. Respir Care 64 (11) 1392-1400, 2019
PubMed
4) Paneroni M, Ambrosino N, Simonelli C : Physical activity in patients with chronic obstructive pulmonary disease on long-term oxygen therapy : A cross-sectional study. Int J Chron Obstruct Pulmon Dis 14 : 2815-2823, 2019
PubMed
5) Rantala HA, Korpela SL, Lehtimaki L et al : Predictors of impaired survival in subjects with long-term oxygen therapy. Respir Care 64 (11) : 1401-1409, 2019
 
6) Lacasse Y, Series F, Corbeil F et al : Randomized trial of nocturnal oxygen in chronic obstructive pulmonary disease. N Engl J Med 383 : 1129-1138, 2020
PubMed
7) Khor YH, Ng Y, Sweeney D et al : Nocturnal hypoxaemia in interstitial lung disease : a systematic review. Thorax, 2021 [online ahead of print]
 
P.243 掲載の参考文献
8) Ergan B, Oczkowski S, Rochwerg B et al : European respiratory society guidelines on long-term home non-invasive ventilation for management of COPD. Eur Respir J 54 : 1901003, 2019
PubMed
9) Macrea M, Oczkowski S, Rochwerg B et al : Long-term noninvasive ventilation in chronic stable hypercapnic chronic obstructive pulmonary disease an Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 202 (4) : e74-e87, 2020
 
P.244 掲載の参考文献
10) Gantzhorn EK, Prior TS, Hilberg O : Long-term non-invasive ventilation for stable chronic hypercapnic COPD. Eur Clin Respir J 6 (1) : 1644893, 2019
PubMed
11) Theunisse C, Huibert H, Ponssen HH et al : The effects of low pressure domiciliary non-invasive ventilation on clinical outcomes in patients with severe COPD regardless having hypercapnia. Int J Chron Obstruct Pulmon Dis 16 : 817-824, 2021
 
12) Wilson ME, Dobler CC, Morrow AS et al : Association of home noninvasive positive pressure ventilation with clinical outcomes in chronic obstructive pulmonary disease : a systematic review and meta-analysis. JAMA 323 (5) : 455-465, 2020
PubMed
13) He X, Luo L, Ma Y et al : Efficacy of domiciliary noninvasive ventilation on clinical outcomes in posthospital chronic obstructive pulmonary disease patients : a meta-analysis of randomized controlled trials : Ann Palliat Med 10 (5) : 5137-5145, 2021
PubMed
P.245 掲載の参考文献
14) Frazier WD, Murphy R, Eijndhoven EV : Non-invasive ventilation at home improves survival and decreases healthcare utilization in medicare beneficiaries with Chronic Obstructive Pulmonary Disease with chronic respiratory failure. Respir Med 177 : 106291, 2021
 
15) Storgaard LH, Hockey HU, Laursen BS et al : Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis 13 : 1195-1205, 2018
PubMed
16) Weinreich UM : Domiciliary high-flow treatment in patients with COPD and chronic hypoxic failure : In whom can we reduce exacerbations and hospitalizations? PLoS One 14 (12) : e0227221, 2019
 
17) Storgaard LH, Hockey HU, Weinreich UM : Development in PaCO2 over 12 months in patients with COPD with persistent hypercapnic respiratory failure treated with high-flow nasal cannula-post-hoc analysis from a randomised controlled trial. BMJ Open Respir Res 7 (1) : e000712, 2020
 
18) McKinstry S, Singer J, Baarsma JP et al : Nasal high-flow therapy compared with non-invasive ventilation in COPD patients with chronic respiratory failure : A randomized controlled cross-over trial. Respirology 24 : 1081-1087, 2019
PubMed
19) Braunlich J, Dellweg D, Bastian A et al : Nasal high-flow versus noninvasive ventilation in patients with chronic hypercapnic COPD. Int J Chron Obstruct Pulmon Dis 14 : 1411-1421, 2019
PubMed
P.247 掲載の参考文献
1) Fujishima S, Gando S, Saitoh D et al : Demographics, treatments, and outcomes of acute respiratory distress syndrome : the Focused Outcomes Research in Emergency Care in Acute Respiratory Distress Syndrome, Sepsis, and Trauma (FORECAST) Study. Shock 53 (5) : 544-549, 2020
PubMed
P.248 掲載の参考文献
2) Gartlehner G, Wagner G, Affengruber L et al : Point-of-care ultrasonography in patients with acute dyspnea : An evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med 174 (7) : 967-976, 2021
PubMed
3) Matthay MA, Thompson BT, Ware LB : The Berlin definition of acute respiratory distress syndrome : should patients receiving high-flow nasal oxygen be included? Lancet Respir Med 9 : 933-936, 2021
PubMed
4) Vignon P, Evrard B, Asfar P et al : Fluid administration and monitoring in ARDS : which management? Intensive Care Med 46 (12) : 2252-2264, 2020
PubMed
5) Palmer E, Post B, Klapaukh R et al : The association between supraphysiologic arterial oxygen levels and mortality in critically ill patients. A multicenter observational cohort study. Am J Respir Crit Care Med 200 (11) : 1373-1380, 2019
PubMed
P.249 掲載の参考文献
6) Chu DK, Kim LH, Young PJ et al : Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA) : a systematic review and meta-analysis. Lancet 391 (10131) : 1693-1705, 2018
PubMed
7) Schjorring OL, Klitgaard TL, Perner A et al : Lower or higher oxygenation targets for acute hypoxemic respiratory failure. N Engl J Med 384 (14) : 1301-1311, 2021
 
8) Echevarria C, Steer J, Wason J et al : Oxygen therapy and inpatient mortality in COPD exacerbation. Emerg Med J 38 (3) : 170-177, 2021
PubMed
9) Qaseem A, Etxeandia-Ikobaltzeta I, Fitterman N et al : Appropriate use of high-flow nasal oxygen in hospitalized patients for initial or postextubation management of acute respiratory failure : A clinical guideline from the American College of Physicians. Ann Intern Med 174 (7) : 977-984, 2021
PubMed
10) Rochwerg B, Brochard L, Elliott MW et al : Official ERS/ATS clinical practice guidelines : noninvasive ventilation for acute respiratory failure. Eur Respir J 50 (2) : 1602426, 2017
PubMed
11) Goligher EC, Costa ELV, Yarnell CJ et al : Effect of lowering Vt on mortality in acute respiratory distress syndrome varies with respiratory system elastance. Am J Respir Crit Care Med 203 (11) : 1378-1385, 2021
PubMed
12) Santa Cruz R, Villarejo F, Irrazabal C et al : High versus low positive end-expiratory pressure (PEEP) levels for mechanically ventilated adult patients with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev 3 : CD009098, 2021
 
13) Pensier J, de Jong A, Hajjej Z et al : Effect of lung recruitment maneuver on oxygenation, physiological parameters and mortality in acute respiratory distress syndrome patients : a systematic review and meta-analysis. Intensive Care Med 45 (12) : 1691-1702, 2019
PubMed
14) Sud S, Friedrich JO, Adhikari NKJ et al : Comparative effectiveness of protective ventilation strategies for moderate and severe acute respiratory distress syndrome. A network meta-analysis. Am J Respir Crit Care Med 203 (11) : 1366-1377, 2021
PubMed
P.250 掲載の参考文献
15) Alhazzani W, Belley-Cote E, Moller MH et al : Neuromuscular blockade in patients with ARDS : a rapid practice guideline. Intensive Care Med 46 (11) : 1977-1986, 2020
PubMed
16) National Heart, Lung, and Blood Institute PETAL Clinical Trial Network, Moss M, Huang DT et al : Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med 380 (21) : 1997-2008, 2019
PubMed
17) Villar J, Ferrando C, Martinez D et al : Dexamethasone treatment for the acute respiratory distress syndrome : a multicentre, randomised controlled trial. Lancet Respir Med 8 (3) : 267-276, 2020
PubMed
18) Chaudhuri D, Sasaki K, Karkar A et al : Corticosteroids in COVID-19 and non-COVID-19 ARDS : a systematic review and meta-analysis. Intensive Care Med 47 (5) : 521-537, 2021
PubMed
19) Lewis SR, Pritchard MW, Thomas CM et al : Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst Rev 7 : CD004477, 2019
PubMed
20) Munshi L, Walkey A, Goligher E et al : Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome : a systematic review and meta-analysis. Lancet Respir Med 7 (2) : 163-172, 2019
PubMed
21) Goligher EC, Tomlinson G, Hajage D et al : Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc bayesian analysis of a randomized clinical trial. JAMA 320 (21) : 2251-2259, 2018
 
22) Combes A, Hajage D, Capellier G et al : Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med 378 (21) : 1965-1975, 2018
PubMed
23) Argenziano MG, Bruce SL, Slater CL et al : Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York : retrospective case series. BMJ 369 : m1996, 2020
PubMed
24) Goligher EC, Ranieri VM, Slutsky AS : Is severe COVID-19 pneumonia a typical or atypical form of ARDS? And does it matter? Intensive Care Med 47 (1) : 83-85, 2021
PubMed
P.251 掲載の参考文献
25) Mathews KS, Soh H, Shaefi S et al : Prone positioning and survival in mechanically ventilated patients with coronavirus disease 2019-related respiratory failure. Crit Care Med 49 (7) : 1026-1037, 2021
PubMed
26) Badulak J, Antonini MV, Stead CM et al : Extracorporeal membrane oxygenation for COVID-19 : Updated 2021 Guidelines from the Extracorporeal Life Support Organization. ASAIO J 67 (5) : 485-495, 2021
PubMed
27) RECOVERY Collaborative Group ; Horby P, Lim WS, Emberson JR et al : Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384 (8) : 693-704, 2021
 
28) Tomazini BM, Maia IS, Cavalcanti AB et al : Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19 : The CoDEX randomized clinical trial. JAMA 324 (13) : 1307-1316, 2020
 
29) 日本静脈学会, 肺塞栓症研究会, 日本血管外科学会他 : 新型コロナウイルス感染症 (COVID-19) における静脈血栓塞栓症予防の診療指針. 2021年4月5日版 (Version 2.0)
Medical*Online
30) Lemos ACB, do Espirito Santo DA, Salvetti MC et al : Therapeutic versus prophylactic anticoagulation for severe COVID-19 : A randomized phase II clinical trial (HESACOVID). Thromb Res 196 : 359-366, 2020
PubMed
31) Lopes RD, de Barros ESPGM, Furtado RHM et al : Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION) : an open-label, multicentre, randomised, controlled trial. Lancet 397 (10291) : 2253-2263, 2021
 
32) INSPIRATION Investigators ; Sadeghipour P, Talasaz AH, Rashidi F et al : Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit : The INSPIRATION randomized clinical trial. JAMA 325 (16) : 1620-1630, 2021
PubMed
33) ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators et al : Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med 385 (9) : 790-802, 2021
PubMed
P.252 掲載の参考文献
34) REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators et al : Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med 385 (9) : 777-789, 2021
PubMed

XII章 肺腫瘍

P.255 掲載の参考文献
1) 肺癌診療ガイドライン-悪性胸膜中皮腫・胸腺腫瘍含む-2020年版. 金原出版, 2021
 
2) Bradley SH, Abraham S, Callister ME et al : Sensitivity of chest X-ray for detecting lung cancer in people presenting with symptoms : a systematic review. Br J Gen Pract 69 : e827-e835, 2019
PubMed
3) 経済産業省/国立研究開発法人日本医療研究開発 : 医用画像診断支援システム (人工知能技術を利用するものを含む) 開発ガイドライン 2019 (手引き) https://www.meti.go.jp/policy/mono_info_service/healthcare/iryou/downloadfiles/pdf/47_guideline.pdf
 
4) 厚生労働省 : 人工知能技術を利用した医用画像診断支援システムに関する評価指標 https://www.mhlw.go.jp/content/10601000/000515843.pdf
 
5) Nasrullah D, Sang J, Alam M et al : Automated lung nodule detection and classification using deep learning combined with multiple strategies. Sensors 19 : 3722, 2019
 
6) Bhandary A, Prabhu A, Rajinikanth V et al : Deep-learning framework to detect lung abnormality-a study with chest X-ray and lung CT scan images. Pattern Recognition Letters 129 : 271-278, 2020
 
7) Hoffman RM, Atallah RP, Struble RD et al : Lung cancer screening with low-dose CT : a meta-analysis. J Gen Intern Med 35 : 3015-3025, 2020
PubMed
8) US Preventive Services Task Force, Krist AH, Davidson KW et al : Screening for Lung Cancer : US Preventive Services Task Force. JAMA 325 : 962-970, 2021
PubMed
P.256 掲載の参考文献
9) 滝口裕一 : 低線量CTによる肺癌検診の進歩. 日内会誌 109 : 611-616, 2020
 
10) Cheng Z, Shan F, Yang Y et al : CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation : a systematic review and meta-analysis. BMC Medical Imaging 17 : 5, 2017
PubMed
11) Zhang H, Cai W, Wang Y et al : CT and clinical characteristics that predict risk of EGFR mutation in non-small cell lung cancer : a systematic review and meta-analysis. Int J Clin Oncol 24 : 649-659, 2019
 
P.257 掲載の参考文献
12) Du B, Wang S, Cui Y et al : Can 18F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis. BMJ Open 11 : e044313, 2021
 
13) Mendoza DP, Stowell J, Muzikansky A et al : Computed tomography imaging characteristics of non-small-cell lung cancer with anaplastic lymphoma kinase rearrangements : a systematic review and meta-analysis. Clin Lung Cancer 20 : 339-349, 2019
PubMed
14) Kim TH, Woo S, Yoon SH et al : CT characteristics of non-small cell lung cancer with anaplastic lymphoma kinase rearrangement : a systematic review and meta-analysis. AJR Am J Roentgenol 213 : 1059-1072, 2019
PubMed
15) Digumarthy SR, Mendoza DP, Lin JJ et al : Computed tomography imaging features and distribution of metastases in ROS1-rearranged non small-cell lung cancer. Clin Lung Cancer 21 : 153-159.e9, 2020
 
16) Halpenny DF, Plodkowski A, Riely G et al : Radiogenomic evaluation of lung cancer-Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations? Clin Imaging 42 : 147-151, 2017
PubMed
17) Mendoza DP, Dagogo-Jack I, Chen T et al : Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class. Lung Cancer 129 : 80-84, 2019
PubMed
18) Digumarthy SR, Mendoza DP, Zhang EW et al : Clinicopathologic and imaging features of non-small-cell lung cancer with MET exon 14 skipping mutations. Cancers (Basel) 11 : 2033, 2019
PubMed
19) Digumarthy SR, Mendoza DP, Lin JJ et al : Imaging features and patterns of metastasis in non-small cell lung cancer with RET rearrangements. Cancers (Basel) 12 : 693, 2020
PubMed
20) Li M, Zhang L, Tang W et al : Identification of epidermal growth factor receptor mutations in pulmonary adenocarcinoma using dual-energy spectral computed tomography. Eur Radiol 29 : 2989-2997, 2019
 
21) Zhang G, Cao Y, Zhang J et al : Epidermal growth factor receptor mutations in lung adenocarcinoma : associations between dual-energy spectral CT measurements and histologic results. J Cancer Res Clin Oncol 147 : 1169-1178, 2021
PubMed
P.258 掲載の参考文献
22) Yoon J, Suh YJ, Han K et al : Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas. Thorac Cancer 11 : 993-1004, 2020
PubMed
23) Zhao L, Liu J, Wang H et al : Association between 18F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC) resection specimens. Br J Radiol 94 : 20200397, 2021
PubMed
24) 梁川雅弘, 富山憲幸 : 肺癌の定量的CT診断. 肺癌 59 : 29-36, 2019
Medical*Online
25) Ferreira-Junior JR, Koenigkam-Santos M, Magalhaes Tenorio AP et al : CT-based radiomics for prediction of histologic sub-type and metastatic disease in primary malignant lung neoplasms. Int J Comput Assist Radiol Surg 15 : 163-172, 2020
 
P.259 掲載の参考文献
26) Zhan Y, Peng X, Shan F et al : Attenuation and morphologic characteristics distinguishing a ground-glass nodule measuring 5-10mm in diameter as invasive lung adenocarcinoma on thin-slice CT. Am J Roentgenol 213 : W162-W170, 2019
 
27) Sun J, Liu K, Tong H et al : CT texture analysis for differentiating bronchiolar adenoma, adenocarcinoma in situ, and minimally invasive adenocarcinoma of the lung. Front Oncol 11 : 634564, 2021
PubMed
28) Zhao W, Xu Y, Yang Z et al : Development and validation of a radiomics nomogram for identifying invasiveness of pulmonary adenocarcinomas appearing as subcentimeter ground-glass opacity nodules, Eur J Radiol 112 : 161-168, 2019
 
29) Meng F, Guo Y, Li M et al : Radiomics nomogram : A noninvasive tool for preoperative evaluation of the invasiveness of pulmonary adenocarcinomas manifesting as ground-glass nodules. Transl Oncol 14 : 100936, 2021
 
30) Jiang C, Luo Y, Yuan J et al : CT-based radiomics and machine learning to predict spread through air space in lung adenocarcinoma. Eur Radiol 30 : 4050-4057, 2020
 
31) Yin Q, Wang H, Cui H et al. Meta-analysis of association between CT-based features and tumor spread through air spaces in lung adenocarcinoma. J Cardiothorac Surg 15 : 243, 2020
PubMed
32) Hong D, Xu K, Zhang L et al : Radiomics signature as a predictive factor for EGFR mutations in advanced lung adenocarcinoma. Front Oncol 10 : 28, 2020
PubMed
33) Tu W, Sun G, Fan L et al : Radiomics signature : A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology. Lung Cancer 132 : 28-35, 2019
 
34) Park S, Lee SM, Kim S et al : Volume doubling times of lung adenocarcinomas : correlation with predominant histologic subtypes and prognosis. Radiology 295 : 703-712, 2020
 
P.260 掲載の参考文献
35) Hong JH, Park S, Kim H et al : Volume and mass doubling time of lung adenocarcinoma according to WHO histologic classification. Korean J Radiol 22 : 464-475, 2021
 
36) Hong D, Zhang L, Xu K et al : Prognotic value of pre-treatment CT radiomics and clinical factors for the overall survival of advanced (IIIB-IV) lung adenocarcinoma patients. Front Oncol 11 : 628982, 2021
 
37) Wong CW, Chaudhry A : Radiogenomics of lung cancer. J Thorac Dis 12 : 5104-5109, 2020
PubMed
P.261 掲載の参考文献
1) Oki M, Saka H, Asano F et al : Use of an ultrathin vs thin bronchoscope for peripheral pulmonary lesions : A randomized trial. Chest 156 (5) : 954-964, 2019
PubMed
P.262 掲載の参考文献
2) Xu CH, Wang JW, Wang W et al : The diagnosis value of endobronchial ultrasound transbronchial lung biopsy combined with rapid on-site evaluation in peripheral lung cancer. Clin Respir J 14 (5) : 447-452, 2020
PubMed
3) Umeda Y, Otsuka M, Nishikiori H et al : Feasibility of rapid on-site cytological evaluation of lung cancer by a trained pulmonologist during bronchoscopy examination. Cytopathology 30 (6) : 628-633, 2019
PubMed
4) Souma T, Minezawa T, Yatsuya H et al : Risk factors of infectious complications after endobronchial ultrasound-guided transbronchial biopsy. Chest 158 (2) : 797-807, 2020
PubMed
5) Gotoh Y, Yamaguchi T, Yatsuya H et al : Predictive risk factors for pneumothorax after transbronchial biopsy using endobronchial ultrasonography with a guide sheath. BMC Pulm Med 21 (1) : 181, 2021
PubMed
P.263 掲載の参考文献
6) Liu Y, Wang F, Zhang QC et al : Value of virtual bronchoscopic navigation and transbronchial ultrasound-guided sheath-guided exploration in diagnosis of peripheral lung cancer. World J Clin Cases 8 (16) : 3450-3457, 2020
 
7) Li S, Yan W, Chen M et al : Virtual bronchoscopic navigation without fluoroscopy guidance for peripheral pulmonary lesions in inexperienced pulmonologist. Chin J Cancer Res 32 (4) : 530-539, 2020
 
8) Steinhauser Motta JP, Steffen RE, Samary Lobato C et al : Endobronchial ultrasound-guided transbronchial needle aspiration versus mediastinoscopy for mediastinal staging of lung cancer : A systematic review of economic evaluation studies. PLoS One 15 (6) : e0235479, 2020
 
9) Leong TL, Loveland PM, Gorelik A et al : Preoperative staging by EBUS in cN0/ N1 lung cancer : Systematic review and meta-analysis. J Bronchology Interv Pulmonol 26 (3) : 155-165, 2019
PubMed
10) Ozturk A, Gullu YT : Excellence in non-small cell lung cancer staging by endobronchial-TBNA : Comparison with PETCT and surgery. Minim Invasive Ther Allied Technol 28 (4) : 213-219, 2019
PubMed
P.264 掲載の参考文献
11) Fujiwara T, Nakajima T, Inage T et al : The combination of endobronchial elastography and sonographic findings during endobronchial ultrasound-guided transbronchial needle aspiration for predicting nodal metastasis. Thorac Cancer 10 (10) : 2000-2005, 2019
PubMed
12) Kuijvenhoven JC, Leoncini F, Crombag LC et al : Endobronchial Ultrasound for the Diagnosis of Centrally Located Lung Tumors : A Systematic Review and Meta-Analysis. Respiration 99 (5) : 441-450, 2020
PubMed
13) Shen Y, Qin S, Jiang H : Endobronchial ultrasound-guided transbronchial needle aspiration combined with either endoscopic ultrasound-guided fine-needle aspiration or endoscopic ultrasound using the EBUS scope-guided fine-needle aspiration for diagnosing and staging mediastinal diseases : a systematic review and meta-analysis. Clinics (Sao Paulo) 75 : e1759, 2020
 
14) Yoshimura K, Inoue Y, Karayama M et al : Heterogeneity analysis of PD-L1 expression and copy number status in EBUSTBNA biopsy specimens of non-small cell lung cancer : Comparative assessment of primary and metastatic sites. Lung Cancer 134 : 202-209, 2019
PubMed
15) Tsunoda A, Morikawa K, Inoue T et al : A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer. BMC Cancer 19 (1) : 546, 2019
 
16) Tajarernmuang P, Ofiara L, Beaudoin S et al : Real-world outcomes of patients with advanced non-small cell lung cancer treated with Anti-PD1 therapy on the basis of PD-L1 results in EBUS-TBNA vs Histological Specimens. Chest, 2021 [online ahead of print]
 
17) Sakairi Y, Nakajima T, Yoshino I : Role of endobronchial ultrasound-guided transbronchial needle aspiration in lung cancer management. Expert Rev Respir Med 13 (9) : 863-870, 2019
PubMed
P.265 掲載の参考文献
18) Udagawa H, Kirita K, Naito T et al : Feasibility and utility of transbronchial cryobiopsy in precision medicine for lung cancer : Prospective single-arm study. Cancer Sci 111 (7) : 2488-2498, 2020
PubMed
19) Tone M, Inomata M, Awano N et al : Comparison of adequacy between transbronchial lung cryobiopsy samples and endobronchial ultrasound-guided transbronchial needle aspiration samples for nextgeneration sequencing analysis. Thorac Cancer 12 (2) : 251-258, 2021
PubMed
20) Matsumoto Y, Nakai T, Tanaka M et al : Diagnostic outcomes and safety of cryobiopsy added to conventional sampling methods : An observational study. Chest, 2021 [online ahead of print]
 
21) Herth FJ, Mayer M, Thiboutot J et al : Safety and performance of transbronchial cryobiopsy for parenchymal lung lesions. Chest, 2021 [online ahead of print]
 
22) Inomata M, Kuse N, Awano N et al : Prospective multicentre study on the safety and utility of transbronchial lung cryobiopsy with endobronchial balloon. ERJ Open Res 6 (2) : 00008-2020, 2020
PubMed
23) Inomata M, Kuse N, Awano N et al : Utility of radial endobronchial ultrasonography combined with transbronchial lung cryobiopsy in patients with diffuse parenchymal lung diseases : a multicentre prospective study. BMJ Open Respir Res 8 (1) : e000826, 2021
 
P.266 掲載の参考文献
24) Kage H, Kohsaka S, Shinozaki-Ushiku A et al : Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing. Cancer Sci 110 (8) : 2652-2657, 2019
PubMed
25) Furuya N, Matsumoto S, Kakinuma K et al : Suitability of transbronchial brushing cytology specimens for next-generation sequencing in peripheral lung cancer. Cancer Sci 112 (1) : 380-387, 2021
PubMed
P.267 掲載の参考文献
1) 肺癌診療ガイドライン https://www.haigan.gr.jp/modules/guideline/index.php?content_id=3
 
2) Rudin CM et al. J Clin Oncol 33 (34) : 4106-4111, 2015
PubMed
3) NCCN Guideline 2022, version 1 https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
 
4) Pignon JP et al. N Engl J Med 327 (23) : 1618-1624, 1992
PubMed
5) Warde P et al. J Clin Oncol 10 (6) : 890-895, 1992
 
6) Turrisi AT 3rd et al. N Engl J Med 340 (4) : 265-271, 1999
PubMed
7) Takada M et al. J Clin Oncol 20 (14) : 3054-3060, 2002
PubMed
P.268 掲載の参考文献
8) Faivre-Finn C, Snee M, Ashcroft L et al : Concurrent once-daily versus twicedaily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT) : an open-label, phase 3, randomised, superiority trial. Lancet Oncol 18 (8) : 1116-1125, 2017
PubMed
9) Horn L, Mansfield AS, Szczesna A et al : First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379 (23) : 2220-2229, 2018
PubMed
10) Paz-Ares L, Dvorkin M, Chen Y et al : Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : a randomised, controlled, open-label, phase 3 trial. Lancet 39 (10212) : 1929-1939, 2019
 
11) Welsh JW, Heymach JV, Guo C et al : Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. J Thorac Oncol 15 (12) : 1919-1927, 2020
PubMed
P.269 掲載の参考文献
12) Salem A, Mistry H, Hatton M et al : Association of chemoradiotherapy with outcomes among patients with stage I to II vs stage III small cell lung cancer : Secondary analysis of a randomized clinical trial. JAMA Oncol 5 (3) : e185335, 2019
 
P.270 掲載の参考文献
13) Takahashi T, Yamanaka T, Seto T et al : Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer : a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 18 (5) : 663-671, 2017
PubMed
14) Levy A, Pechoux CL, Mistry H et al : Prophylactic cranial irradiation for limited-stage small-cell lung cancer patients : Secondary findings from the prospective randomized phase 3 CONVERT Trial. J Thorac Oncol 14 (2) : 294-297, 2019
 
15) Daly ME, Ismalia N, Decker RH et al : Radiation therapy for small-cell lung cancer : ASCO Guideline Endorsement of an ASTRO Guideline. J Clin Oncol 39 : 931-939, 2021
 
16) Radriguez de Dios N, Counago F, Murcia-Mejia M et al : Randomized phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for smallcell lung cancer (PREMER) : A GICOR-GOECP-SEOR Study. J Clin Oncol 39 : 3118-3127, 2021
PubMed
P.272 掲載の参考文献
1) Noda K et al. N Engl J Med 346 (2) : 85-91, 2002
PubMed
2) 日本肺癌学会編 : 肺癌診療ガイドライン 2020年版. 2021
 
3) Liu SV, Reck M, Mansfield AS et al : Updated overall survival and PD-L1 subgroup analysis of patients with extensivestage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 39 (6) : 619-630, 2021
PubMed
4) Mansfield AS, Kazarnowicz A, Karaseva N et al : Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133) : a randomized phase I/III trial. Ann Oncol 31 (2) : 310-317, 2020
PubMed
5) Nishio M, Sugawara S, Atagi S et al : Subgroup analysis of Japanese patients in a phase III study of atezolizumab in extensive-stage small-cell lung cancer (IMpower133). Clin Lung Cancer 20 (6) : 469-476.e1, 2019
 
6) Paz-Ares L, Dvorkin M, Chen Y et al : Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : a randomised, controlled, open-label, phase 3 trial. Lancet 394 (10212) : 1929-1939, 2019
PubMed
7) Goldman JW, Dvorkin M, Chen Y et al : Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 22 (1) : 51-65, 2021
 
P.273 掲載の参考文献
8) Rudin CM, Awad MM, Navarro A et al : Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer : Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol 38 (21) : 2369-2379, 2020
 
9) Leal T, Wang Y, Dowlati A et al : Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC) : ECOG-ACRIN EA5161. J Clin Oncol 38 (15_suppl) : 9000-9000, 2020
 
10) Chen J, Wang J, Xu H : Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer. Medicine 100 (15) : e25180, 2021
 
P.274 掲載の参考文献
11) Coutinho AD, Shah M, Lunacsek OE et al : Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy. Lung Cancer 127 : 53-58, 2019
PubMed
12) Baize N, Monnet I, Greillier L et al : Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer : an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 21 (9) : 1224-1233, 2020
PubMed
13) Trigo J, Subbiah V, Besse B et al : Lurbinectedin as second-line treatment for patients with small-cell lung cancer : a single-arm, open-label, phase 2 basket trial. Lancet Oncol 21 (5) : 645-654, 2020
PubMed
P.275 掲載の参考文献
14) Singh S, Jaigirdar AA, Mulkey F et al : FDA approval summary : Lurbinectedin for the treatment of metastatic small cell lung cancer. Clin Cancer Res 27 (9) : 2378-2382, 2021
PubMed
15) Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA et al : ATLANTIS : a phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future Oncol 15 (3) : 231-239, 2019
PubMed
16) Marabelle A, Le DT, Ascierto PA et al : Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer : Results from the phase II KEYNOTE-158 Study. J Clin Oncol 38 (1) : 1-10, 2020
PubMed
17) Le DT, Durham JN, Smith KN et al : Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357 (6349) : 409-413, 2017
 
18) Ott PA, Elez E, Hiret S et al : Pembrolizumab in patients with extensive-stage small-cell lung cancer : Results from the phase Ib KEYNOTE-028 study. J Clin Oncol 35 (34) : 3823-3829, 2017
PubMed
19) Chung HC, Lopez-Martin JA, Kao SCH etal : Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC) : KEYNOTE-158. J Clin Oncol 36 (15_suppl) : 8506-8506, 2018
 
20) Chung HC, Piha-Paul SA, Lopez-Martin J et al : Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC : Results from the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac Oncol 15 (4) : 618-627, 2020
 
P.276 掲載の参考文献
21) Ready NE, Ott PA, Hellmann MD et al : Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer : Results from the CheckMate 032 Randomized Cohort. J Thorac Oncol 15 (3) : 426-435, 2020
PubMed
22) Spigel DR, Vicente D, Ciuleanu TE et al : Second-line nivolumab in relapsed smallcell lung cancer : CheckMate 331☆. Ann Oncol 32 (5) : 631-641, 2021
 
P.277 掲載の参考文献
1) Goldstraw P, Chansky K, Crowley J et al ; The IASLC Lung Cancer Staging Project : Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 11 : 39-51, 2016
PubMed
2) Travis WD, Asamura H, Bankier AA et al ; The IASLC Lung Cancer Staging Project : Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classication of Lung Cancer. J Thorac Oncol 11 (8) : 1204-1223, 2016
 
P.278 掲載の参考文献
3) Sebio Garcia R, Yanez Brage MI, Gimenez Moolhuyzen E et al : Functional and postoperative outcomes after preoperative exercise training in patients with lung cancer : a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg 23 (3) : 486-497, 2016
PubMed
4) Lai Y, Su J, Qiu P et al : Systematic short-term pulmonary rehabilitation before lung cancer lobectomy : a randomized trial. Interact Cardiovasc Thorac Surg 25 (3) : 476-483, 2017
PubMed
5) Bhatia C, Kayser B : Preoperative high-intensity interval training is effective and safe in deconditioned patients with lung cancer : A randomized clinical trial. J Rehabil Med 51 (9) : 712-718, 2019
PubMed
6) Palma S, Hasenoehrl T, Jordakieva G et al : High-intensity interval training in the prehabilitation of cancer patients-a systematic review and meta-analysis. Supportive Care in Cancer 29 : 1781-1794, 2021
PubMed
7) Eba J, Nakamura K, Mizusawa J et al : Stereotactic body radiotherapy versus lobectomy for operable clinical stage IA lung adenocarcinoma : comparison of survival outcomes in two clinical trials with propensity score analysis (JCOG1313-A). Jpn J Clin Oncol 46 (8) : 748-753, 2016
PubMed
8) Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Shimizu H, Okada M et al : Thoracic and cardiovascular surgeries in Japan during 2018. Annual report by the Japanese Association for Thoracic Surgery. Gen thorac Cardiovasc Surg 69 : 179-212, 2021
PubMed
P.279 掲載の参考文献
9) Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Masuda M, Endo S, Natsugoe S et al : Thoracic and cardiovascular surgeriy in Japan during 2015. Annual report by the Japanese Association for Thoracic Surgery. Gen thorac Cardiovasc Surg 66 : 581-615, 2018
 
10) Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Shimizu H, Okada M et al : Thoracic and cardiovascular surgeries in Japan during 2017. Annual report by the Japanese Association for Thoracic Surgery. Gen thorac Cardiovasc Surg 68 : 414-449, 2020
PubMed
11) Ikeda N : Updates on minimally invasive surgery in non-small cell lung cancer. Curr Treat Options in Oncol 20 : 16, 2019
PubMed
12) Ikeda N, Endo S, Fukuchi E et al : Current status of surgery for clinical stage IA lung cancer in Japan : analysis of the national clinical database. Surg Today 50 : 1644-1651, 2020
PubMed
P.280 掲載の参考文献
13) Emmert A, Straube C, Buentzel J et al : Robotic versus thoracoscopic lung resection : a systematic review and meta-analysis. Medicine (Baltimore) 96 (35) : e7633, 2017
 
14) Hu X, Wang M : Efficacy and safety of robot-assisted thoracic surgery (RATS) compare with video-assisted thoracoscopic surgery (VATS) for lung lobectomy in patients with non-small cell lung cancer. Comb Chem High Throughput Screen 22 (3) : 169-178, 2019
PubMed
15) Suzuki K, Koike T, Asakawa T et al : A prospective radiological study of thinsection computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol 6 (4) : 751-756, 2011
PubMed
16) Suzuki K, Watanabe S, Wakabayashi M et al : A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer. J Thorac Cardiovasc Surg, 2020 [online ahead of print]
 
17) Nakamura K, Saji H, Nakajima R et al : A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol 40 : 271-274, 2010
PubMed
P.281 掲載の参考文献
18) Okada M, Tsubota N, Yoshimura M et al : Proposal for reasonable mediastinal lymphadenectomy in bronchogenic carcinomas role of subcarinal nodes in selective dissection. J Thorac Cardiovasc Surg 116 (6) : 949-953, 1998
PubMed
19) Asamura H, Nakayama H, Kondo H et al : Lobe-specific extent of systematic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastasis and prognosis. J Thorac Cardiovasc Surg 117 (6) : 1102-1111, 1999
PubMed
20) Darling GE, Allen MS, Decker PA : Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma : results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 141 (3) : 662-670, 2011
PubMed
21) Hishida T, Saji H, Watanabe S et al : A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I- IInon-small cell lung cancer (JCOG1413). Jpn J Clin Oncol 48 (2) : 190-194, 2018
 
22) Hamada C, Tanaka F, Ohta M et al : Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23 (22) : 4999-5006, 2005
PubMed
P.282 掲載の参考文献
23) Zhong WZ, Wang Q, Mao WM et al : Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II- IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104) : a randomised, open-label, phase 3 study. Lancet Oncol 19 (1) : 139-148, 2018
 
24) Zhong WZ, Wang Q, Mao WM et al : Gefitinib versus vinorelbine plus Ccisplatin as adjuvant treatment for stage II-III 282
 
25) Tada H, Mithudomi T, Yamanaka T et al : Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II- III non-small cell lung cancer (IMPACT, WJOG6410L) : A randomized phase 3 trial. J Clin Oncol 39 (15) : 8501, 2021
 
26) Wu YL, Tsuboi M, He J et al : Osimertinib in Resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 383 (18) : 1711-1723, 2020
PubMed
27) Yotsukura M, Nakagawa K, Suzuki K et al : Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer. Jpn J Clin Oncol 51 (1) : 28-36, 2021
PubMed
P.283 掲載の参考文献
1) Moore S, Leung B, Wu J : Real-world treatment of stage III NSCLC : The role of trimodality treatment in the era of immunotherapy. J Thorac Oncol 14 (8) : 1430-1439, 2019
PubMed
P.284 掲載の参考文献
2) Zenke Y, Tsuboi M, Chiba Y et al : Effect of second-generation vs third-generation chemotherapy regimens with thoracic radiotherapy on unresectable stage III non-small-cell lung cancer : 10-year follow-up of a WJTOG0105 phase 3 randomized clinical trial. JAMA Oncology 7 (6) : 904-909, 2021
PubMed
3) Horinouchi H, Atagi S, Oizumi S et al : Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer : The SOLUTION study. Cancer Med 9 (18) : 6597-6608, 2020
PubMed
P.285 掲載の参考文献
4) Faivre-Finn C, Vicente D, Kurata T et al : Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC Trial. J Thorac Oncol 16 (5) : 860-867, 2021
 
5) Hui R, Ozguroglu M, Villegas A et al : Patient- reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC) : a randomised, controlled, phase 3 study. Lancet Oncol 20 (12) : 1670-1680, 2019
PubMed
6) Socinski MA, Ozguroglu M, Villegas A et al : Durvalumab after concurrent chemoradiotherapy in elderly patients with unresectable stage III non-small-cell lung cancer (PACIFIC). Clin Lung Cancer, 2021
PubMed
7) Paz-Ares L, Spira A, Raben D et al : Outcomes with durvalumab by tumour PDL1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol 31 (6) : 798-806, 2020
PubMed
P.286 掲載の参考文献
8) Faivre-Finn C, Spigel DR, Senan S et al : Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer 151 : 30-38, 2021
PubMed
9) Hellyer JA, Aredo JV, Das M et al : Role of consolidation durvalumab in patients with EGFR- and HER2-mutant unresectable stage III NSCLC. J Thorac Oncol 16 (5) : 868-872, 2021
PubMed
10) Sugimoto T, Fujimoto D, Sato Y et al : Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy : a multicenter prospective cohort study. Invest New Drugs 39 (3) : 853-859, 2021
PubMed
11) Saito S, Abe T, Kobayashi N et al : Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer. Clin Translational Rad Oncol 23 : 85-88, 2020
 
12) Inoue H, Ono A, Kawabata T et al : Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer. Investigational New Drugs 38 : 1612-1617, 2020
PubMed
13) Kenmotsu H, Yamamoto N, Yamanaka T et al : Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage II to IIIA nonsquamous non-small-cell lung cancer. J Clin Oncol 38 (19) : 2187-2196, 2020
 
14) Sakai K, Tsuboi M, Kenmotsu H et al : Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANGTR). Cancer Sci 112 (1) : 388-396, 2021
PubMed
P.287 掲載の参考文献
15) Lei T, Li J, Zhong H et al : Postoperative radiotherapy for patients with resectable stage III-N2 non-small cell lung cancer : A systematic review and meta-analysis. Front Oncol 11 : 680615, 2021
 
16) Zhong WZ, Wang Q, Mao WM et al : Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC : Final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol 39 (7) : 713-722, 2021
 
17) Wu YL, Tsuboi M, He J et al : Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 383 (18) : 1711-1723, 2020
PubMed
18) Tsuboi M, Weder W, Escriu C et al : Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-smallcell lung cancer : NeoADAURA. Future Oncol, 2021
PubMed
19) Leonetti A, Minari R, Boni L et al : Phase II, open-label, single-arm, multicenter study to assess the activity and safety of alectinib as neoadjuvant treatment in surgically resectable stage III ALK-positive NSCLC : ALNEO Trial. Clin Lung Cancer 22 : 473-477, 2021
PubMed
P.288 掲載の参考文献
20) Cascone T, William Jr WN, Weissferdt A et al : Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer : the phase 2 randomized NEOSTAR trial. Nat Med 27 (3) : 504-514, 2021
 
21) Provencio M, Nadal E, Insa A et al : Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM) : an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21 (11) : 1413-1422, 2020
PubMed
22) Hamada A, Soh J, Hata A et al : Phase II study of neoadjuvant concurrent chemoimmuno-radiation therapy followed by surgery and adjuvant immunotherapy for resectable stage IIIA-B (Discrete N2) non-small-cell lung cancer : SQUAT trial (WJOG 12119L). Clin Lung Cancer, 2021 [online ahead of print]
 
P.290 掲載の参考文献
1) Ohe Y, Imamura F, Nogami N et al : Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC : FLAURA Japanese subset. Jpn J Clin Oncol 49 (1) : 29-36, 2019
PubMed
P.291 掲載の参考文献
2) Soria JC, Ohe Y, Vansteenkiste J et al : Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378 (2) : 113-125, 2018
PubMed
3) Ramalingam SS, Vansteenkiste J, Planchard D et al : Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382 (1) : 41-50, 2020
PubMed
4) Cho JH, Lim SH, An HJ et al : Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations : A multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol 38 (5) : 488-495, 2020
PubMed
5) Wu YL, Cheng Y, Zhou X et al : Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050) : a randomised, open-label, phase trial. Lancet Oncol 18 (11) : 1454-1466, 2017
PubMed
P.292 掲載の参考文献
6) Park K, Tan EH, O'Byrne K et al : Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7) : a phase 2B, open-label, randomised 7) : a phase 2B, open-label, randomis Lancet Oncol 17 (5) : 577-589, 2016
 
7) Paz-Ares L, Tan EH, O'Byrne K et al : Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer : overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 28 (2) : 270-277, 2017
PubMed
8) Yang JCH et al. Lancet Oncol 16 (7) : 830-838, 2015
PubMed
9) Hosomi Y, Morita S, Sugawara S et al : Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor : NEJ009 Study. J Clin Oncol 38 (2) : 115-123, 2020
PubMed
10) Noronha V, Patil VM, Joshi A et al : Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol 38 (2) : 124-136, 2020
PubMed
11) Seto T et al. Lancet Oncol 15 (11) : 1236-1244, 2014
PubMed
12) Yamamoto N, Seto T, Nishio M et al : Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer : Survival follow-up results of the randomized JO25567 study. Lung Cancer 151 : 20-24, 2021
PubMed
P.293 掲載の参考文献
13) Saito H, Fukuhara T, Furuya N et al : Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026) : interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 20 (5) : 625-635, 2019
PubMed
14) Nakagawa K, Garon EB, Seto T et al : Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20 (12) : 1655-1669, 2019
PubMed
P.294 掲載の参考文献
15) Hida T, Nokihara H, Kondo M et al : Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (JALEX) : an open-label, randomised phase 3 trial. Lancet 390 (10089) : 29-39, 2017
PubMed
16) Nakagawa K, Hida T, Nokihara H et al : Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer 139 : 195-199, 2020
 
17) Yoshioka H, Hida T, Nokihara H et al : Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK + NSCLC). J Clin Oncol 39 (15_suppl) : 9022, 2021
 
18) Peters S, Camidge DR, Shaw AT et al : Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377 (9) : 829-838, 2017
PubMed
19) Zhou C, Kim SW, Reungwetwattana T et al : Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA) : a randomised phase 3 study. Lancet Respir Med 7 (5) : 437-446, 2019
PubMed
20) Wu YL, Lu S, Lu Y et al : Results of PROFILE 1029, a phase III comparison of firstline crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol 13 (10) : 1539-1548, 2018
PubMed
21) Solomon BJ et al. N Engl J Med 371 (23) : 2167-2177, 2014
PubMed
22) Soria JC, Tan DSW, Chiari R et al : Firstline ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4) : a randomised, open-label, phase 3 study. Lancet 389 (10072) : 917-929, 2017
PubMed
23) Shaw AT, Bauer TM, De Marinis F et al : First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383 (21) : 2018-2029, 2020
 
P.295 掲載の参考文献
24) Camidge DR, Kim HR, Ahn M-J et al : Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med 379 (21) : 2027-2039, 2018
PubMed
25) Shaw AT et al. N Engl J Med 371 (21) : 1963-1971, 2014
PubMed
26) Shaw AT, Riely GJ, Bang YJ et al : Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC) : updated results, including overall survival, from PROFILE 1001. Ann Oncol 30 (7) : 1121-1126, 2019
PubMed
27) Michels S, Massuti B, Schildhaus HU et al : Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS) : A European phase II clinical trial. J Thorac Oncol 14 (7) : 1266-1276, 2019
PubMed
28) Landi L, Chiari R, Tiseo M et al : Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS) : A phase II, prospective, multicenter, two-arms trial. Clin Cancer Res 25 (24) : 7312-7319, 2019
PubMed
29) Moro-Sibilot D, Cozic N, Perol M et al : Crizotinib in c-MET- or ROS1-positive NSCLC : results of the AcSe phase II trial. Ann Oncol 30 (12) : 1985-1991, 2019
PubMed
30) Drilon A, Siena S, Dziadziuszko R et al : Entrectinib in ROS1 fusion-positive non-small-cell lung cancer : integrated analysis of three phase 1-2 trials. Lancet Oncol 21 (2) : 261-270, 2020
PubMed
31) Planchard D, Smit EF, Groen HJM et al : Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer : an open-label, phase 2 trial. Lancet Oncol 18 (10) : 1307-1316, 2017
PubMed
32) Paik PK, Felip E, Veillon R et al : Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med 383 (10) : 931-943, 2020
PubMed
P.296 掲載の参考文献
33) Seto T, Ohashi K, Sugawara S et al : Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC : GEOMETRY mono-1 study. Cancer Sci 112 (4) : 1556-1566, 2021
 
P.297 掲載の参考文献
34) Reck M et al. N Engl J Med 375 (19) : 1823-1833, 2016
 
35) Reck M, Rodriguez-Abreu D, Robinson AG et al : Updated analysis of KEYNOTE-024 : Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37 (7) : 537-546, 2019
PubMed
36) Mok TSK, Wu Y-L, Kudaba I et al : Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042) : a randomised, open-label, controlled, phase 3 trial. Lancet 393 (10183) : 1819-1830, 2019
PubMed
P.298 掲載の参考文献
37) Herbst RS, Giaccone G, De Marinis F et al : Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med 383 (14) : 1328-1339, 2020
PubMed
38) Gandhi L, Rodriguez-Abreu D, Gadgeel S et al : Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378 (22) : 2078-2092, 2018
PubMed
39) Gadgeel S, Rodriguez-Abreu D, Speranza G et al : Updated analysis from KEYNOTE-189 : Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 38 (14) : 1505-1517, 2020
 
40) Paz-Ares L, Luft A, Vicente D et al : Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379 (21) : 2040-2051, 2018
PubMed
P.299 掲載の参考文献
41) Socinski MA, Jotte RM, Cappuzzo F et al : Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378 (24) : 2288-2301, 2018
PubMed
42) Reck M, Mok TSK, Nishio M et al : Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150) : key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 7 (5) : 387-401, 2019
 
43) West H, McCleod M, Hussein M et al : Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130) : a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20 (7) : 924-937, 2019
PubMed
P.300 掲載の参考文献
44) Hellmann MD, Paz-Ares L, Bernabe Caro R et al : Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381 (21) : 2020-2031, 2019
PubMed
45) Paz-Ares L, Ciuleanu TE, Cobo M et al : First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA) : an international, randomised, open-label, phase 3 trial. Lancet Oncol 22 (2) : 198-211, 2021
PubMed

XIII章 縦隔の疾患

P.302 掲載の参考文献
1) Miyazawa R, Matsusako M, Nozaki T et al : Incidental mediastinal masses detected at low-dose CT screening : prevalence and radiological characteristics. Jpn J Radiol 38 (12) : 1150-1157, 2020
PubMed
2) Hsu CH, Chan JK, Yin CH et al : Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States. PLoS One 14 (12) : e0227197, 2019
 
P.303 掲載の参考文献
3) Menon D, Katzberg H, Barnett C et al : Thymoma pathology and myasthenia gravis outcomes. Muscle Nerve 63 (6) : 868-873, 2021
PubMed
4) Lee J, Cho YS, Kim J et al : Prognostic significance of metabolic parameters by 18F-FDG PET/CT in Thymic Epithelial Tumors. Cancers (Basel) 13 (4) : 712, 2021
 
5) Jung W, Cho S, Yum S et al : Differentiating thymoma from thymic cyst in anterior mediastinal abnormalities smaller than 3 cm. J Thorac Dis 12 (4) : 1357-1365, 2020
 
6) Bilaceroglu S : How to obtain adequate biopsy specimen in suspected thymic tumors. J Thorac Dis 12 (12) : 7598-7606, 2020
PubMed
7) Shintani Y, Funaki S, Ose N et al : Surgical management of thymic epithelial tumors. Surg Today 51 (3) : 331-339, 2021
PubMed
8) Tassi V, Vannucci J, Ceccarelli S et al : Stage-related outcome for thymic epithelial tumours. BMC Surg 18 (Suppl 1) : 114, 2019
 
P.304 掲載の参考文献
9) Pulle MV, Asaf BB, Puri HV et al : Meta-analysis of limited thymectomy versus total thymectomy for Masaoka stage I and II thymoma. J Chest Surg 54 (2) : 127-136, 2021
 
10) Yang CJ, Hurd J, Shah SA et al : A national analysis of open versus minimally invasive thymectomy for stage I to III thymoma. J Thorac Cardiovasc Surg 160 (2) : 555-567.e15, 2020
 
11) Weng W, Li X, Meng S et al : Video-assisted thoracoscopic thymectomy is feasible for large thymomas : a propensity-matched comparison. Interact Cardiovasc Thorac Surg 30 (4) : 565-572, 2020
 
12) Jiang L, Chen H, Hou Z et al : Subxiphoid versus unilateral VATS thymectomy for thymomas : A propensity score-matching analysis. Ann Thorac Surg, 2021 [online ahead of print]
 
13) Jiang SC, Hu H, Guo CY et al : Thoracic tumor resection combined with SVC replacement using autologous pericardium. World J Surg Oncol 17 (1) : 227, 2019
 
14) Clermidy H, Maury JM, Collaud S et al : Lymph node dissection in thymoma : Is it worth it?, Lung Cancer 157 : 156-162, 2021
PubMed
15) Muslim Z, Baig MZ, Connery C et al : Thymic tumors : Which patients should receive post-operative radiotherapy? Chest 158 (4) : 1179a, 2020
 
16) Tateishi Y, Horita N, Namkoong H et al : Postoperative radiotherapy for completely resected Masaoka/Masaoka-Koga Stage II/III thymoma improves overall survival : An updated meta-analysis of 4746 patients. J Thorac Oncol 16 (4) : 677-685, 2021
PubMed
17) Yu Z, Yu L, Yu T et al : Surgical feasibility and long-term outcome of superior vena cava replacement for advanced thymoma in patients undergoing preoperative chemotherapy or chemoradiotherapy. Thorac Cancer 12 (7) : 1074-1083, 2021
PubMed
18) Kimura K, Kanzaki R, Kimura T et al : Long-term outcomes after surgical resection for pleural dissemination of thymoma. Ann Surg Oncol 26 (7) : 2073-2080, 2019
PubMed
P.305 掲載の参考文献
19) Chiappetta M, Grossi U, Sperduti I et al : Which is the best treatment in recurrent thymoma? A systematic review and meta-analysis. Cancers 13 (7) : 1559, 2021
PubMed
20) Yang AJ, Choi SH, Byun HK et al : The role of salvage radiotherapy in recurrent thymoma, Radiat Oncol J 37 (3) : 193-200, 2019
PubMed
21) Aprile V, Bacchin D, Korasidis S et al : Surgical treatment of pleural recurrence of thymoma : is hyperthermic intrathoracic chemotherapy worthwhile? Interact Cardiovasc Thorac Surg 30 (5) : 765-772, 2020
PubMed
22) Kato T, Kawaguchi K, Fukui T et al : Risk factors for the exacerbation of myasthenic symptoms after surgical therapy for myasthenia gravis and thymoma. Semin Thorac Cardiovasc Surg 32 (2) : 378-385, 2020
PubMed
23) Na KJ, Hyun K, Kang CH et al : Predictors of post-thymectomy long-term neurological remission in thymomatous myasthenia gravis : an analysis from a multi-institutional database. Eur J Cardiothorac Surg 57 (5) : 867-873, 2020
 
24) Yang X, Zhuo M, Shi A et al : Optimal first-line treatment for advanced thymic carcinoma. Thorac Cancer 10 (11) : 2081-2087, 2019
PubMed
25) Koizumi T, Otsuki K, Tanaka Y et al : National incidence and initial therapy for thymic carcinoma in Japan : based on analysis of hospital-based cancer registry data, 2009-2015. Jpn J Clin Oncol 50 (4) : 434-439, 2020
 
26) Kang CH, Na KJ, Park S et al : Long-term outcomes of robotic thymectomy in patients with thymic epithelial tumors. Ann Thorac Surg 112 : 430-435, 2020
PubMed
27) Liu L, Zhang J, Wang G et al : Extended thymectomy with blood vessel resection and reconstruction improves therapeutic outcome for clinical stage III thymic carcinoma patients : a real-world research. J Cardiothorac Surg 15 (1) : 267, 2020
 
28) Yamato H, Funaki S, Shimamura K et al : Salvage surgery for stage IV a thymic carcinoma combined with aortic arch resection-case report. J Cardiothorac Surg 15 (1) : 305, 2020
 
29) Kim S, Bull DA, Hsu CH et al : The role of adjuvant therapy in advanced thymic carcinoma : A National Cancer Database analysis. Ann Thorac Surg 109 (4) : 1095-1103, 2020
 
30) Suveg K, Putora PM, Joerger M et al : Radiotherapy for thymic epithelial tumours : a review. Transl Lung Cancer Res 10 (4) : 2088-2100, 2021
PubMed
P.306 掲載の参考文献
31) Sato J, Satouchi M, Itoh S et al : Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA) : a ulticentre, phase 2 trial. Lancet Oncol 21 (6) : 843-850, 2020
PubMed
32) Okumura M, Yoshino I, Yano M et al : Tumour size determines both recurrence-free survival and disease-specific survival after surgical treatment for thymoma. Eur J Cardiothorac Surg 56 (1) : 174-181, 2019
PubMed
33) Veraar C, Janik S, Thanner J et al : Clinical prognostic scores for patients with thymic epithelial tumors, Sci Rep 9 (1) : 18581, 2019
PubMed
34) Kumar N, Madan R, Dracham CB et al : Primary mediastinal germ cell tumors : Survival outcomes and prognostic factors-10 years experience from a tertiary care institute. Rare Tumors 12 : 2036361320972220, 2020
PubMed
35) Koizumi T, Kanda S, Nihonmatu R et al : Primary mediastinal germ cell tumors-A retrospective analysis of > 30 years of experience in a single institution. Thorac Cancer 12 (6) : 807-813, 2021
 
P.307 掲載の参考文献
36) Pfau D, Smith DA, Beck R et al : Primary Mediastinal Large B-Cell Lymphoma : A Review for Radiologists. AJR Am J Roentgenol 213 (5) : W194-W210, 2019
 
37) Galetta D, Spaggiari L : Primary intrathoracic neurogenic tumors : Clinical, pathological, and long-term outcomes. Thorac Cardiovasc Surg, 2020 [online ahead of print]
 
P.308 掲載の参考文献
1) 日本肺癌学会編 : 肺癌診療ガイドライン 2020年版 ver.1.1 (悪性胸膜中皮腫・胸腺腫瘍含む) https://www.haigan.gr.jp/modules/guideline/index.php?content_id=3
 
P.309 掲載の参考文献
2) Fornasiero A, Daniele O, Ghiotto C et al : Chemotherapy for invasive thymoma. A 13-year experience. Cancer 68 (1) : 30-33, 1991
PubMed
P.310 掲載の参考文献
3) Loehrer PJ Sr, Kim K, Aisner SC et al : Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma : final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 12 (6) : 1164-1168, 1994
PubMed
4) Kunitoh H, Tamura T, Shibata T et al : A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma : report of a Japan Clinical Oncology Group trial (JCOG 9605). Br J Cancer 101 (9) : 1549-1554, 2009
 
5) Kim ES, Putnam JB, Komaki R et al : Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas : final report. Lung Cancer 44 (3) : 369-379, 2004
PubMed
6) Yokoi K, Matsuguma H, Nakahara R et al : Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2 (1) : 73-78, 2007
PubMed
7) Loehrer PJ Sr, Jiroutek M, Aisner S et al : Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma : an intergroup trial. Cancer 91 (11) : 2010-2015, 2001
PubMed
8) Lemma GL, Lee JW, Aisner SC et al : Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29 (15) : 2060-2065, 2011
PubMed
9) Giaccone G, Ardizzoni A, Kirkpatrick A et al : Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14 (3) : 814-820, 1996
PubMed
P.311 掲載の参考文献
10) Okuma Y, Saito M, Hosomi Y et al : Key components of chemotherapy for thymic malignancies : a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. J Cancer Res Clin Oncol 141 (2) : 323-331, 2015
PubMed
11) Gbolahan OB, Porter RF, Salter JT et al : A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma. J Thorac Oncol 13 (12) : 1940-1948, 2018
PubMed
12) Hellyer JA, Gubens MA, Cunanan KM et al : Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Lung Cancer 137 : 71-75, 2019
PubMed
13) Loehrer PJ Sr, Wang W, Johnson DH et al : Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma : an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 22 (2) : 293-299, 2004
PubMed
14) Palmieri G, Montella L, Martignetti A et al : Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 94 (5) : 1414-1420, 2002
PubMed
15) Sato J, Satouchi M, Itoh S et al : Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA) : a multicentre, phase 2 trial. Lancet Oncol 21 (6) : 843-850, 2020
PubMed

XIV章 新テクノロジーと肺疾患

P.315 掲載の参考文献
1) Meltzer C, Fagman E, Vikgren J et al : Surveillance of small, solid pulmonary nodules at digital chest tomosynthesis : data from a cohort of the pilot Swedish CArdioPulmonary bioImage Study (SCAPIS). Acta Radiol 62 (3) : 348-359, 2021
PubMed
2) Mogami H, Onoike Y, Miyano H et al : Lung cancer screening by single-shot dualenergy subtraction using flat-panel detector. Jpn J Radiol, 2021 [online ahead of print]
 
3) Endo K, Kaneko A, Horiuchi Y et al : Detectability of pulmonary nodules on chest radiographs : bone suppression versus standard technique with single versus dual monitors for visualization. Jpn J Radiol 38 : 676-682, 2020
PubMed
4) Capone C, Valentini A, Spinillo SL et al : Radiological differences between chronic thromboembolic pulmonary disease (CTEPD) and chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 31 (8) : 6230-6238, 2021
PubMed
5) Gietema HA, Walraven KHM, Posthuma R et al : Dual-energy computed tomography compared to lung perfusion scintigraphy to assess pulmonary perfusion in patients screened for endoscopic lung volume reduction. Respiration, 2021 [online ahead of print]
 
6) Hwang HJ, Lee SM, Seo JB et al : Visual and quantitative assessments of regional xenon-ventilation using dual-energy CT in asthma-chronic obstructive pulmonary disease overlap syndrome : A comparison with chronic obstructive pulmonary disease. Korean J Radiol 21 (9) : 1104-1113, 2020
PubMed
P.316 掲載の参考文献
7) Jia Y, Zhai B, He T et al : Effect of new model-based iterative reconstruction on quantitative analysis of airway tree by computer-aided detection software in chest computed tomography. J Comput Assist Tomogr 45 (1) : 166-170, 2021
PubMed
8) Hao W, Li M, Pang Y et al : Increased chemokines levels in patients with chronic obstructive pulmonary disease : correlation with quantitative computed tomography metrics. Br J Radiol 94 (1118) : 20201030, 2021
 
9) Kim M, Doganay O, Hwang HJ et al : Lobar ventilation in patients with COPD assessed with the full-scale airway network flow model and xenon-enhanced dualenergy CT. Radiology 299 (2) : E257, 2021
 
10) Takker M, Kristjansdottir B, Graumann O et al : Diagnostic accuracy of low-dose and ultra-low-dose CT in detection of chest pathology : a systematic review. Clin Imaging 74 : 139-148, 2021
 
11) Higaki T, Nakamura Y, Tatsugami F et al : Improvement of image quality at CT and MRI using deep learning. Jpn J Radiol 37 : 73-80, 2019
PubMed
12) Niedbalski PJ, Hall CS, Castro M et al : Protocols for multi-site trials using hyperpolarized 129Xe MRI for imaging of ventilation, alveolar-airspace size, and gas exchange : A position paper from the 129Xe MRI clinical trials consortium. Magn Reson Med, 2021 [online ahead of print]
 
P.317 掲載の参考文献
13) Ohno Y, Seo JB, Parraga G et al : Pulmonary functional imaging : Part 1-State-of-the-Art Technical and Physiologic Underpinnings. Radiology 299 (3) : 508-523, 2021
PubMed
14) 胸部 : CQ5 肺癌のリンパ節転移診断においてMRIは推奨されるか? "画像診断ガイドライン" 日本医学放射線 学会編, 金原出版, pp143-145, 2021
 
15) Carlin D, Weller A, Kramer G et al : Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy. BJR Open 1 : 20190029, 2019
PubMed
16) 胸部 : CQ4 肺癌のT因子病気診断においてMRIは推奨されるか? "画像診断ガイドライン" 日本医学放射線 学会編, 金原出版, pp140-142, 2021
 
17) I. 肺癌の診断 : CQ3. 肺癌の検出にPET/CT検査は有用か? "肺癌診療ガイドライン 2020年版" 日本肺癌 学会編, 金原出版, pp12-13, 2021
 
18) I. 肺癌の診断 : CQ5. 高分解能CTで肺癌かどうか判断できない結節に, 造影CTやMRI, FDG-PETを行うことは有用か? "肺癌診療ガイドライン 2020年版" 日本肺癌 学会編, 金原出版, pp16-17, 2021
 
19) 胸部 : CQ3 肺結節の良悪性の鑑別診断においてFDG-PET/CTは推奨されるか? "画像診断ガイドライン" 日本医学放射線 学会編, 金原出版, pp136-137, 2021
 
20) I. 肺癌の診断 : CQ21. N因子診断のために, 必要な検査は何か? "肺癌診療ガイドライン 2020年版" 日本肺癌 学会編, 金原出版, pp49-51, 2021
 
21) I. 肺癌の診断 : CQ22. M因子診断のために, 必要な検査は何か? "肺癌診療ガイドライン 2020年版" 日本肺癌 学会編, 金原出版, pp51-52, 2021
 
22) Christensen TN, Andersen PK, Langer SW et al : Prognostic Value of 18F-FDG-PET parameters in patients with small cell lung cancer : A meta-analysis and review of current literature. Diagnostics (Basel) 11 (2) : 174, 2021
 
P.318 掲載の参考文献
23) Seban RD, Assie JB, Giroux-Leprieur E et al : Prognostic value of inflammatory response biomarkers using peripheral blood and 18F-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. Lung Cancer 159 : 45-55, 2021
 
24) Danti G, Berti V, Abenavoli E et al : Diagnostic imaging of typical lung carcinoids : relationship between MDCT, 111In-Octreoscan and 18F-FDG-PET imaging features with Ki-67 index. Radiol Med 125 (8) : 715-729, 2020
PubMed
25) Mirvis E, Toumpanakis C, Mandair D et al : Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs). Lung Cancer 150 : 70-75, 2020
PubMed
26) Zhang J, Liu Q, Singh A et al : Prognostic value of 18F-FDG PET/CT in a large cohort of patients with advanced metastatic neuroendocrine neoplasms treated with peptide receptor radionuclide therapy. J Nucl Med 61 (11) : 1560-1569, 2020
 
27) Halder A, Dey D, Sadhu AK : Lung nodule detection from feature engineering to deep learning in thoracic CT Images : a comprehensive review. J Digit Imaging 33 (3) : 655-677, 2020
PubMed
28) Gierada DS, Rydzak CE, Zei M et al : Improved interobserver agreement on lung-RADS classification of solid nodules using semiautomated CT volumetry. Radiology 297 (3) : 675-684, 2020
PubMed
P.319 掲載の参考文献
29) de Margerie-Mellon C, Ngo LH, Gill RR et al : The growth rate of subsolid lung adenocarcinoma nodules at chest CT. Radiology 297 (1) : 189-198, 2020
PubMed
30) Kim SK, Kim C, Lee KY et al : Accuracy of model-based iterative reconstruction for CT volumetry of part-solid nodules and solid nodules in comparison with filtered back projection and hybrid iterative reconstruction at various dose settings : An anthropomorphic chest phantom study. Korean J Radiol 20 (7) : 1195-1206, 2019
 
31) Fusco R, Granata V, Mazzei MA et al : Quantitative imaging decision support (QIDSTM) tool consistency evaluation and radiomic analysis by means of 594 metrics in lung carcinoma on chest CT scan. Cancer Control 28 : 1073274820985786, 2021
PubMed
P.320 掲載の参考文献
1) Rao V, Kumar R, Rajaganesan S et al : Remote reporting from home for primary diagnosis in surgical pathology : A tertiary oncology center experience during the COVID-19 pandemic. J Pathol Inform 12 : 3, 2021
 
2) Lujan GM, Savage J, Shana'ah A et al : Digital pathology initiatives and experience of a large academic institution during the coronavirus disease 2019 (COVID-19) pandemic. Arch Pathol Lab Med, 2021 [online ahead of print]
 
3) CAP Secures Remote Work Waiver for Pathologists (during the COVID-19 public health emergency). 2020 Mar https://www.cap.org/laboratory-improvement/news-and-updates
 
P.321 掲載の参考文献
4) Tabata K, Mori I, Sasaki T et al : Wholeslide imaging at primary pathological diagnosis : Validation of whole-slide imagingbased primary pathological diagnosis at twelve Japanese academic institutes. Pathol Int 67 (11) : 547-554, 2017
PubMed
5) Mukhopadhyay S, Feldman MD, Abels E et al : Whole slide imaging versus microscopy for primary diagnosis in surgical pathology : A multicenter blinded randomized noninferiority study of 1992 cases (Pivotal Study). Am J Surg Pathol 42 (1) : 39-52, 2018
PubMed
6) Pantanowitz L, Sinard JH, Henricks WH et al : Validating whole slide imaging for diagnostic purposes in pathology : guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med 137 (12) : 1710-1722, 2013
PubMed
7) Retamero JA, Aneiros-Fernandez J, Del Moral RG : Complete digital pathology for routine histopathology diagnosis in a multicenter hospital network. Arch Pathol Lab Med 144 (2) : 221-228, 2019
 
P.322 掲載の参考文献
8) Sakamoto T, Furukawa T, Lami K et al : A narrative review of digital pathology and artificial intelligence : focusing on lung cancer. Transl Lung Cancer Res 9 (5) : 2255-2276, 2020
PubMed
9) Fujisawa T, Mori K, Mikamo M et al : Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. Eur Respir J 53 (5) : 1802243, 2019
PubMed
P.324 掲載の参考文献
10) Ehteshami Bejnordi B, Veta M, Johannes van Diest P et al : Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. JAMA 318 (22) : 2199-2210, 2017
PubMed
11) Pham HHN, Futakuchi M, Bychkov A et al : Detection of lung cancer lymph node metastases from whole-slide histopathologic images using a two-step deep learning approach. Am J Pathol 189 (12) : 2428-2439, 2019
PubMed
P.325 掲載の参考文献
12) Coudray N, Ocampo PS, Sakellaropoulos T et al : Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med 24 (10) : 1559-1567, 2018
PubMed
13) Mobadersany P, Yousefi S, Amgad M et al : Predicting cancer outcomes from histology and genomics using convolutional networks. Proc Natl Acad Sci U S A 115 (13) : E2970-E2979, 2018
 
P.326 掲載の参考文献
14) Iizuka T, Fukasawa M, Kameyama M : Deep-learning-based imaging-classification identified cingulate island sign in dementia with Lewy bodies. Sci Rep 9 (1) : 8944, 2019
PubMed
15) Kitamura S, Takahashi K, Sang Y et al : Deep learning could diagnose diabetic nephropathy with renal pathological immunofluorescent images. Diagnostics (Basel) 10 (7) : 466, 2020
PubMed
16) Diao JA, Wang JK, Chui WF et al : Human-interpretable image features derived from densely mapped cancer pathology slides predict diverse molecular phenotypes. Nat Commun 12 (1) : 1613, 2021
PubMed
17) Uegami W, Bychkov A, Ozasa M et al : MIXTURE of human expertise and deep learning-Developing an explainable model for predicting pathological diagnosis and survival in patients with interstitial lung disease. medRxiv, 2021.07.21.21260920, 2021
 
P.327 掲載の参考文献
1) Raghu G, Remy-Jardin M, Myers JL et al : Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198 (5) : e44-e68, 2018
 
2) Kaul B, Lee JS, Zhang N et al : Epidemiology of idiopathic pulmonary fibrosis among U.S. veterans, 2010-2019. Ann Am Thorac Soc, 2021 [online ahead of print]
 
3) Walsh SLF, Maher TM, Kolb M et al : Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis : an international case-cohort study. Eur Respir J 50 (2) : 1700936, 2017
 
4) Thomeer M et al. Eur Respir J 31 (3) : 585-591, 2008
PubMed
P.328 掲載の参考文献
5) Wang L, Lin ZQ, Wong A : COVID-Net : a tailored deep convolutional neural network design for detection of COVID-19 cases from chest X-ray images. Sci Rep 10 (1) : 19549, 2020
 
6) Nishikiori H, Chiba H, Hirota K et al : Development of an artificial intelligence software to detect interstitial pneumonias. Eur Respir J 56 (suppl 64) : 3716, 2020
 
7) Romei C, Tavanti LM, Taliani A et al : Automated Computed Tomography analysis in the assessment of Idiopathic Pulmonary Fibrosis severity and progression. Eur J Radiol 124 : 108852, 2020
PubMed
8) Ferrazza AM, Gigante A, Gasperini ML et al : Assessment of interstitial lung disease in systemic sclerosis using the quantitative CT algorithm CALIPER. Clin Rheumatol 39 (5) : 1537-1542, 2020
PubMed
9) Humphries SM, Swigris JJ, Brown KK et al : Quantitative high-resolution computed tomography fibrosis score : performance characteristics in idiopathic pulmonary fibrosis. Eur Respir J 52 (3) : 1801384, 2018
PubMed
10) Shaish H, Ahmed FS, Lederer D et al : Deep learning of computed tomography virtual wedge resection for prediction of histologic usual interstitial pneumonitis. Ann Am Thorac Soc 18 (1) : 51-59, 2021
PubMed
P.329 掲載の参考文献
11) Walsh SLF, Calandriello L, Silva M et al : Deep learning for classifying fibrotic lung disease on high-resolution computed tomography : a case-cohort study. Lancet Respir Med 6 (11) : 837-845, 2018
PubMed
12) Nakano A, Ohkubo H, Taniguchi H et al : Early decrease in erector spinae muscle area and future risk of mortality in idiopathic pulmonary fibrosis. Sci Rep 10 (1) : 2312, 2020
PubMed
13) Raghu G, Flaherty KR, Lederer DJ et al : Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples : a prospective validation study. Lancet Respir Med 7 (6) : 487-496, 2019
PubMed
P.330 掲載の参考文献
14) Zhavoronkov A, Ivanenkov YA, Aliper A et al : Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol 37 (9) : 1038-1040, 2019
PubMed
15) 古川大記, 大山慎太郎, 横田秀夫他 : 間質性肺炎診断と予後深層学習を用いた機械学習による特発性肺線維症診断アルゴリズム. 日呼吸誌 8 (増刊) : 167, 2019
 
16) Furukawa T, Oyama S, Yokota H et al : Development of a machine learning combination with deep learning for diagnosing idiopathic pulmonary fibrosis in chronic interstitial lung disease. Eur Respir J 56 (suppl 64) : 808, 2020
 
17) 古川大記, 大山慎太郎, 近藤康博他 : 深層学習を用いた間質性肺炎の高精度予後予測アルゴリズム. 日呼吸誌 9 (増刊) : 117, 2020
 
P.331 掲載の参考文献
18) Fujisawa T, Mori K, Mikamo M et al : Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. Eur Respir J 53 (5), 2019
PubMed
19) 冨岡洋海, 坂東政司, 近藤康博 : びまん性肺疾患のmultidisciplinary discussion診断に関するアンケート調査結果. 日呼吸誌 10 (2) : 97-101, 2021
 
P.332 掲載の参考文献
20) Furukawa T, Taniguchi H, Ando M et al : The St. George's Respiratory Questionnaire as a prognostic factor in IPF. Respir Res 18 (1) : 18, 2017
 
21) Moor CC, Mostard RLM, Grutters JC et al : Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial. Am J Respir Crit Care Med 202 (3) : 393-401, 2020
PubMed
22) Noth I, Cottin V, Chaudhuri N et al : Home spirometry in patients with idiopathic pulmonary fibrosis : data from the INMARK trial. Eur Respir J 58 (1) : 2001518, 2021
PubMed
23) Cox NS, Dal Corso S, Hansen H et al : Telerehabilitation for chronic respiratory disease. Cochrane Database Syst Rev, 2021
PubMed

XV章 その他

P.335 掲載の参考文献
1) McCormack FX, Gupta N, Finlay GR et al : Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines : Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med 194 : 748-761, 2016
 
2) Gupta N, Finlay GA, Kotloff RM et al : Lymphangioleiomyomatosis diagnosis and management : High-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med 196 : 1337-1348, 2017
 
3) 林田美江, 安藤克利, 関谷充晃他 : LAMを有する成人女性においてmTOR阻害薬は第一選択となりますか? 日呼会誌 5 : 166-171, 2016
 
4) 林田美江, 安藤克利, 関谷充晃他 : 孤発性LAMに伴う腎血管筋脂肪腫においてmTOR阻害薬の投与を考慮しますか? 日呼会誌 6 : 225-234, 2017
 
5) 林田美江, 和田洋典, 北口良晃他 : リンパ脈管筋腫症に伴う気胸の再発予防策として胸腔鏡下全胸膜カバリング術は推奨されますか? 日呼会誌 9 : 151-159, 2020
 
6) Okamoto S, Suzuki K, Hayashi T et al : Transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis : the severity of cystic lung destruction assessed by the modified Goddard scoring system as a predictor for establishing the diagnosis. Orphanet J Rare Dis 15 : 125, 2020
PubMed
P.336 掲載の参考文献
7) Yoshida M, Awano N, Inomata M et al : Diagnostic usefulness of transbronchial lung cryobiopsy in two patients mildly affected with pulmonary lymphangioleiomyomatosis. Respir Investig 58 : 295-299, 2020
PubMed
8) Sekimoto Y, Suzuki K, Okura M et al : Uncommon radiologic computed tomography appearances of the chest in patients with lymphangioleiomyomatosis. Sci Rep 11 : 7170, 2021
PubMed
9) Ogorek B, Hamieh L, Lasseter K et al : Generalised mosaicism for TSC2 mutation in isolated lymphangioleiomyomatosis. Eur Respir J 54 : 1900938, 2019
PubMed
10) Lim JS, Gopalappa R, Kim SH et al : Somatic mutations in TSC1 and TSC2 cause focal cortical dysplasia. Am J Hum Genet 100 : 454-472, 2017
PubMed
11) Ko Y, Asakawa K, Tobino K et al ; Multicenter Lymphangioleiomyomatosis Sirolimus Trial for Safety Study Group : Quantitative analysis of computed tomography of the lungs in patients with lymphangioleiomyomatosis treated with sirolimus. Heliyon 6 : e03345, 2020
 
P.337 掲載の参考文献
12) Tian X, Glass JE, Kwiatkowski DJ et al : Lymphangioleiomyomatosis association with underlying genotype in patients with tuberous sclerosis complex. Ann Am Thorac Soc 18 : 815-819, 2021
PubMed
P.338 掲載の参考文献
13) Matthew BP, Hasani AM, Chen YC et al : Ultra-small lung cysts impair diffusion without obstructing air flow in lymphangioleiomyomatosis. Chest 160 : 199-208, 2021
PubMed
14) Nishino K, Yoshimatsu Y, Muramatsu T et al : Isolation and characterisation of lymphatic endothelial cells from lung tissues affected by lymphangioleiomyomatosis. Sci Rep 11 : 8406, 2021
PubMed
P.339 掲載の参考文献
15) Kosmas K, Filippakis H, Khabibullin D et al : TSC2 interacts with HDLBP/Vigilin and regulates stress granule formation. Mol Cancer Res 19 : 1389-1397, 2021
 
16) Kovalenko A, Sanin A, Kosmas K et al : Therapeutic targeting of DGKA-mediated macropinocytosis leads to phospholipid reprogramming in tuberous sclerosis complex. Cancer Res 81 : 2086-2100, 2021
PubMed
18) Mahi NA, Zhang EY, Sherman S et al : Connectivity map analysis of a single-cell RNA-sequencing -derived transcriptional signature of mTOR signaling. Int J Mol Sci 22 : 4371, 2021
 
19) Tang Y, Kwiatkowski DJ, Henske EP : mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes : implications for COVID-19. Eur Respir J 57 : 2002737, 2021
PubMed
21) Seyama K, Nukiwa T, Sato T et al : Safety and pharmacokinetics of Alpha-1 MP (Prolastin(R) -C) in Japanese patients with alpha1-antitrypsin (AAT) deficiency. Respir Investig 57 : 89-96, 2019
 
22) 平井豊博, 瀬山邦明, 巽浩一郎 : α1アンチトリプシン欠乏症 診療の手引き 2016 https://www.jrs.or.jp/uploads/uploads/files/information/AATD2016.pdf
 
23) Nakanishi T, Forgetta V, Handa T et al : The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes. Eur Respir J 56 : 2001441, 2020
PubMed
24) Schouten IGM, Kasteleyn MJ, Tsonaka R et al : Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients : an analysis of the AIR database. ERJ Open Research 7 : 00194-2021, 2021
 
P.340 掲載の参考文献
17) Guo M, Yu JJ, Perl AK et al : Single-cell transcriptomic analysis identifies a unique pulmonary lymphangioleiomyomatosis cell. Am J Respir Crit Care Med 202 : 1373-1387, 2020
 
P.341 掲載の参考文献
20) Seyama K et al. Respir Investig 54 (3) : 201-206, 2016
PubMed
P.342 掲載の参考文献
25) Schouten IGM, Mumford RA, Moes DJAR et al : The course of AαVal541 as a proteinase 3 specific neo-epitope after alpha-1-antitrypsin augmentation in severe deficient patients. Int J Mol Sci 22 : 8031, 2021
 
26) Laffranchi M, Elliston ELK, Gangemi F et al : Characterisation of a type II functionally-deficient variant of alpha-1-antitrypsin discovered in the general population. PLoS One 14 : e0206955, 2019
PubMed
P.343 掲載の参考文献
1) Chambers DC, Cherikh WS, Harhay MO et al : The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation : Thirty-sixth adult lung and heartlung transplantation Report-2019 ; Focus theme : Donor and recipient size match. J Heart Lung Transplant 38 : 1042-1055, 2019
PubMed
P.344 掲載の参考文献
2) 日本肺および心肺移植研究会 http://www2.idac.tohoku.ac.jp/dep/surg/shinpai/pg185.html
 
P.345 掲載の参考文献
3) 日本臓器移植ネットワーク https://www.jotnw.or.jp/data/
 
P.346 掲載の参考文献
4) Sato M et al. J Heart Lung Transplant 30 : 735-742, 2011
 
5) Glanville AR, Verleden GM, Todd JL et al : Definition and update of restrictive allograft syndrome-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant 38 : 483-492, 2019
PubMed
6) Verleden GM, Glanville AR, Lease ED et al : Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant 38 : 493-503, 2019
PubMed
7) Sugimoto S, Yamamoto H, Kurosaki T et al : Impact of chronic lung allograft dysfunction, especially restrictive allograft syndrome, on the survival after livingdonor lobar lung transplantation compared with cadaveric lung transplantation in adults : a single-center experience. Surg Today 49 : 686-693, 2019
PubMed
P.347 掲載の参考文献
8) Meyer KC et al. Eur Respir J 44 : 1479-1503, 2014
PubMed
P.348 掲載の参考文献
9) Stewart S et al. J Heart Lung Transplant 26 : 1229-1242, 2007
 
P.349 掲載の参考文献
10) Martinu T, Koutsokera A, Benden C et al : bronchoalveolar lavage standardization workgroup. International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation. J Heart Lung Transplant 39 : 1171-1190, 2020
PubMed
11) 日本移植学会成人臓器移植予防接種ガイドライン策定委員会 : 成人臓器移植予防接種ガイドライン 2018年版. 2018
 
P.350 掲載の参考文献
12) 日本移植学会 : 新型コロナウイルスワクチンに関する提言 (第2版). 2021
 
P.351 掲載の参考文献
13) Bharat A, Machuca TN, Querrey M et al : Early outcomes after lung transplantation for severe COVID-19 : a series of the first consecutive cases from four countries. Lancet Respir Med 9 : 487-497, 2021
PubMed

書評

最近チェックした商品履歴

Loading...